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ABSTRACT 
Background 
Changes in the structure and function of the peritoneal membrane limit the duration of PD. Rarely 
(and unpredictably) these changes progress to severe fibrosis and bowel encapsulation 
(encapsulating peritoneal sclerosis, EPS) with substantial morbidity and mortality.  
Methods 
PD fluid and serum samples from 50 patients were added to 100 previously analysed samples (Dr S 
Ahmad). CCL18, IL-6, MCP-1 and angiogenin were measured by ELISA. CCL15 was measured for the 
first time in 125 serum and dialysate samples. Fifty one year follow up samples were analysed. 
Serum cytokines were measured in patients with and without EPS. Peritoneal mesothelial cells were 
cultured and media cytokine levels measured. CCL15 stimulation of cytokine production was 
investigated. Protein transfer across the peritoneal membrane by size was investigated. CT scans 
from 20 pre-EPS PD patients were scored and compared with scans of non-EPS patients. 
Results 
Levels of CCL18, MCP-1, CCL15, angiogenin and IL-6 in dialysate correlate with clinically important 
measures such as glucose exposure and D/P creatinine. Mesothelial cells in culture produce MCP-1, 
IL-6, angiogenin and CCL18. High dialysate levels of MCP-1, IL-6 and CCL15 are found in patients who 
subsequently developed EPS. High levels of CCL18 are also seen in haemodialysis patients with EPS. 
CT screening of PD patients used alone does not predict future EPS; in combination with abdominal 
symptoms CT scans may be of use. 
Conclusions 
There is local peritoneal production of chemokines such as MCP-1, CCL18, IL-6 and angiogenin, and 
the correlation of levels of these cytokines with clinically relevant parameters suggests they may be 
involved in the pathogenesis of long term changes in the peritoneum. At present neither clinical nor 
cytokine levels can reliably be used to predict future EPS. CT scanning may be helpful in patients at 
risk of EPS who develop new abdominal symptoms.  
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CHAPTER 1: 
 
INTRODUCTION 
 
Worldwide there are an increasing number of people dependent on renal replacement therapy, as 
their own renal function has declined to a level not compatible with life. Many will receive a kidney 
transplant, but due to anatomical or co-morbid considerations, age, immunological barriers and the 
shortage of donor organs, some will remain dependent on dialysis therapy for many years. Renal 
replacement therapy may be performed by haemodialysis or by peritoneal dialysis. 
Peritoneal dialysis is a frequently used mode of dialysis therapy worldwide and is appealing to 
patients as it may be used easily in the home setting, with no complex machinery. However, the 
duration of peritoneal dialysis therapy is limited by structural changes in the peritoneal membrane 
which affect both dialysis adequacy and fluid removal. The mechanisms by which these changes 
occur over a period of years are not yet fully understood. In addition, in a minority of long term 
peritoneal dialysis patients, a severe form of peritoneal fibrosis develops. This results in the 
formation of a cocoon of thick fibrous material that surrounds the bowel and causes obstruction. 
This condition, termed encapsulating peritoneal sclerosis (EPS), is uncommon yet important as it 
causes substantial morbidity and mortality. As yet there is no reliable way to predict its occurrence. 
 
1.1 Basic concepts in peritoneal dialysis 
1.1(i) Performance of peritoneal dialysis (PD) 
In order to perform peritoneal dialysis, a permanent catheter is placed with the tip in the pelvis. The 
catheter is tunnelled subcutaneously and the end is brought out through the skin at a convenient 
point (the exit site). To achieve removal of uraemic toxins and excess fluid from the body, dialysate 
(commonly 1.5 to 2.5 litres) is instilled into the peritoneal cavity via the catheter. The fluid is left 
within the peritoneal cavity for a variable time period during which solutes diffuse across the 
peritoneum, which acts as a semi-permeable membrane, into the dialysate. Removal of excess fluid 
from the body occurs by two mechanisms: there is convective movement of fluid with the transfer of 
small solutes to the dialysate, and also the dialysate composition is hyperosmotic to blood 
(containing a high concentration of glucose) so that fluid moves by osmosis into the dialysate. After a 
specified time the fluid is drained out and fresh fluid is instilled. The excess fluid volume drained out 
(compared to that originally instilled) is termed the ultrafiltration volume. 
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Peritoneal dialysis may be performed by manual exchange of fluid carried out usually four times 
each day – this is termed continuous ambulatory peritoneal dialysis, (CAPD). Alternatively, a 
machine may perform exchanges during the night. This is automated peritoneal dialysis (APD).The 
peritoneal cavity may be left empty during the day, or to maximise dialysis opportunity a daytime 
dwell of fluid may be instilled.  
 
1.1(ii) Mechanism of dialysis and ultrafiltration 
The effective barrier to fluid and solute transport is the endothelial cell layer of the peritoneal 
capillaries. Mathematical modelling based on observed membrane transport characteristics 
predicted the existence of three types of pore in the peritoneal membrane (Rippe et al., 1991). 
Firstly, ultra-small pores, small enough (<4A°) to permit only the passage of water, are formed by 
aquaporin 1. Small pores (40-50A°) are probably formed by clefts between the endothelial cells and 
permit the passage of small solutes and water. Large pores (250A°) may be inter-cell clefts in 
venules; the number of these pores is small (<5% of the total) (Nishino and Devuyst, 2008). 
Macromolecules pass through these larger pores. Recent refinements of this model have 
demonstrated how fluid and solute movement through these pores may be modified by the 
interstitial matrix density (Rippe and Venturoli, 2007). The structure of the peritoneal membrane is 
critical in determining the success or failure of peritoneal dialysis; it is clear that changes in the 
numbers of pores or the thickness of the membrane will significantly affect dialysis adequacy. 
 
1.1(iii) Adequacy of dialysis 
Adequacy of dialysis in the peritoneal dialysis patient is defined in terms of small solute clearance; 
fluid removal is also of major importance to patient well-being. Creatinine clearance is measured in 
litres per week and urea clearance as a weekly Kt/V, where Kt is the dialysate urea content/serum 
urea and V the total body water, usually derived by formulae such as Watson’s (Daugirdas et 
al., 2001). Ultrafiltration is measured using a timed fluid exchange with a defined dialysate glucose 
concentration. Clinical outcome data has demonstrated a clear relationship between total 
(peritoneal and residual renal) clearance and patient outcomes (Churchill, 1998), but prospective 
data from the ADEMEX trial indicated that above a minimum threshold, increasing peritoneal 
clearance had no outcome benefit (Paniagua et al., 2002); further investigation in anuric APD 
patients (the EAPOS trial) confirmed this finding (Brown et al., 2003), (Davies and Brown, 2007) and 
highlighted the importance of adequate ultrafiltration in this group. Residual renal function 
contributes significantly to overall clearances in many peritoneal dialysis patients and it is residual 
function which underlies the relationship between total clearance and clinical outcomes. 
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1.1(iv) Quantifying peritoneal membrane transport characteristics 
The time course of fluid and solute movement across the peritoneal membrane is complex and 
dependent on the physical characteristics of the peritoneal membrane in a particular patient. In 
clinical practice a standardised assessment of peritoneal membrane transport characteristics is 
performed - the Peritoneal Equilibration Test (PET) - as developed by Twardowski (Zbylut et al., 
1987). For this test a standard glucose concentration bag is instilled for 4 hours and samples of 
dialysate taken at time 0, 2 and 4 hours. A blood sample is taken at the mid-point of the dwell to 
measure urea, creatinine and glucose. Small solute transfer is expressed as the ratio of dialysate to 
plasma creatinine (D/P creatinine) at 4 hours. Historically a 2.27% glucose solution has been widely 
used but a 3.86% solution is now advocated, which allows more detailed assessment of 
ultrafiltration capacity since the volumes involved are larger (Mujais et al., 2000). In our institution a 
2.27% glucose solution has been used for PET tests throughout the duration of this study. The D/P 
creatinine result is stratified into four groups – low, low average, high average and high – for clinical 
purposes. In general high transporters clear creatinine and other small solutes quickly, but 
experience rapid dissipation of the osmotic gradient for ultrafiltration as glucose is rapidly absorbed. 
Achieving adequate ultrafiltration may be difficult with the prolonged dwell times of CAPD, since 
fluid will be reabsorbed from the dialysate later in the dwell. Low transporters will have good UF 
volumes but will need prolonged dwell times to achieve adequate small molecule clearances. These 
issues are clinically significant; data from the CANUSA study, derived from patients on CAPD, showed 
an increased risk of mortality in patients with a high transport rate (Churchill, 1998). The use of APD 
mitigates this risk (Brown et al., 2003), which may be manifest through the failure to achieve 
adequate ultrafiltration (Davies et al., 2006). 
More detailed information about solute and water transfer can be obtained by using an intra-
peritoneal volume marker such as dextran70 and serial measurements of dialysate electrolytes and 
small solutes – the standard peritoneal permeability analysis. The degree of dilution of dextran70 
can be used to calculate the initial ultrafiltration rate. This represents convective movement of fluid 
and solute through the small pores and osmotic fluid movement through small pores and aquaporin. 
Because water moving via the aquaporin channels is not accompanied by any solute movement, the 
dialysate sodium concentration shows an initial fall. It then increases later in the dwell as fluid 
resorption occurs with loss of the glucose-dependent osmotic gradient. This phenomenon is called 
sodium sieving and is maximal between and one and two hours into the dwell. The fall in dialysate 
sodium can be used to calculate the component of total ultrafiltration which is due to free water 
transfer, although a small correction is required to estimate the effect of sodium diffusion on 
dialysate sodium concentration (Krediet et al., 2008). Other parameters describing solute and fluid 
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transport characteristics, such as the membrane reflection coefficient for glucose, can also be 
calculated. An ideal osmotic agent has a reflection coefficient of 1; for the peritoneal membrane the 
reflection coefficient for glucose is 0.03.  Although aquaporins make up a small proportion of the 
peritoneal membrane area the reflection coefficient for glucose across aquaporins is much higher 
and aquaporin-mediated free water transfer makes up a significant (about 50%) contribution to total 
ultrafiltration.  
 
1.2 Changes in membrane structure and function during PD therapy 
1.2(i) Histology 
Histologically the peritoneum consists of a mesothelial cell layer and the underlying tissues. 
Structural changes develop in the peritoneal membrane during time on PD. Williams et al (2002) 
demonstrated that there is progressive thickening of the submesothelial fibrous level secondary to 
uraemia and the use of peritoneal dialysis . Non-uraemic patients had a peritoneal thickness of 
50μm; this increased to 140μm with uraemia (without peritoneal dialysis) and over 700μm in 
patients who have been on peritoneal dialysis for more than 7 years (Williams et al., 2002). Fibrin 
deposition is seen with large proliferative fibroblasts (Honda and Oda, 2005). There is also an 
increase in the surface area of peritoneal blood vessels (Numata et al., 2003) and a vasculopathy 
(Sherif et al., 2006) which is similar to that seen in diabetes. These structural changes have 
functional implications: in a series of papers Davies demonstrated that there are longitudinal 
changes in membrane function with time on PD and particularly with cumulative glucose exposure 
(Davies et al., 1996; Davies, 2004; Davies et al., 2001); this was also seen in the EAPOS cohort (Davies 
et al., 2005). Increasing solute transport status, with resultant loss of ultrafiltration capacity, is a 
prominent cause of technique failure (Kawaguchi et al., 1997), (Heimbürger et al., 1990) and 
correlates with blood vessel area (Numata et al., 2003). The structural changes may also render the 
vessel more permeable to macromolecules; permeability to β2microglobulin also correlates with 
blood vessel area (Numata et al., 2003). Together these structural changes are termed peritoneal 
sclerosis. Peritoneal sclerosis does not cause abdominal symptoms; the impact on the patient is due 
to the loss of dialysis adequacy as the structural change of peritoneal membrane affects function.  
Epithelial to mesenchymal transition: One of the key histological changes is the epithelial to 
mesenchymal transition of the cells forming the mesothelial cell layer. This may be the first step in 
peritoneal damage. Cultures of mesothelial cells derived from peritoneal effluent can take an 
epithelioid, transitional or fibroblast-like form and the pattern observed varies with the time on PD 
(López-Cabrera et al., 2006; Yáñez-Mó et al., 2003). Within the first two years on PD, before the 
development of vasculopathy and often before much submesothelial thickening has occurred, 
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submesothelial cells are present in peritoneal biopsies which express both epithelial (cytokeratin) 
and mesothelial (α-smooth muscle actin) markers. Combined with loss of the mesothelium this is 
suggestive of epithelial-to-mesenchymal transition (EMT) (Del Peso et al., 2008). The process of EMT 
was reviewed by Aroeira et al; during EMT, peritoneal mesothelial cells lose tight junctions, adherent 
junctions, desmosomes and cellular polarity. The cell cytoskeleton is reorganised and the cell takes 
on mesenchymal morphology and expresses mesenchymal markers. There is degradation of the 
basement membrane and migration of cells into the interstitium (Aroeira et al., 2007). In a study of 
peritoneal biopsies the presence of myofibroblasts, positive for the mesenchymal marker α smooth 
muscle actin (α-SMA), was noted in biopsies from peritoneal dialysis patients. In addition modified 
mesothelial cells were seen, also expressing α-SMA, which suggests the source of the myofibroblasts 
was the mesothelium (Jiménez-Heffernan et al., 2004). EMT is recognised as part of the pathology in 
renal fibrosis, where TGF-β is thought to be an important mediator (Liu, 2004). Using adenovirus-
mediated transfer of TGF-1β to the rodent peritoneum it has been shown that peritoneal fibrosis 
and EMT can be induced (Margetts et al., 2005). There are likely to be multiple upstream and 
downstream mediators involved in this process – for example, although advanced glycosylation end-
products (AGE) are implicated, blockade of the AGE receptor only partly reduces peritoneal fibrosis 
in a uraemic rat model (De Vriese et al., 2006). Methylglyoxal, a glucose degradation product found 
in the dialysate, can also induce EMT (Hirahara et al., 2009), but it is not clear whether this is via 
advanced glycosylation end-product (AGE)-mediated activation of the AGE receptor, or via a direct 
oxidant action. Other candidate factors involved in the causation of EMT include angiotensin II, 
fibroblast growth factor and connective tissue growth factor (CTGF) (Liu, 2010). 
The precise molecular pathways that mediate EMT are the subject of investigation and are likely to 
be multiple. For example, smad3 knock-out mice were protected from fibrosis and angiogenesis 
induced by TGF-β, but an attenuated EMT was still observed, suggesting a parallel pathway not 
involving smad3 (Patel et al., 2010). TGF-β may also act via smad2, Notch (Zhu et al., 2010) and RhoA 
(Liu, 2004). Other pathways, such as the integrin and β-catenin signalling pathways may also be 
important (Liu, 2010). In the renal tubule cell model, production of matrix metalloproteases (MMP) 
is necessary for EMT to occur (Cheng et al., 2006) and inhibition of MMP2 had a beneficial effect on 
fibrosis and angiogenesis in a chlorhexidine-induced peritonitis model (Ro et al., 2007). Matrix 
metalloproteases may act by disruption of the basement membrane, permitting cell migration and 
invasion of the interstitium. 
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1.2(ii) Encapsulating peritoneal sclerosis (EPS) 
EPS is an uncommon but devastating complication of long term PD in which there is massive 
deposition of fibrin on the surface of the bowel, forming a thick encasing layer. The incidence 
increases with time on PD (Maruyama and Nakayama, 2008) and hence much of the literature 
originates from Japan, where there is a large cohort of long term PD patients. The clinical 
consequences are severe with the development of bowel obstruction associated with vomiting, 
ascites and abdominal pain. Malnutrition and septicaemia may lead to death. Total parenteral 
nutrition may be required; surgical release of bowel from the fibrotic cocoon is technically highly 
demanding and is successful only in specialist hands (de Freitas et al., 2008; Kawanishi et al., 2008). 
Whether EPS represents an extension of the sclerotic process seen in long term peritoneal dialysis, 
or whether it is a separate entity, has been debated (Nakayama et al., 2005; Garosi et al., 2006). It is 
not unique to peritoneal dialysis patients, being associated with the use of practolol (Eltringham et 
al., 1977), intra-peritoneal contamination with chlorhexidine (Lo et al., 1991) and is seen in patients 
with chronic ascites (Mekeel et al., 2009). The frequently seen changes of peritoneal sclerosis and 
EMT seen in most long term PD patients fortunately do not usually progress to EPS and it is unclear 
what triggers some patients to develop the severe, symptomatic fibrosis of EPS. Honda and Oda 
proposed a “two-hit” model, in which the abnormal peritoneum post-long term PD undergoes a 
second, inflammatory, insult which triggers EPS. They suggest that the severity of the second insult 
required to cause EPS would vary depending on the level of chronic damage which had already 
occurred (Honda and Oda, 2005).  
The source of fibrin may be the abnormal blood vessels seen in the peritoneum, but it is not clear 
how closely the processes of neoangiogenesis and fibrosis are linked. Margetts et al were able to 
reduce fibrosis (using the TGF-β inhibitor decorin) and angiogenesis (using angiostatin) selectively 
(Margetts et al., 2002). The cessation of PD itself aids fibrin deposition as there is no longer wash-out 
of fibrin by the process of dialysis. This has led some to advocate continued peritoneal lavage after 
change in renal replacement modality to attempt to reduce the risk of EPS (Yamamoto et al., 2010); 
there are no randomised trials and the risk of peritonitis is a concern. 
There are currently no validated screening methods to identify which patients will develop EPS, 
although a number of risk markers (such as very severe peritonitis and duration of PD) are 
recognised (Yamamoto et al., 2005). The overall incidence of EPS in PD patients is low (1.8 per 1000 
patient years in the Australian data (Johnson et al., 2010) and 2.5% of patients in the Japanese EPS 
Registry (Kawanishi and Moriishi, 2005)), but after 8-10 years of peritoneal dialysis as many as 20% 
(Brown et al., 2009a; Brown et al., 2009b) of patients may develop EPS. The incidence of EPS in the 
Japanese data after 3, 5, 8, 15 and longer than 15 years on PD was 0%, 0.7%, 5.9%, 8.6% and 17.2%, 
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demonstrating the effect of PD duration. EPS frequently manifests clinically after change of renal 
replacement modality – whether to haemodialysis or, perhaps increasingly, post transplantation 
(Fieren et al., 2007; Korte et al., 2007). Early elective modality change remains controversial: 
haemodialysis is not possible in all patients, and not all countries offer both peritoneal and 
haemodialysis due to resource constraints. Changing to haemodialysis after a set period of PD is not 
advocated by the ISPD for all patients (Brown et al., 2009a) as some, particularly the elderly and 
those not suitable for transplantation, may be better remaining on PD. Conversely, a young patient 
who has chosen PD to accommodate work commitments may be reluctant to change dialysis 
modality despite an increasing risk of EPS – yet there is limited information available which would 
allow assessment of individual EPS risk and tailored advice. 
EPS is a serious condition. The mortality as well as the incidence increases with the preceding PD 
duration; in the Japanese registry no patient who had performed PD for less than five years died of 
EPS but after eight years on PD those patients who developed EPS had a mortality of 8.3%, 
increasing to 28.6% when EPS followed ten years of PD, 61.5% after fifteen years and 100% if more 
than fifteen years of PD had preceded EPS. The Pan-Thames group found 53% of 111 EPS patients 
died (again risk of death was related to duration of PD) (Balasubramaniam et al., 2009). EPS can be a 
particularly bitter blow post transplantation. In a recent large study of all (1241) transplanted PD 
patients in the Netherlands (Korte et al., 2011), the incidence of EPS was only 3% but nearly half of 
these patients died during the follow-up period (compared to 16% of non-EPS transplant patients).  
 
1.2(iii) Ultrafiltration failure and loss of dialysis adequacy 
PD patients can experience failure of dialysis technique after a variable period on PD, so that even 
increasing the amounts of dialysis fluid used and optimising the timing of exchanges does not confer 
adequate clearance of solutes, salt and water. Loss of ultrafiltration (along with peritonitis) is one of 
the leading causes of technique failure. Serial PET results can give some warning of loss of dialysis 
adequacy, which may be impaired small solute clearance or more frequently loss of ultrafiltration, 
facilitating timely modality change before significant symptoms develop. The current definition of 
ultrafiltration failure is less than 400mls ultrafiltration from a four hour dwell with 3.86% glucose 
(Mujais et al., 2000). This phenomenon has been considered to have four possible underlying 
mechanisms which reduce the net transfer of fluid from patient to dialysate (Krediet et al., 2000): 
1.  A large vascular surface area – this results in a high transport state and rapid loss of the 
osmotic gradient for fluid transfer 
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2. A decreased osmotic conductance to glucose. The osmotic conductance is related to the 
hydraulic permeability of the membrane, the surface area and the reflection coefficient for 
glucose. It would be expected to decrease with aquaporin loss or membrane fibrosis. 
3. Increased re-absorption of fluid via lymphatic channels 
4. Small peritoneal area – rare, and could be caused, for example, by adhesions 
When a standard peritoneal permeability analysis is performed on patients who have ultrafiltration 
failure the sodium sieving is lost and the reflection coefficient is reduced, suggesting that aquaporin 
dysfunction may be involved in ultrafiltration failure (Smit et al., 2004). Other factors reducing 
ultrafiltration are a high MTAC (mass transfer area coefficient, the maximal theoretical diffusive 
clearance of a substance at t=0) with rapid loss of the osmotic gradient for absorption and high 
effective lymphatic absorption rate. A high MTAC for creatinine and urea is associated with a high 
MTAC for glucose and rapid dissipation of the osmotic gradient. However La Milia et al found 
reduction of ultrafiltration was present even in the early stages of a dwell (La Milia et al., 2007). This 
would not be expected if the structural change was predominantly neo-vascularisation leading to 
increased small solute transfer rate, since early in the dwell there would be increased ultrafiltration. 
The incidence of ultrafiltration failure increases with increasing duration of PD but lymphatic re-
absorption has not been shown to increase consistently with duration of PD (Michels et al., 2004), 
making it unlikely that increased lymphatic resorption is the major factor. Analysis of ultrafiltration 
in long term (>5 years) patients by Parikova et al showed a low total ultrafiltrate volume and 
reduced free water transport. The osmotic conductance to glucose was reduced in this group, 
without any change in the reflection coefficient (Parikova et al., 2006). Modelling by Rippe et al 
(Rippe and Venturoli, 2007) has shown how an increase in fibrosis in the interstitium can lead to 
these changes in membrane permeability: diffusion is related to the square of pore size but 
convective transport is related to pore size to the power four. A decrease in the interstitium pore 
size due to fibrosis thus affects small solute diffusive movement less than convective movement. 
It appears that loss of ultrafiltration is a complex process, sometimes related to an increase in 
membrane transport status, but the underlying pathology may differ from one patient to another 
and different structural changes such as fibrosis, neo-angiogenesis or loss of aquaporin function may 
be responsible. Hence clinical markers alone may not be sufficient to predict either the timing of 
technique failure or the later development of EPS. It is possible that a biochemical marker which 
predicted incipient ultrafiltration failure might also predict future EPS, since some aspects of the 
pathology are similar. However it is important to note that patients with poor ultrafiltration may be 
particularly heavily exposed to high dialysate glucose levels and large dialysate volumes and that 
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these factors may predispose to both worsening membrane function and also to EPS after the 
cessation of PD. 
 
1.2(iv) Predicting EPS risk and technique failure 
For the above reasons, a clinical, radiological or biochemical screening tool which would aid the 
clinical decision to change dialysis modality could be of great value. However, at present there are 
no screening tools available to clinicians. There are potential problems with the use of peritoneal 
biopsy and CT scanning has not been validated as a screening tool. Although clinical features are 
useful, there are no factors which can be used to reliably predict EPS in the individual patient, as 
discussed below. 
Biopsy: As well as being an invasive procedure, biopsy findings do not differentiate between 
asymptomatic PD patients and EPS patients. When biopsy specimens from 12 EPS patients were 
compared with those of non-EPS patients, perivascular bleeding, capillary angiogenesis, 
inflammatory mononuclear cells and swollen, proliferating fibroblasts were seen in both groups 
(Honda et al., 2003). Immunohistochemical markers of peritoneal sclerosis such as α-smooth muscle 
actin (α-SMA), fibroblast growth factor and macrophage inhibitory factor were also investigated. The 
expression of these markers was more prominent in the EPS patients, but all the markers could be 
found in the non-EPS group. Fibrosis is a patchy process and biopsy of a limited region of parietal 
peritoneum may not be representative of the visceral peritoneum. It is therefore difficult to 
distinguish EPS from uncomplicated peritoneal sclerosis by biopsy alone. 
Radiology: It is not currently known whether radiological screening by CT scanning can predict 
incipient EPS and facilitate timely modality change. Tarzi et al (Tarzi et al., 2008) examined the role 
of CT scans in the diagnosis of EPS, using a scoring system to assess CT features of EPS such as 
peritoneal thickening, peritoneal calcification, bowel wall thickening, bowel dilatation and bowel 
tethering. CT was found to be a useful adjunct in the diagnosis of EPS, with good inter-observer 
variability between radiologists. Other imaging modalities such as MRI (Hüser et al., 2006) and cine 
MRI (Wright et al., 2011), fluorodeoxyglucose positron emission tomography (Tarzi et al., 2006) and 
contrast studies of the small bowel (Hur et al., 2004) have been used to image EPS patients and PD 
patients but are much less readily available. CT scanning is the imaging modality of choice in most PD 
units when EPS is suspected on clinical grounds. However it was noted by Tarzi et al that many of the 
patients with a firm diagnosis of EPS had had CT scans within the last year which did not show any 
changes. It is therefore important to examine the issue of whether CT screening for EPS, which is 
widely practised in PD units, has any basis by examining a larger group of pre-diagnostic CT scans.  
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Clinical features: little is known about symptoms experienced by patients on peritoneal dialysis. 
Available evidence, such as that from the NECOSAD population (Thong et al., 2009; Ring et al., 2000) 
suggests that physical symptoms are common and do not always correlate with expected clinical 
variables. The Dialysis Symptoms Index (DSI) has been used in a study of haemodialysis patient 
symptoms (Weisbord et al., 2005) and it was demonstrated that the format used (a Likert scale 
where 1= “not at all bothersome” and 5= “bothers very much”) showed good test/re-test 
repeatability (Weisbord et al., 2004). A similar set of symptoms was used in the MDRD cross-
sectional symptoms survey (Rocco et al., 1997), although the emphasis was perhaps more firmly on 
physical symptoms.  To establish the frequency of physical symptoms in our PD population we 
developed a modified version of the DSI (see Appendix A), which had a greater emphasis on 
abdominal symptoms. Each symptom was scored for frequency and severity. Ethical approval was 
obtained and questionnaires were administered at routine PD clinic visits by the peritoneal dialysis 
nursing team.  
The purpose was to establish the frequency of symptoms in the peritoneal dialysis population and to 
determine whether abdominal symptoms are frequent in stable peritoneal dialysis patients. Clearly 
if abdominal symptoms are very common it is unlikely that the presence of minor abdominal 
symptoms could be used as a risk marker for future EPS. We found that abdominal symptoms were 
not infrequent in stable PD patients, but not usually severe (data presented at EuroPD 2009, 
Strasbourg; see Appendix C); thus monitoring the patient population for new onset abdominal 
discomfort, distension, constipation and loss of appetite may at least provide an early warning of 
more severe symptoms. However even if only mild symptoms have become apparent in a stable PD 
patient symptomatic EPS might occur later, after cessation of PD; more marked abdominal 
symptoms may be a late warning sign and therefore of little use as a screening tool. 
Other clinical data such as membrane functional changes - ultrafiltration failure and high membrane 
transporter status - may correlate with symptoms and relate to technique failure, but have not 
always successfully predicted which patients will develop EPS. The risk of EPS was found to be high 
(50%) in a group of patients who continued on PD for more than three years after a diagnosis of 
ultrafiltration failure (Sampimon et al., 2010a) (in general this would not be usual clinical practice). 
The membrane transport characteristics of this group of patients with ultrafiltration failure were 
studied in detail and the only potential marker for future EPS was a low effective lymphatic 
absorption rate. This test requires the use of an intra-peritoneal volume marker and is not currently 
part of routine peritoneal membrane assessment. The Stoke group noted an early disproportionate 
decrease in ultrafiltration capacity, with only a later increase in dialysate to plasma creatinine ratios, 
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in nine pre-EPS patients and hypothesise that this pattern of change in peritoneal function is due to 
fibrosis and hence may predict EPS (Lambie et al., 2010). 
 
The current lack of well-defined screening tools and predictors of EPS has prompted interest in a 
biochemical marker of EPS. In addition, finding a biochemical marker for EPS risk may help elucidate 
the pathogenesis of this condition and hence lead to a method of preventing or treating EPS in the 
future. 
 
1.3 Potential causative factors for changes in peritoneal membrane function 
and EPS 
1.3(i) Glucose 
One of the most important factors in the development of peritoneal fibrosis and vasculopathy is 
likely to be the effect of chronic exposure to the high glucose concentrations found in dialysate. 
Historically glucose has been used as the osmotic agent to promote ultrafiltration of fluid into the 
dialysate. Data from the European APD Outcomes Study showed that patients with greater exposure 
to glucose experienced more rapid changes in membrane transport function and decline in 
ultrafiltration capacity (Davies et al., 2005). Dialysate is heat treated to sterilise it and this process 
generates glucose degradation products (GDPs) such as methylglyoxal and 3-deoxyglucosone. These 
reactive carbonyl compounds may themselves be toxic to the peritoneum as well as mediating the 
production of advanced glycosylation end-products (AGEs). In a rat model the GDP methylglyoxal 
was shown to increase the formation of matrix metalloprotease (MMP), collagen IV and vascular 
endothelial growth factor (VEGF) (Hirahara et al., 2009). High concentrations of methylglyoxal even 
induced the formation of an abdominal cocoon, the key feature of EPS. Although the concentrations 
required were higher (20mmol) than those typically found in PD fluid (range 2-33µmol), the duration 
of exposure was much shorter. Intraperitoneal N-acetyl cysteine acts to prevent the formation of 
reactive oxygen species by GDPs and alleviates the increases in TGF-β, VEGF and collagen I 
production caused by conventional dialysate (Noh et al., 2006). 
AGEs are formed by non-enzymatic glycosylation of proteins; a reducing sugar condenses with a free 
amino acid to form a Schiff base. Rearrangements produce a stable ketamine called an Amadori 
adduct. Dehydration and fragmentation then result in the formation of stable covalent adducts; 
these are AGEs. Rapid AGE formation occurs if a protein reacts with a glucose auto-oxidation 
product such as methylglyoxal (Mandl-Weber et al., 2001), but high glucose concentrations alone 
can result in the accumulation of AGEs. AGE are known to be formed in dialysate (Lamb et al., 1995) 
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and are found deposited in the abnormal microvasculature of the peritoneum. This deposition is 
more marked in patients with low ultrafiltration (Honda et al., 1999). This may be due to the 
increased amounts of glucose exposure needed to achieve adequate ultrafiltration in these patients, 
but it seems possible that AGE are involved in the generation of fibrosis and hence are causative in 
the development of ultrafiltration failure. 
Further evidence suggests that AGEs are important in peritoneal fibrosis; de Vriese et al showed that 
in uraemic (sub-total nephrectomised) rats there were high levels of AGE and the AGE receptor 
RAGE. Peritoneal fibrosis had developed by the time the rats were sacrificed at 6 weeks. 
Histologically, uraemic rats had developed EMT, with co-staining of cytokeratin and alpha SMA seen 
in the submesothelial layer; these changes were reduced if an anti-RAGE antibody was administered 
(De Vriese et al., 2006). Anti-RAGE antibody also partially blocked the uraemic up-regulation of TGF-
β. AGE also promote neo-angiogenesis via the release of VEGF from endothelial cells (Boulanger et 
al., 2007). 
Glucose metabolism via the polyol pathway and by glycolysis generates reduced nicotinamide 
adenine dinucleotide (NADH) and increases the NADH/NAD+ ratio (the ratio of reduced to oxidised 
nicotinamide adenine dinucleotide). This mimics cellular ischaemia (pseudohypoxia) and prompts 
angiogenesis (van Westrhenen et al., 2008).  Lactate buffer in the dialysate also increases flux via the 
polyol pathway since the conversion both of pyruvate to lactate and NADH to NAD+ are reduced. 
Glucose induces the pro-fibrotic mediator TGF-β and the chemokine MCP-1 in mesothelial cells, 
possibly by the induction of aldose reductase and the intracellular accumulation of sorbitol (Wong et 
al., 2003). This pathway is implicated in the generation of diabetic complications and the 
vasculopathy seen in the peritoneum resembles the pathological changes of diabetic vasculopathy.  
 
1.3(ii) Lactate and other causes of poor dialysate biocompatibility 
Standard dialysate bags have an acidic pH and contain lactate as a buffer; both of these factors may 
cause damage to the peritoneum and more modern solutions have utilised a pyruvate buffer and a 
more physiological pH (van Westrhenen et al., 2008; Chan and Yung, 2007). There is evidence that 
more biocompatible solutions may have benefits in terms markers of inflammation in the dialysate 
and systemic circulation: Pajek et al used a randomised cross-over design to investigate the effects 
of changing between “conventional” dianeal and the more biocompatible physioneal. They found 
increased mesothelial cell HLA expression in the physioneal group, which they hypothesise is a 
marker of mesothelial cell well-being. Ca 125, which is a marker of mesothelial cell mass, was found 
at higher levels in the dialysate using physioneal and dialysate IL-6 levels were lower. No differences 
were found in the serum levels of CRP or IL-6, which may reflect the fact that there are many other 
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factors driving inflammation in dialysis patients – uraemia, infection and carbonyl stress, for example 
(Pajek et al., 2008). Clinical studies show a similar D/P creatinine with the conventional and newer 
fluids (Choi et al.; Fang et al.) but ultrafiltration is sometimes less. Where bicarbonate is used with 
pyruvate as a buffer this would be expected because bicarbonate has a lower reflection coefficient 
than lactate, reducing the effective osmolarity. Inflow pain is consistently less. There is some 
evidence that peritoneal immune function is improved (Libetta et al., 2011), and one single centre 
study has seen a reduction in peritonitis rates (Ahmad et al., 2006); this was however not confirmed 
in the Euro-Balance study (Williams et al., 2004), a multicentre cross-over trial. 
 
1.3(iii) Uraemia 
Even if PD is never used, uraemia itself is associated with thickening of the mesothelial zone. This 
was demonstrated by studies of peritoneal biopsies (Williams et al., 2002); there is also a 
vasculopathy seen in association with uraemia. Chronic uraemia alters peritoneal permeability. This 
may occur due to the increased carbonyl stress associated with uraemia (Miyata et al., 2000) and 
alterations in nitric oxide synthase (NOS) expression (Combet et al., 2001). 
 
1.3(iv) Infection 
The role of infection – peritonitis – in the development of peritoneal damage and hence failure of 
peritoneal dialysis seems intuitive. However systematic review of available RCTs by Wiggins et al 
(Wiggins et al., 2007) did not find evidence that repeated episodes of peritonitis had a measurable 
impact on mortality. Nor is there a higher frequency of peritonitis in patients who develop EPS than 
in those who do not (Johnson et al., 2010). In fact many EPS patients have no history at all of 
peritonitis (Johnson et al., 2010; Brown et al., 2009b; Balasubramaniam et al., 2009). This may be 
because EPS is associated with a long duration of PD and those patients who repeatedly develop 
peritonitis may be withdrawn from PD at an earlier stage. Although EPS may not be associated with 
a high total number of peritonitis episodes, in an individual patient an episode of peritonitis may 
accelerate changes in peritoneal membrane structure. Peritonitis triggers the release of 
inflammatory cytokines such as interleukin 1-β (IL-β) and tumour necrosis factor α (TNFα). This 
increases the production of TGF-β by mesothelial cells above the basal level induced by chronic 
dialysate exposure (Kang et al., 1999). If peritonitis is recurrent, levels of cytokines are higher at each 
subsequent infection, with a sustained alteration in peritoneal cytokine regulation (Fielding et al., 
2008). Certain pathogens are regarded as both difficult to treat and more likely to lead to technique 
failure – fungi in particular (Lui et al., 2007). Gram negative organisms are also associated with 
increased risk of adverse outcome (Szeto and Chow, 2007). The duration of unresolving peritonitis 
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seems to be the key factor, with white cell count and CRP at 72 hours post onset of peritonitis being 
predictors of adverse outcomes (Moon et al., 2008). 
 
1.4(v) Angiotensin 
The angiotensin system is well established in the pathogenesis of fibrosis in the renal and cardiac 
systems (Kim et al., 2011; Kagami, 2011; Shahbaz et al., 2010).  
The use of angiotensin blockade to modify the progression of peritoneal membrane changes has 
been investigated by several groups. Nakamoto et al used olmesartan in a rat model of peritoneal 
fibrosis, and found that animals which had olmesartan added to an acidic dialysate did not develop 
the peritoneal inflammation and fibrosis seen in control rats (Nakamoto et al., 2008). Similarly Chun-
Yen Ke et al showed that aliskiren reduced peritoneal fibrosis and TGF-β production in a rat model of 
chlorhexidine induced peritoneal fibrosis (Ke et al., 2010). Angiotensin was shown by Chang et al to 
induce EMT in rat peritoneal mesothelial cells, an effect which could be attenuated by either 
losartan (an angiotensin receptor blocker) or NADPH oxidase inhibitors (Chang et al., 2011). This 
suggests that the effects of angiotensin may be mediated through the production of reactive oxygen 
species. Noh et al also found that either anti-oxidants or losartan reduced peritoneal membrane 
thickening, TGF-β production and VEGF production in a rat model of peritoneal dialysis (Noh et al., 
2006). The same group found that human peritoneal cells express all the components of the renin-
angiotensin system and application of angiotensin II increases the expression of TGF-β, fibronectin 
and cellular reactive oxygen species (Noh et al., 2005). Inhibition of oxidant activity prevented the 
increase in TGF-β, as did losartan. Thus beneficial effects of angiotensin blockade may occur via 
attenuation of ROS production; however, an alternative mechanism of action was proposed by 
Sauter et al (Sauter et al., 2007), who found that angiotensin converting enzyme inhibitors and 
angiotensin receptor blockers reduced both the basal level of VEGF production from human 
mesothelial cells and the increase in VEGF production which occurs when peritoneal cells are 
stimulated by the inflammatory cytokines TNFα and interleukin-1α. Angiotensin may therefore be 
involved in the development of neoangiogenesis in the peritoneum as well as contributing to 
fibrosis. 
An observational study by Kolesnyk et al (Kolesnyk et al., 2009) looking at peritoneal membrane 
characteristics in the NECOSAD (Netherlands Cooperative Study on Adequacy of Diabetes) 
population found that the use of ACE inhibitors or angiotensin receptor blockers reduced the 
increase in dialysate/plasma creatinine ratio seen over time in peritoneal dialysis patients. 
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1.3(vii) Fluid flow stress 
During peritoneal dialysis there will be an impact of the dialysate fluid on the peritoneal cells which 
is related to fluid flow stress, generated by patient movements and peristalsis. Aoki et al (Aoki et al., 
2011a; Aoki et al., 2011b) investigated the response of rat peritoneal mesothelial cells grown under 
conditions of enhanced fluid shear stress (cultured in a rotary shaker). The cells cultured in the 
shaker showed mesothelial cell hypertrophy and hypercellularity, whatever the concentration of 
glucose in the culture medium, whereas those not exposed to fluid stress only developed 
mesothelial expansion when a high glucose (4500mg/L) culture solution was used. EMT was 
demonstrated in all cells cultured under the fluid stress conditions. The mechanism of mesothelial 
hyperplasia was thought to be via the inhibition of the p38 mitogen activated kinase (MAP kinase) 
pathway by fluid stress.  Of note, the authors hypothesised that the effects on the peritoneal MAP 
kinase system might be different under the influence of dynamic as compared to static cultures 
(where low glucose was associated with lower levels of MAP kinase activity). The effects of fluid flow 
stress on protein phosphatase activation were found to persist after reversion to static culture 
conditions; thus previous fluid flow stress might continue to pose a risk of EPS for some time after 
peritoneal dialysis has ceased. The role of fluid stress in the generation of peritoneal fibrosis may 
explain the observation that some patients with cirrhotic ascites develop encapsulating peritoneal 
sclerosis with no history of exposure to PD. 
 
 
1.4 Cytokine mediators of peritoneal fibrosis and vasculopathy 
A large number of cytokines have been suggested as potential mediators of the processes of 
peritoneal fibrosis and vasculopathy. Hence these cytokines are also candidates as biomarkers for 
the development of EPS and for technique failure. Some, such as vascular endothelial growth factor 
(VEGF), TGF-β and interleukin-6 (IL-6) are well known to have roles in angiogenesis and 
inflammation. IL-6, VEGF and cancer antigen 125 (ca125) have already been investigated as 
biomarkers of EPS (Sampimon et al., 2010b). It was found that VEGF did not predict EPS risk, but a 
combination of low levels of ca125 and high levels of IL-6 had a specificity of 89% for later EPS. 
However the sensitivity of this test was only 70%. The actions of TGF-β, VEGF and IL-6 within the 
peritoneum are first summarised and then the possible actions of less extensively investigated 
cytokines are discussed. 
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1.4(i) Transforming growth factor β (TGF-β) 
 TGF-β is established in the literature as a potential cause of peritoneal membrane changes. TGF-β is 
implicated in epithelial to mesenchymal transition (EMT), one of the earliest histological changes in 
the peritoneal membrane (see section 1.2). In addition it has been shown to have a role in fibrosis 
and angiogenesis. Using an adenovirus gene transfer model, Margetts et al showed that TGF-β 
causes submesothelial fibrosis, increased matrix production and increased VEGF production 
(Margetts et al., 2001). Part of the angiogenic response to TGF-β may be the hypoxic conditions in 
induced fibro-proliferative material. Sekiguchi et al showed that there is both direct TGF-β induced 
VEGF production and hypoxia induced VEGF; the hypoxia-induced pathway is mediated by hypoxia 
inducible factor (HIF)1α (Sekiguchi et al., 2011). 
TGF-β production by human peritoneal mesothelial cells is increased by high glucose concentrations 
and this then leads to an increase in fibronectin levels which can be blocked by anti-TGF-β antibodies 
(Medcalf et al., 2001). This shows that TGF-β is one possible link between glucose exposure and 
changes in the peritoneal membrane. Antagonism of the action of TGF-β by bone morphogenetic 
protein 7 (BMP-7) via smad-5 prevents EMT in a rodent model; antagonism of the action of TGF-β by 
blocking peptides also preserved mesothelial integrity in a mouse model of peritoneal sclerosis 
(Loureiro et al., 2011).  
It is difficult to demonstrate any association between the levels of TGF-β measured in spent 
dialysate and clinical outcomes. This may be because TGF-β is found in both an active and inactive 
form and total TGF-β levels do not reflect TGFβ activity adequately. Additionally there are three 
forms of TGF-β and two major families of receptors. TGF-β signalling is further modulated by the co-
factors betaglycan and endoglin (Santibañez et al., 2011), making assessment of overall activity 
levels more difficult. 
 
1.4(ii) Vascular endothelial growth factor (VEGF) 
Levels of VEGF are higher in the dialysate than in serum, suggesting local production (Selgas et al., 
2001). VEGF has been shown to be a mediator of angiogenesis and increased capillary density. 
Human umbilical vein endothelial cells (HuVEC) which are co-cultured with human peritoneal 
mesothelial cells (HPMC) or with supernatant from HPMC show capillary tube formation that can be 
prevented by anti-VEGF antibodies (Boulanger et al., 2007). Interestingly a genetic polymorphism of 
VEGF has been shown to have an impact on the longitudinal changes in peritoneal transport – 
patients with the genotype of note had high dialysate VEGF levels and a progressive increase in 
transport status (Szeto et al., 2004), indicating the clinical relevance of VEGF levels. In a rat model in 
which streptozocin was given to cause diabetes, an increase in peritoneal transport was seen which 
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was blocked by anti-VEGF antibodies. Anti-VEGF antibodies prevented the formation of new 
irregularly arranged dense vascular networks in the peritoneum and blocked an increase in 
membrane albumin permeability (De Vriese et al., 2001). This suggests that VEGF could mediate the 
changes in blood vessels secondary to the chronic exposure to high dialysate glucose concentrations. 
Glycated albumin also increases the amount of VEGF mRNA production by human peritoneal cells 
(Mandl-Weber et al., 2002), and activation of the mesothelial receptor for AGE by AGEs enhances 
VEGF release (Boulanger et al., 2007). There is evidence that VEGF production increases in 
mesothelial cells that have developed a non-epithelioid morphology as part of the process of EMT, 
thus providing a link between the fibrotic and the vasculopathic elements of peritoneal damage. The 
MTAC creatinine has been shown to correlate with VEGF levels (Aroeira et al., 2005), suggesting 
VEGF has a role in the development of an increased vascular surface area. Measurement of total 
VEGF levels could be complicated by the existence of multiple splice variants of VEGF, some of which 
may have anti-angiogenic effects (Woolard et al., 2004). 
 
1.4(iii) Interleukin-6 (IL-6) 
IL-6 has an established role as a mediator of both acute and chronic inflammation. In both peritoneal 
and haemodialysis patients systemic IL-6 levels are a risk factor for mortality (Pecoits-Filho et al., 
2002b). IL-6 levels rise as renal function deteriorates due to reduced renal excretion of IL-6; thus 
systemic IL-6 levels would be expected to rise with duration of peritoneal dialysis as the majority of 
patients experience a decrease in residual renal function over a long time period on PD. Raised IL-6 is 
also seen in fluid overload and congestive cardiac failure and thus again systemic IL-6 levels might be 
predicted to rise in long term PD patients who had developed ultrafiltration failure and might be 
raised in such patients without having a direct role in the development of peritoneal membrane 
failure. Dialysate IL-6 levels are theoretically more likely to be relevant; effluent IL-6 levels have been 
shown to reflect a chronic inflammatory state in the peritoneum as demonstrated by increased 
peritoneal permeability to macromolecules (Kawanishi et al., 2005). Both dialysate and plasma VEGF 
and IL-6 levels are associated with peritoneal transport rate (Pecoits-Filho et al., 2002a) and IL-6 can 
be found at higher levels in the dialysate than plasma, indicating local production may determine IL-
6 levels. IL-6 is produced by peritoneal mesothelial cells (Topley et al., 1993). 
A further role has been suggested for IL-6 in the switch from early phase leucocyte responses to 
chronic inflammation. IL-6 mediated responses are modified and regulated by the soluble IL-6 
receptor (sIL-6R). IL-6 binds sIL-6R and this permits it to induce a response from cells which would 
not normally respond to IL-6 alone. For example, IL-6 levels were shown to be high in dialysate early 
in the course of peritonitis associated with an influx of neutrophils. The levels of sIL-6R increased at 
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around 72 hours post diagnosis and this was followed by a change to increasing dialysate 
mononuclear cell levels and chemokine levels (Hurst et al., 2001). 
Mesothelial cells may not possess a cognate IL-6 receptor, since increased chemokine production in 
response to IL-6 by human peritoneal mesothelial cells was noted only in the presence of soluble IL-6 
receptor (Hurst et al., 2001).  
 
Cytokines of interest for further investigation: 
Other cytokines are currently less well characterised with respect to any role within the peritoneum. 
Our group has had an interest in the role of small inflammatory molecules called chemokines 
(chemotactic cytokines). These molecules have the ability to induce the migration of inflammatory 
cells into the peritoneum. When a multiplex antibody array was used to investigate the cytokine 
profile in dialysate, it was noted that some cytokines were present at particularly high levels (Ahmad 
et al., 2010). Chemokines selected as of potential interest as mediators of the changes in the 
peritoneum were monocyte chemotactic protein-1 (MCP-1), CCL15 (leukotactin), and CCL18 (also 
known as pulmonary and activation regulated cytokine, PARC). These chemokines were chosen on 
the basis of high levels in the dialysate and the known actions of these chemokines, which could 
plausibly be involved in the development of fibrotic or angiogenic changes in the peritoneal 
membrane. Angiogenin was also noted to be present in dialysate in the multiplex array; this small 
protein (as its name suggests) is important in angiogenesis. In the following sections the rationale for 
the investigation of each of these chemokines in the dialysate effluent and serum of PD patients is 
discussed. 
 
1.4 (iv) Monocyte Chemotactic Protein (MCP-1) 
MCP-1 is a chemokine with monocyte specificity which is readily detectable in the dialysate effluent 
(Malik et al., 2007). It has been shown that glucose – found at high levels in dialysate to permit 
ultrafiltration - increases MCP-1 mRNA expression in the supernatant of cell cultures of peritoneal 
mesothelial cells. This supernatant can be shown to have increased chemotactic ability for 
monocytes (Lee et al., 2001). In the presence of high concentrations of glucose, glucose is converted 
to sucrose by aldose reductase (the rate limiting step) and metabolised via the polyol pathway. The 
effect of hyperglycaemia in causing MCP-1 and TGF-β secretion can be blocked by the addition of 
aldose reductase inhibitors, suggesting that polyol pathway metabolites are important in the release 
of MCP-1 and TGF-β (Wong et al., 2003). Lactate (previously used as a buffer in dialysate) promotes 
the polyol pathway and potentiates the effects of glucose. Hyperosmolality may have a similar but 
smaller effect to induce MCP-1 (and TGF-β) (Wong et al., 2003).  
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Thus the high glucose levels found in dialysate might cause high levels of MCP-1 production. MCP-1 
could then trigger migration of circulating monocytes into the peritoneum and these may be a 
source of fibrogenic factors. In support of a role for MCP-1 in the pathogenesis of peritoneal 
membrane changes, Malik et al (work from Dr Tam’s group) found that dialysate MCP-1 correlated 
with the D/P creatinine, the duration of PD and the number of previous peritonitis episodes (Malik et 
al., 2007). Dialysate MCP-1 levels are higher than those of many other cytokines and are similar in 
magnitude to those seen in serum.  
MCP-1 is known to have a role in fibrogenesis, for example after lung injury (Moore et al., 2006) and 
may be important in fibrocyte regulation (Sakai et al., 2006; Wada et al., 2007). In a mouse model of 
chlorhexidine-induced peritoneal fibrosis, levels of MCP-1 mRNA were up-regulated. A p38 mitogen-
activated protein kinase (MAP kinase) inhibitor reduced both the degree of fibrosis and the 
expression of MCP-1 in a mouse model of peritoneal fibrosis (Kokubo et al., 2011). Similarly a MAP-
kinase inhibitor attenuated EMT in light-chain induced renal interstitial fibrosis as well as reducing 
MCP-1 secretion (Li et al., 2008); in this model EMT was independent of the action of TGF-β. 
MCP-1 is a 76 amino acid protein with a molecular weight of 8.7kDaltons in the non-glycosylated 
form, but is usually found glycosylated with a molecular weight of around 11kDa. As such it is 
somewhat smaller than albumin, and might potentially pass through the small pores. It could be 
argued that the high levels of MCP-1 in dialysate originate from the circulation, but other 
chemokines of a similar size do not have the same high dialysate concentrations as MCP-1. 
Additionally, mesothelial cells in culture have been shown to produce MCP-1 (Wong et al., 2003), 
implying that there is local production within the peritoneum. The question would be whether 
dialysate MCP-1 concentrations are determined by circulating MCP-1 levels or by the amount of 
MCP-1 produced locally. Dialysate [MCP-1] correlates strongly with transporter status (Malik et al., 
2007), which might confer a relationship with circulating MCP-1 levels. Alternatively, circulating 
[MCP-1] may be influenced by the same factors that predispose to peritoneal fibrosis and increase 
intraperitoneal MCP-1 levels. Further investigation of MCP-1 levels in dialysate and serum is 
indicated to establish whether the levels of MCP-1 found in the dialysate are determined by local 
production or by diffusion across the peritoneal membrane from the circulation, and whether MCP-1 
levels in the dialysate can be used to predict the later onset of EPS.  
 
1.4(v) CCL18 (Pulmonary and activation-regulated cytokine, PARC) 
CCL18 is a 7.8kDa chemokine produced by monocytes, macrophages and dendritic cells (Schutyser et 
al., 2005). The receptor is as yet uncharacterised but was thought probably to be a G-protein 
coupled protein. However in a recent paper by Chen et al (Chen et al., 2011) it was shown that 
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CCL18 binds to a membrane-associated phosphotidylinositol transfer protein called PITPNM3 on 
breast cancer cells. The localisation of CCL18 on the cell surface was abrogated when expression of 
PITPNM3 was blocked using a silencing RNA. Interestingly this potential receptor for CCL18 was not 
found on investigation of a gastric cancer cell line, so it is possible that CCL18 acts via a different 
membrane protein in non-breast cancer cells. CCL18 production can be up-regulated by bacterial 
compounds such as peptidoglycan and lipopolysaccharide (so CCL18 could perhaps be up-regulated 
by intraperitoneal infection). CCL18 is produced by alternatively activated macrophages and Th2 
pattern cytokines such as IL-4 (perhaps as part of a tissue repair response) increase CCL18 
production. Within germinal centres CCL18 has a role in the development of both the immune 
response and also tolerance induction. CCL18 recruits T lymphocytes (Hieshima et al., 1997). 
Monocytes stimulated by CCL18 differentiate into macrophages with the M2 phenotype (in the 
absence of IL-4). These cells have increased production of MCP-1 and other cytokines associated 
with inflammation and the attraction of further inflammatory cells, but also produce the anti-
inflammatory cytokine IL-10 (Schraufstatter et al., 2011). 
There is some evidence that CCL18 may be involved in angiogenesis; it is produced by early pro-
angiogenic cells which are involved in neovascularisation (Urbich et al., 2011) and is found at lower 
than normal levels in the placentas of women with HELLP syndrome (with endothelial and 
angiogenic dysfunction) than those with normal pregnancies (Tranquilli et al., 2007). 
CCL18 has been detected in numerous pathological conditions in humans (reviewed in (Schutyser et 
al., 2005)). For example, it is produced by alternatively activated macrophages and involved in 
chronic inflammation and fibrogenesis in chronic sinusitis (Peterson et al., 2012). In tumours CCL18 
can have both an immunoactivating effect (gastric cancer) or be associated with a tumour 
tolerogenic state with suppression of the host anti-tumour immune response (ovarian cancer). It is 
also found at high levels in response to staphylococcal infections such as septic arthritis.  
However in humans the best characterised and most relevant situation is the role of CCL18 in 
pulmonary fibrosis/systemic sclerosis. CCL18 acts via an extracellular signal-regulated kinase (ERK) 
mediated pathway to increase collagen mRNA production in adult lung and dermal fibroblast cells 
(Atamas et al., 2003). In a mouse lung model, Luzina et al showed that over-expression of CCL18 by 
an adenovirus vector resulted in T cell infiltration and accumulation of collagen. This increase in 
collagen was blocked if the T cell influx was abrogated, suggesting that the action of CCL18 was 
mediated via the T lymphocyte influx (Luzina et al., 2006a). CCL18 may have a direct effect on the 
fibroblast. CCL18 treated pulmonary fibroblasts do not show an increase in TGF-β protein or mRNA 
production and TGF-β blocking antibody does not prevent CCL18-mediated up-regulation of collagen 
production (Luzina et al., 2006b) suggesting CCL18 acts either downstream of TGF-β or via a separate 
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pathway. Interestingly, as well as the amount of CCL18 in broncho-alveolar lavage fluid, systemic 
serum levels of CCL18 have been shown to correlate with the activity of lung fibrosis in patients with 
systemic sclerosis (Kodera et al., 2005). Here it may be a marker of activated alveolar macrophages. 
Similarly plasma levels of CCL18 produced by glycolipid-laden Gaucher cells in the spleen can be 
used to monitor the response to treatment in Gaucher’s disease (Boot et al., 2004). This raises the 
possibility that serum/plasma levels of CCL18 may mirror the fibrosing process in the peritoneum. A 
serum or plasma marker of the fibrosing process would be of use for those patients who have 
transferred renal replacement modality (either to haemodialysis or transplantation) and who had 
symptoms suspicious of ongoing peritoneal fibrosis. 
Work from Dr Tam’s group suggests CCL18 is detectable in dialysate. CCL18 was measured in the 
dialysate of over 100 peritonitis patients and was found to correlate with duration of PD, membrane 
transport properties and glucose exposure (Ahmad et al., 2010). The number of patients who 
developed EPS was naturally small, and the role of CCL18 as a biomarker for future EPS requires 
further investigation in a larger group of patients. CCL18 mRNA production has been demonstrated 
in alternatively activated macrophages from human peritoneal effluent (Bellón et al., 2011); the 
same group detected CCL18 in the dialysate of 25 patients. Levels of CCL18 were highest in patients 
who went on to develop EPS, but again the number of patients was small (6 EPS, 19 non-EPS) (Bellón 
et al., 2011). It is not known whether mesothelial cells can produce CCL18, or indeed whether the 
majority of CCL18 detected in the dialysate effluent has entered from the circulation or been 
produced within the peritoneum. 
 
1.4(vi) CCL15 (MIP-1δ, leukotactin 1) 
CCL15 is also known as macrophage inhibitory protein-1δ (MIP-1δ) and leukotactin 1. It is a relatively 
novel (Youn et al., 1997) chemokine which has been shown to be involved in endothelial 
differentiation and angiogenesis (Hwang et al., 2004). Coupled with apparently high levels in an 
initial screen of dialysate using a multiplex antibody array for multiple cytokines (Dr Ahmad, data not 
published) this suggests it could be involved in angiogenesis within the peritoneum of PD patients.  
In addition CCL15 has an interesting pattern of activity as a chemoattractant. The 92 amino acid 
form is chemotactic for neutrophils (not a usual property for a CC chemokine). This 92 amino-acid 
form is then truncated by neutrophil cathespin G to produce a shortened (approximately 68 amino-
acids) form which is instead chemotactic for monocytes/dendritic cells/T lymphocytes, and which 
has far greater activity in the activation of lymphocytes (Richter et al., 2005; Forssmann et al., 2001). 
The shortened form is not detected in human serum or plasma and it is thought that the conversion 
process is a localised process (quantum proteolytic processing) occurring only in the presence of 
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activated neutrophils expressing proteases such as cathespin G or elastase; such a process would be 
expected to be limited by plasma-derived  inhibitors of neutrophil proteases. The shortened form is 
found in haemofiltrate (Forssmann et al., 2001), which has been exposed to activated neutrophils. 
Activation of CCL15 has also been demonstrated by matrix metalloproteases  (Starr et al., 2011) in 
human synovial fluid; the authors suggest that this is a mechanism by which monocytes may be 
selectively attracted into an inflamed joint. CCL15 could therefore be involved in the initial 
inflammatory response to dialysate exposure as a neutrophil chemoattractant. Local activation to 
the shortened form might then be involved in transition to a chronic inflammatory state involving 
monocyte influx. CCL15 induces the production of cytokines such as MCP-1 by monocytes (the 
human acute monocytic leukaemia cell line (THP-1) cell line) that might be involved in a more 
sustained, chronic inflammatory response (Lee et al., 2002). CCL15 levels (as measured by an assay 
detecting both the truncated and non-truncated forms) may be expected to be high in dialysis 
patients with ongoing chronic inflammation and in patients with an acute inflammatory process, but 
would not necessarily remain high once the later, fibrosing phase of disease was established.  
In humans CCL15 was found at high levels in the broncho-alveolar lavage (BAL) fluid of patients with 
sarcoidosis. CCL15 levels were high in those with a more advanced disease stage, at which time a 
high number of neutrophils is usually found in the BAL fluid, and high levels of CCL15 were 
associated with disease progression (Arakelyan et al., 2009). This is consistent with a role for CCL15 
in a disease known to cause human fibrosis, and also with the possibility that CCL15 is associated 
with the presence of neutrophils. Up-regulation of CCL15 is also seen in arthritis (Haringman et al., 
2006), being found in synovial tissue in patients with rheumatoid arthritis. CCL15 has been shown to 
induce increased expression of matrix metalloprotease-9 (MMP-9) from activated macrophages 
(Kwon et al., 2008); this may also be relevant given the role of MMPs in the initiation of EMT. There 
is no reference in the literature to the measurement of CCL15 in dialysate effluent. 
 
1.4(vii) Angiogenin 
Angiogenin is a 14.4kDa protein originally isolated from colon cancer cells (Fett et al., 1985). It is a 
potent angiogenic factor. It binds to α-actin on vascular endothelial cells. The angiogenin-actin 
complex can activate tissue plasminogen activator and hence start the process of generating 
collagenases to degrade the basement membrane and allow endothelial cells to migrate and form 
new blood vessels (Strydom, 1998). In these invading endothelial cells where there is a low cell 
density, a specific angiogenin receptor is expressed which facilitates endocytosis of angiogenin and 
transfer to the nucleus. This is necessary for endothelial proliferation. Angiogenin also causes arterial 
smooth muscle cell proliferation after binding to α-actinin-2 (Tello-Montoliu et al., 2006). Angiogenin 
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is essential for the action of fibroblast growth factor and VEGF on blood vessels (Kishimoto et al., 
2005); loss of proliferation induced by these factors was seen in an angiogenin knock-down model. 
In humans angiogenin is known to have a role in the pathogenesis of many tumours – for example 
lung cancer (Yuan et al., 2009) and breast cancer (Nilsson Åberg et al., 2011). It is found at increased 
levels in the serum of ALS patients (Cronin et al., 2006), and in the induced sputum of asthmatics 
(Kristan et al., 2009). Angiogenin may be a marker of endothelial damage, being found at high levels 
in patients with vascular disease (Lip and Blann, 2004). Interestingly angiogenin has been found at 
high levels in young patients with diabetes, and correlated with HbA1c and the degree of 
microvascular complications; reduction in glucose levels was associated with a fall in angiogenin 
levels (Chiarelli et al., 2002). This suggests that the high glucose levels of dialysis fluid could prompt 
neo-vascular development in the peritoneum via the action of angiogenin. However another study in 
type II diabetics found lower levels of angiogenin with increasing HbA1c (Siebert et al., 2010). 
In patients with EPS, tamoxifen has been used as a medical treatment (del Peso et al., 2003; Korte et 
al., 2010). It is thought to have beneficial effects on EMT, angiogenesis and fibrosis (Selgas et al., 
2006). Tamoxifen may act at least partly via blockade of the action of angiogenin (Nilsson et al., 
2010; Nilsson Åberg et al., 2011), although it may have other important effects mediated by other 
pathways.  
 
Summary  
It is likely that the structural changes in the peritoneal membrane are driven by an inflammatory, 
fibrotic and vasculogenic response to the presence of dialysis fluid within the peritoneum. The exact 
pathways involved are not yet fully defined in the literature and may well be multiple. Many factors 
may be damaging to the peritoneal membrane – glucose exposure, infection, uraemia, angiotensin 
system activation and mechanical stresses on the peritoneum have all been implicated. Epithelial to 
mesenchymal transition is an important step in the development of a thickened and denuded 
peritoneum. Once these changes have occurred over a long period of time on peritoneal dialysis, the 
patient is at risk of developing encapsulating peritoneal sclerosis, especially after the cessation of 
peritoneal dialysis. Currently this is an unpredictable event; the majority of long term peritoneal 
dialysis patients do not develop EPS. For those who do, however, it is a serious complication. The 
ability to assess EPS risk more accurately would be of great help to the clinician and patient, but CT 
based screening may not be reliable and requires investigation. There is great interest in the 
possibility of predictive biomarkers which could be measured in stable peritoneal dialysis patients. 
While IL-6, VEGF and TGF-β are already implicated in the inflammatory, angiogenic and fibrotic 
changes within the peritoneum, other cytokines are also found in the dialysate effluent and might be 
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potential biomarkers for the future development of EPS. Whether or not a cytokine is directly 
involved in the pathogenesis of EPS it may still be able to act as a biomarker if dialysate effluent 
concentrations are found to differ in patient who do and do not subsequently develop EPS. The 
advantage of measuring cytokine levels in the dialysate is that it is a non-invasive procedure, with 
dialysate samples readily available from PD patients.  
Cytokines such as CCL15 and MCP-1 could play a role in the progression of inflammation and 
recruitment of inflammatory cells. Angiogenin is a well-known promoter of neo-vascularisation in 
tumours and areas of hypoxia which might be involved in new vessel development in the membrane. 
CCL18 is a mediator of fibrosis; the development of thickening and fibrosis of the membrane is 
another key change in long term PD patients. Cytokines could therefore plausibly play a role in the 
development of membrane changes, but it is not known whether the quantities of these cytokines 
detected in the dialysate have any correlation with the present or future clinical features of the 
patient. It is also unclear whether cytokines are produced within the peritoneum or are diffusing into 
the dialysate from the circulation. In addition, levels of cytokines within the dialysate may not reflect 
the biological effect or activity of the cytokine in tissue; low levels of a cytokine in the dialysate 
effluent do not exclude an important role for the cytokine in the peritoneum, especially if there is 
evidence for local production of the cytokine by cells of the peritoneum. 
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CHAPTER 2: 
 AIMS OF THE STUDY AND HYPOTHESIS 
 
As part of the West London Prospective PD study, our group (Dr S Ahmad) has previously measured 
the levels of cytokines (CCL18, angiogenin, monocyte chemotactic protein-1 (MCP-1) and interleukin 
6 (IL-6)) in dialysate fluid and serum in a group of 106 patients. The number of patients with EPS in 
this group was small at that time and a larger group of patients have now developed the condition. 
This study further investigates the possibility that cytokines are mediators in the development of the 
long term peritoneal damage which is thought to lead to later EPS. 
 
Aim: assess whether cytokine levels correlate with clinical data and membrane function 
The first aim of the study is to investigate whether cytokines may have a role in the development of 
pathological changes in the peritoneal membrane. The work done by Dr Ahmad (Ahmad et al., 2010) 
and Dr Malik  (Malik et al., 2007) indicates that the cytokines CCL18 and MCP-1 are present in the 
dialysate at levels which correlate with clinically relevant data. CCL18 appeared to correlate with the 
D/P creatinine and glucose exposure in a group of 106 patients (Ahmad et al., 2010), while MCP-1 
correlated with the past peritonitis history in a group of 45 patients (Malik et al., 2007). Other 
cytokines which were shown by Dr Ahmad using a multiplex antibody array to be present in the 
dialysate at apparently high levels were angiogenin and CCL15. As discussed in the introduction, the 
known biological effects of MCP-1, CCL18, CCL15 and angiogenin means they are plausible 
candidates as mediators of peritoneal damage. IL-6 is well documented in the literature as important 
in inflammation both generally (Pecoits-Filho et al., 2003) and specifically within the peritoneum 
(Hurst et al., 2001).  
In this study the original West London prospective peritoneal dialysis study patient group has been 
extended and a further 45 baseline patient samples have been collected to be analysed together 
with the results of cytokine measurements made by Dr Ahmad in the original 106 patients. In 
addition, measurements of the chemokine CCL15 (leukotactin) (which has not previously been 
investigated in dialysate effluent) have been made on 126 of the patient samples. The aim is to 
discover whether the previously observed correlations still hold in the larger patient group and 
whether any new associations between cytokine levels and clinical results emerge. It is known from 
longitudinal studies of membrane function that factors such as fluid type, glucose exposure and 
residual renal function are important in technique survival; an association between high glucose 
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exposure, for example, and higher cytokine levels would suggest that the cytokine might potentially 
be involved in mediating the effect of high glucose levels on the peritoneum. 
 
Aim – establish the source of cytokines detected in the dialysate 
The second aim of the study is to establish whether cytokines are produced within the peritoneum 
or enter by passive diffusion from the circulation. Human peritoneal cells from used overnight 
dialysate have been collected and cultured. Cells have been stained for epithelial and mesenchymal 
markers to demonstrate typical features of mesothelial cells in culture. The culture medium has 
been analysed to assess whether there is evidence that peritoneal cells produce the cytokines of 
interest. Passive transfer of cytokines from the circulation might also determine dialysate levels of 
chemokines; in order to establish whether this could be the case the transfer of small proteins, of 
the same range of molecular weights as cytokines, from the circulation to the dialysate is 
investigated.  
 
Aim – assess the role of cytokines as biomarkers for later EPS 
The third aim of the study is to investigate whether cytokine levels can improve our ability to predict 
the onset of EPS. In clinical practice a method for identifying which patients are at higher risk of EPS 
is greatly needed.  There is now a larger group of patients in our database who have developed EPS 
after the cessation of PD. Cytokine levels measured while all the patients were stable on PD are 
analysed to discover if high dialysate levels of cytokines predict whether a patient will subsequently 
develop EPS. Serum cytokine levels in EPS patients who are no longer using peritoneal dialysis are 
also measured and compared with levels in non-EPS patients who have never used peritoneal 
dialysis to assess whether there is further evidence for a role of these molecules in the ongoing 
fibrotic pathology. 
Although a new biomarker would be of great potential clinical usefulness, it is important to be clear 
whether it actually represents an improvement over the available risk markers. There are well-
known clinical risk factors for EPS, the most secure being duration of dialysis. Patient demographics 
such as age (Johnson et al., 2010) have been significant risk factors in at least one study; markers of 
membrane damage such as raised D/P creatinine and loss of ultrafiltration are more consistent risk 
factors for later EPS. Hence clinical measurements are also investigated to determine whether 
patient demographics, dialysis history, adequacy data or peritoneal membrane function tests can be 
used to predict future EPS.  
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Aim – assess the roles of radiological screening for later EPS 
Computed tomography (CT) scans are used in some peritoneal dialysis units to screen for the future 
development of EPS. As discussed in the introduction (Tarzi et al., 2008; Vlijm et al., 2009), there is 
good evidence to show that CT scans are useful in the diagnosis of symptomatic EPS. However, the 
basis on which CT scans are used to establish the likelihood of future EPS in a current PD patient has 
not previously been investigated. Although CT is used in many PD units it requires validation and 
may not be an appropriate screening method.  
 
Hypothesis:  
 
Cytokines – MCP-1, CCL18, IL-6, CCL15 and angiogenin - are important in the process of peritoneal 
membrane damage. Peritoneal cells from dialysis patients produce these cytokines. Cytokine 
levels in dialysate and perhaps serum of peritoneal dialysis patients: 
1. will reflect clinically important measures of ongoing pathological processes in the 
peritoneal membrane and  
2. may predict adverse outcomes such as ultrafiltration failure and development of EPS 
Clinical and radiological findings may also aid prediction of clinical outcomes. 
 
Definitions 
EPS is defined clinically as a syndrome of persistent or recurrent bowel obstruction with vomiting, 
abdominal distension, abdominal pain and weight loss (Woodrow et al., 2009) in a patient with a 
history of long term peritoneal dialysis. This may be accompanied by evidence of inflammation such 
as raised CRP, fever and hypoalbuminaemia. The characteristic fibrous cocoon of EPS is seen at 
laparotomy only and the majority of our patients did not undergo surgical treatment. As well as the 
typical clinical picture, most EPS patients underwent CT scans showing the typical changes of EPS – 
peritoneal thickening, abnormal bowel pattern due to tethering, bowel dilatation, peritoneal 
calcification and fluid loculation. 
UFF is defined as either 
 less than 750mls of fluid removal in 24 hours - the target for fluid removal in the EAPOS trial 
(Brown et al., 2003) -  in a patient still on PD (measured as part of adequacy assessment) or 
 cessation of PD due to clinical fluid overload (resistant oedema requiring transfer to HD) 
Ultrafiltration capacity data is not available for all patients in the study and PET tests are performed 
in our institution on an annual basis. Hence a clinical definition must be included to avoid 
underestimating the number of patients with technique failure due to limited ultrafiltration. 
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CHAPTER 3:  
 
METHODS 
 
Prospective collection of clinical data and samples of serum/plasma and dialysate from PD patients 
has been undertaken as part of the West London PD study and this is continued in the extended 
patient group. Ethical approval was given for this study (Riverside Research Ethics Committee, 
Charing Cross Hospital; REC reference number 08/H0706/20). Patients are recruited when they 
attend the PD unit for a PET test; the prolonged nature of this visit allows time for informed written 
consent to be obtained. 
Clinical data and samples of serum/plasma from patients with established EPS, and from a control 
group of patients matched for age, sex, treatment modality (HD v. transplant) and duration of end 
stage renal failure that have never used peritoneal dialysis have also been collected. 
Overnight dialysate has been collected as a source of shed peritoneal cells for culture. 
 
3.1 Clinical data  
 
Demographics: age, sex, renal diagnosis, duration of dialysis 
Medication history and biochemistry results on day of sample 
Stoke co-morbidity score: (for symptom study patients) - this is a semi-quantitative co-morbidity 
score developed in the Stoke renal unit which incorporates seven disease domains: malignancy, 
ischaemic heart disease, peripheral vascular disease, left ventricular dysfunction, collagen vascular 
disease and other life-expectancy limiting pathology. Patients are scored from 0 to 2 where 0 = no 
co-morbidities, 1 = one or two co-morbidities and 2 = three or more co-morbidities. This scale has 
been shown to be predictive of mortality in PD patients independently of age, residual renal function 
and membrane function (Davies et al., 2002). 
 
Peritoneal dialysis history: dialysis modality (CAPD v. APD), glucose exposure (mmol/24 hour in the 
current PD prescription), peritonitis history, icodextrin use 
Adequacy data: kT/V, creatinine clearance, and residual renal function 
Membrane transport data: PET result and ultrafiltration volume 
Outcome post cessation of PD: EPS v. no EPS 
Ultrafiltration failure as the cause of PD cessation 
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3.2 Sample Collection 
 
3.2(i) Dialysate and serum samples for cytokine measurement 
For patients currently on peritoneal dialysis samples were taken at the time of PET which provides 
the opportunity for a standardised blood sample at the midpoint of the 4 hour dwell. Dialysate 
samples were taken from the fluid drained at the end of the PET test. The volume of this fluid was 
measured. The peritoneal appearance rate can then be calculated from the chemokine 
concentration and the dialysate volume; this is the quantity of the cytokine produced during the 4 
hour dwell. This permits comparison of results between patients using differing dwell volumes and 
durations. PET tests in our institution are performed annually and after an episode of peritonitis; 
samples were taken only when a PET test was performed routinely and at least six weeks after the 
last episode of peritonitis (since cytokine levels increase during peritonitis and for at least some 
weeks afterwards (Lai et al., 2000; Oymak et al., 2003)). The protocol used during a PET test includes 
patient movement to facilitate mixing of the dialysate within the abdomen, to aid collection of a 
representative sample (Zbylut et al., 1987). 
For patients on haemodialysis blood samples were taken from the dialysis lines after discarding any 
anticoagulant lock. Samples were taken prior to the initiation of dialysis as haemodialysis can cause a 
rise in the levels of cytokines due to exposure to bacterial products (Schindler et al., 1996) and 
components of the dialysis circuit (Pereira et al., 1995); alternatively some cytokine levels may fall 
post-dialysis session (Tarakçioğlu et al., 2003).  
For patients with a renal transplant blood samples were taken at the time of other blood samples at 
routine clinic visits. 
All samples were collected and placed onto ice then spun at 4°C and frozen (-20 to -80⁰C) within 2 
hours. 
Blood samples: serum in gold top vacutainer (contains a clot activator and gel for serum separation) 
  plasma in purple top vacutainer (contains EDTA, an anti-coagulant) 
Both spun at 3000rpm (1107g) at 4⁰C for 10 minutes and aliquoted for storage 
Dialysate samples were taken in plain (Universal) tubes and spun at 3000rpm (1107g) at 4⁰C for 15 
minutes, then aliquoted. 
 
3.2(ii) Samples for cell culture 
For collection of cells for culture the overnight dialysate bag was used. A 50ml aliquot of fluid was 
spun and stored and the remainder of the bag was hung in an incubator at 37°C for two hours to 
allow the cells to settle prior to cell collection. 
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3.3 Cytokine Assays 
3.3(i) ELISA technique 
All cytokines were measured using a sandwich ELISA technique which allows quantification of small 
amounts of antigen. The principle of this method is that the plate is coated with a “capture” 
antibody specific for the molecule of interest. The sample is added and binds to the coating of 
capture antibody in the well. After washing, a biotinylated detection antibody is then added which 
binds to the molecule of interest. Streptavidin (horseradish peroxidise) binds avidly to the biotin and 
the bound streptavidin then drives the colour change in the 3,3’,5,5’ tetramethylbenzidine substrate. 
 
 
 
The general protocol for MCP-1, CCL15, CCL18 and angiogenin is as follows: 
A 96-well ELISA plate is coated with 100µl to each well of the capture antibody in phosphate 
buffered saline (PBS) and refrigerated overnight at 4°C. It is washed and 300µl/well of blocking 
solution applied for one hour. On each wash the plate is rinsed three times with PBS/tween. The 
ELISA plate is kept on a rotary platform in between the applications of antibodies. All standards, 
samples and antibody solutions are mixed on the whirlimix before adding to the ELISA plate. A 
standard curve is constructed using a serial dilution technique. The block is washed off and 
100µl/well each of samples (diluted appropriately) and standard are applied to the plate in 
duplicate. After two hours the plate is washed and a detection antibody applied for two hours. The 
plate is washed and streptavidin (Invitrogen, Life Technologies, Paisley, UK) applied for twenty 
minutes. This is washed off and 3,3’,5,5’ tetramethylbenzidine (TMB), (Cambridge Bioscience, 
Cambridge, UK) substrate reagent added. Once a deep blue colour has developed in the high 
standard the reaction is stopped using 50µl of 2N sulphuric acid/well and the optical density 
measured at 450nm using a plate reader (Anthos Labtec, Wals, Austria). 
For dialysate samples the same diluent solution was used with the detection antibody, the standard 
curve and the sample dilution (see below). For serum and plasma samples solution S was used to 
make the standard and dilute the samples. 
Figure 1: “Sandwich” ELISA 
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The appropriate dilution for each cytokine and each type of sample was established using a series of 
dilutions to be as follows: 
 Serum Dialysate 
CCL15 1:20 1:10 
MCP-1 1:2 1:1 
CCL18 1:200 1:10 
Angiogenin 1:5000 1:50 
IL-6 1:1 1:10 
Table 1: Dilutions for serum and dialysate 
 
Samples from cell culture experiments were measured undiluted using solution S as the diluent for 
the standard curve. Antibodies were purchased from R&D Systems (Minneapolis, USA); the same 
antibody clones were used throughout the study. For IL-6 the quantities found in human serum are 
too low to measure using this technique and a high sensitivity Quantikine ELISA kit (R&D Systems) 
was used to measure the levels of IL-6 in both dialysate and serum. This uses the same basic 
technique, but is supplied with the plate pre-coated with the capture antibody and the necessary 
solutions pre-prepared. This ELISA uses a different colorimetric system, developing a violet colour 
and is therefore read at 490nm. The lower limit of detection of IL-6 using this kit (HS600B, R&D 
systems) is 0.156pg/ml. 
 
3.3(ii) Reagent preparation method for MCP-1, CCL15, CCL18 and angiogenin ELISAs. 
 
PBS (phosphate buffered saline)   g/L    
1. Sodium chloride NaCl                                8.0    
2. Potassium chloride KCl    0.2    
3. Disodium hydrogen phosphate Na2HPO4 2H2O 1.44    
4. Potassium dihydrogen phosphate KH2PO4  0.2     
 
BLOCKING SOLUTION 
1. PBS   200ml 
2. Sucrose  10g 
3. BSA   4g (bovine serum albumin) 
 
STOP SOLUTION 
10ml H2SO4 into 90mls of water   
 
WASH BUFFER (use within the same day) 
500µl of Tween 20 in 1000ml of PBS 
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DILUENT (0.1%BSA, 0.05% Tween 20 in tris-buffered saline pH 7.3) 
1. Water (Millipore)      500ml 
2. NaCl       4.4g 
3. Trisma base F.W.121.1 Sigma T-1503   1.2g 
    (Dissolve completely, and then add HCL until pH 7.3) 
4. BSA       0.5g 
5. Tween 20      0.25ml 
 
SOLUTION S (for dilution of serum samples and standards) 
1. PBS   95ml 
2. NaCl   5g 
3. BSA   1g 
4. Fetal Calf Serum 5ml (filtered and aliquoted in sterile tissue culture hood) 
 
Stock solution details and reconstitution protocols: 
MCP-1  
MCP-1 (standard) 279-MC, 10µg, R&D systems: Reconstitute with sterile Phosphate Buffered Saline 
(PBS) containing 0.1% Bovine Serum Albumin (BSA) to make a stock solution of 10µg/ml. 
MCP-1 (capture Ab) MAB679 500µg, R&D systems: Reconstitute with 1ml sterile PBS to give a stock 
antibody concentration of 500µg/ml. 
MCP-1 (detection Ab) BAF279, 50µg, R&D systems: Reconstitute with 1 ml sterile Tris-buffered saline 
pH 7.3 (20mmol Trizma base, 150mmol NaCl) containing 0.1% BSA. 
 
CCL18 
CCL18 (standard ) 394 - PA, 10µg, R&D systems: Reconstitute with sterile PBS containing at least 
0.1% BSA to make a stock solution of no less than 25µg/ml. Use 0.4ml of PBS with 0.2% BSA (0.2g 
BSA in 100mls of PBS) 
CCL18 (capture Ab) MAB394, 500µg, R&D systems: Reconstitute with 1 ml sterile PBS; the antibody 
concentration will be 500µg/ml. 
CCL18 (detection Ab) BAF394, 50µg, R&D systems: Reconstitute with 1ml sterile Tris-buffered saline 
pH 7.3 (20mmol Trizma base, 150mmol NaCl) containing 0.1% BSA to give antibody concentration of 
50µg/ml. 
 
CCL15 
CCL15 (standard) 363-MG-025, 25µg, R&D systems: Reconstitute with 1ml sterile PBS with 1% BSA to 
make a stock solution of 25µg/ml 
CCL15 (capture Ab) MAB363, 500µg, R&D systems: Reconstitute with 1ml sterile PBS; the antibody 
concentration is 500µg/ml 
CCL15 (detection Ab) BAF363, 50µg, R&D systems: Reconstitute with 1ml sterile Tris-buffered saline 
pH 7.3 (20mmol Trizma base, 150mmol NaCl) containing 0.1% BSA to give antibody concentration of 
50µg/ml. 
 
Angiogenin 
ANG (standard Ab) 265-AN-050, 50 ug, R&D systems: Reconstitute with 1 ml of sterile 0.1%BSA in 
PBS; the stock concentration is 50µg/ml 
ANG (capture Ab) MAB265, 500 ug, R&D systems: Reconstitute with 1 ml of sterile PBS to give a 
stock concentration of 500µg/ml. 
ANG (detection Ab) BAF265, 50 ug, R&D systems: Reconstitute with 1 ml of sterile 0.1% BSA in Tris-
buffered saline pH 7.3 (20mmol Trizma base, 150mmol NaCl); the stock concentration is 50 µg/ml. 
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3.3(iii) Calculation of cytokine levels 
The standard curve is plotted as corrected optical density (corrected OD) versus log [cytokine 
concentration] and the sample concentrations derived from the measured optical density. GraphPad 
Prism version 4 software (GraphPad Software, La Jolla, USA) was used to plot all standard curves. A 
typical standard curve is shown below: 
 
A typical Excel spreadsheet showing how the optical density (OD) readings are used to calculate the 
standard curve and the sample concentrations is shown below:  
Sample pairs which differ by more than 10% are highlighted in yellow. There are also repeats of 
samples on this plate to enable calculation of intra-assay variability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Typical standard curve 
obtained using MCP-1 as an 
example 
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Label [h MCP-1]  log [h MCP-1] OD-1 OD-2 Mean Cor. OD Log[h MCP-1] anti Log MCP-1 dilution  [h MCP-1]   
  0   0.149 0.163 0.1560 0.0000         
  9.76 0.989 0.192 0.202 0.1970 0.0410         
  19.53 1.291 0.227 0.249 0.2380 0.0820         
  39.0625 1.592 0.308 0.323 0.3155 0.1595         
  78.125 1.893 0.426 0.454 0.4400 0.2840         
  156.25 2.194 0.678 0.692 0.6850 0.5290         
  312.5 2.495 1.113 1.177 1.1450 0.9890         
  625.0 2.796 1.615 1.648 1.6315 1.4755         
  1250.0 3.097 1.923 1.915 1.9190 1.7630         
  2500.0 3.398 2.055 2.075 2.0650 1.9090         
60.1     1.224 1.276 1.2500 1.0940 2.554677 358.655091 1 358.655 
59.1     1.056 1.089 1.0725 0.9165 2.446382 279.500121 1 279.500 
58.1     0.913 0.930 0.9215 0.7655 2.350754 224.261127 1 224.261 
57.1     1.115 1.230 1.1725 1.0165 2.507500 321.736253 1 321.736 
55.1     2.102 2.068 2.0850 1.9290     1 > 
54.1     0.727 0.754 0.7405 0.5845 2.223256 167.207595 1 167.208 
60.1     1.210 1.235 1.2225 1.0665 2.537912 345.073811 1 345.074 
59.1     1.033 1.038 1.0355 0.8795 2.423456 265.128247 1 265.128 
58.1     0.877 0.889 0.8830 0.7270 2.325172 211.432624 1 211.433 
57.1     1.111 1.116 1.1135 0.9575 2.471541 296.169955 1 296.170 
55.1     1.928 2.087 2.0075 1.8515 3.241006 1741.830938 1 1741.831 
54.1     0.672 0.732 0.7020 0.5460 2.192983 155.949146 1 155.949 
53.1     1.209 1.215 1.2120 1.0560 2.531523 340.034513 1 340.035 
52.1     0.877 0.893 0.8850 0.7290 2.326521 212.090395 1 212.090 
48.1     0.406 0.429 0.4175 0.2615 1.884698 76.682807 1 76.683 
47.1     0.750 0.725 0.7375 0.5815 2.220962 166.326711 1 166.327 
37.1     0.975 0.978 0.9765 0.8205 2.386298 243.387349 1 243.387 
34.1     1.048 1.008 1.0280 0.8720 2.418775 262.285934 1 262.286 
33.1     1.022 1.076 1.0490 0.8930 2.431849 270.301839 1 270.302 
17.1     0.772 0.728 0.7500 0.5940 2.230520 170.027825 1 170.028 
14.1     0.605 0.609 0.6070 0.4510 2.110702 129.033358 1 129.033 
11.1     0.822 0.818 0.8200 0.6640 2.281778 191.327766 1 191.328 
4.1     0.613 0.634 0.6235 0.4675 2.125935 133.639549 1 133.640 
3.1     1.234 1.223 1.2285 1.0725 2.541564 347.987785 1 347.988 
2.1     0.655 0.717 0.6860 0.5300 2.179954 151.340094 1 151.340 
1.1     1.342 1.379 1.3605 1.2045 2.622941 419.701963 1 419.702 
37.1     0.962 0.922 0.9420 0.7860 2.364141 231.281556 1 231.282 
34.1     0.957 1.078 1.0175 0.8615 2.412223 258.358646 1 258.359 
33.1     1.057 1.077 1.0670 0.9110 2.442992 277.326902 1 277.327 
17.1     0.752 0.742 0.7470 0.5910 2.228226 169.132084 1 169.132 
14.1     0.615 0.579 0.5970 0.4410 2.101262 126.258900 1 126.259 
11.1     0.729 0.841 0.7850 0.6290 2.256578 180.541896 1 180.542 
 
 
 
 
 
Figure 3: Typical ELISA results spreadsheet 
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3.3(iv) Intra and Inter assay variability: 
This has been determined as a coefficient of variation for each cytokine using a minimum of ten 
repeated results pairs for each measure:  
 
 Serum Dialysate 
 Inter assay Intra assay Inter assay Intra assay 
MCP-1 7.73% 6.19% 11.86% 6.33% 
CCL18 7.89% 7.68% 6.23% 4.14% 
CCL15 7.02% 6.58% 5.14% 5.63% 
Angiogenin 7.89% 7.23% 11.01% 6.03% 
IL-6 10.95% 9.83% 9.6% 5.59% 
Table 2: Inter- and intra-assay variability 
 
3.3(v) Consistency of the standard over time 
In order to exclude a systematic change in the standards used over the course of the study, the 
median levels in both dialysate and serum were compared in the first, second and third fifty 
patients. Cytokine levels were also assessed for significant correlations with time since study 
commenced to investigate whether there was any evidence of a progressive change in median 
measured cytokine levels which might be artefactual. A problem with the standard would be 
expected to affect both serum and dialysate levels. 
The only cytokine for which both serum and dialysate levels showed a statistically significant 
difference between samples from early, mid and late points in the study was CCL15. CCL15 was 
higher in the middle period of patient recruitment for both serum (Kruskal-Wallis test, p = 0.0021) 
and dialysate (p = 0.0016) levels. This is unlikely to be due to a change in the standard as CCL15 was 
measured on the majority of samples over a short period of time using the same preparation for the 
standard, and is more likely to represent true higher levels in these patients. 
There were no cytokines for which both serum and dialysate levels showed a significant correlation 
with time since study commenced. 
 
3.3(vi) Serum and plasma levels 
Simultaneous plasma levels were taken and samples analysed for CCL15, CCL18 and MCP-1, to assess 
whether the nature of the blood sample (serum v. plasma) was important. Angiogenin is known to 
be found at very similar levels in serum and plasma samples (McLaughlin et al., 2010), and IL-6 is 
found at slightly (not statistically significantly) higher levels in serum than plasma (O'Neill and Bowie, 
2001).  
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For all three cytokines, a linear relationship was observed between serum and plasma levels: 
          
 
 
 
 
 
 
 
3.4 Cell culture techniques 
3.4(i) Peritoneal mesothelial cell culture method 
Cells were cultured from the overnight dialysate bag. Any aliquots of fluid required for cytokine 
studies were removed and the bag hung for two hours at 37⁰C for 2 hours. 
All but 200mls of the dialysate was aspirated off. This was then pipetted into four 50ml flasks. These 
were centrifuged at 1500rpm at 4°C for 20 minutes and the dialysate discarded. The four cell pellets 
were re-suspended in 10mls of Hank’s balanced salt (calcium-free) solution (Sigma, Gillingham, UK) 
and spun again for 20 minutes at 1500rpm and 4°C. The Hank’s solution was aspirated off and the 
Figure 4: There is a linear relationship 
between serum and plasma levels of 
MCP-1 
Figure 5: There is a linear relationship 
between serum and plasma levels of 
CCL18 
Figure 6: There is a linear relationship 
between serum and plasma levels of 
CCL15 
There is a linear relationship between serum 
and plasma levels for all three cytokines. 
However it is important that one type of 
sample is analysed consistently, as the 
serum levels of MCP-1 are nearly twice as 
high as the plasma levels (205 v.109 pg/ml, 
P<0.001). There was no significant 
difference between levels of CCL18 and 
CCL15 in plasma and serum. In this study 
serum levels are used throughout.  
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cells re-suspended in 10mls of fresh Hank’s solution. This was spun again for 20 minutes at 1500 rpm 
at 4⁰C. The Hank’s solution was aspirated off and 1ml of culture medium (M199 Earl’s base with L-
glutamine, 10% fetal calf serum (PAA, Yeovil, UK) and 10mls penicillin-streptomycin (Invitrogen) was 
added. A 10µl aliquot was taken and tryptan blue used to stain the cells for cell count. A further 
6.5ml more culture medium was added and the cells cultured in a flask in 5% CO2 at 37°C in an 
incubator (Wolf Laboratories, York, UK). 
Cells were split using cell dissociation solution (Geneflow, Fradley, UK) when confluent and samples 
of the culture medium taken to investigate cytokine production by the cells in culture. Cells in 
culture were photographed using a Nikon TS100 camera to demonstrate the variability in 
morphology of peritoneal cells. 
Once sufficient cells were present, the cells were re-suspended and transferred to a twelve well 
culture plate for the stimulation experiments, or used to produce a cytospin preparation for staining 
and characterisation by immunohistochemistry.  
 
3.4(ii) Immunohistochemistry to characterise mesothelial cells 
Cells cultured from dialysate effluent are known to show varying morphology, in keeping with an 
ongoing process of EMT (Yáñez-Mó et al., 2003). Cells were therefore stained for: 
 The epithelial marker cytokeratin 18 
 The mesenchymal marker vimentin 
 Alpha smooth muscle actin (α-SMA), which labels smooth muscle cells and myofibroblasts. 
All antibodies were supplied by Dako (Ely, UK) and were mouse anti-human antibodies used at 1 in 
50 dilution. 
The slides were air-dried then rinsed with PBS. The staining was done with the slides in a humidified 
chamber to prevent over-drying. The cells were ringed with wax and 100µl of Marvel block (1g 
Marvel milk powder in 10mls PBS) applied for 15 minutes. The Marvel was then tapped off and the 
primary antibody added to one cell spot and 100µl of Marvel added to the other cell spot on the 
slide as a negative control. The slides were left for one hour and then rinsed twice with PBS. 
The Dako mouse EnVision kit was used to visualise the primary antibody distribution. 
Diaminobenzidine (DAB) was added to each cell spot; 50µl of DAB at a concentration of 1 in 50 and 
observed until brown staining was seen. The slides were then covered with PBS and washed in 
running water. The cells were counterstained with haematoxylin for 30 seconds then washed in a 
water bath. The slides were then dipped in 1% acid:70% alcohol and returned to the water bath until 
blue. The slides were then dipped in ethanol and xylene for 3 minutes twice and mounted with 
Pertex. 
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3.4(iii) Mesothelial cell stimulation experiment – investigating the action of CCL15 
Cells were transferred to a 12 well culture plate. Baseline samples of culture medium were taken 
once the cells were established. The cells were then stimulated with IL-6 and CCL15. Human 
peritoneal mesothelial cells may however be IL-6 receptor negative (McLoughlin et al., 2004) and 
have been shown to respond to IL-6 in the presence of soluble IL-6 receptor only. It was not 
therefore clear whether mesothelial cells would be expected to respond to IL-6. The peritoneal 
mesothelial cells were stimulated with CCL15 and IL-6 to investigate whether these cytokines caused 
a change in cytokine production by the mesothelial cells. CCL15 has been shown to induce an 
increase in MCP-1 mRNA production in THP-1 cells (Lee et al., 2002) but the response of peritoneal 
mesothelial cells has not previously been investigated.  
Details of stimulation experiment: 
 
Levels of MCP-1, CCL18, CCL15 and angiogenin were measured in the control culture medium for 
comparison with levels in the wells stimulated by IL-6 or CCL15 after 48 hours. The concentrations of 
CCL15 used were chosen with reference to the concentrations used by Lee et al (Lee et al., 2002) and 
that of IL6 to the concentrations used by McLoughlin et al (McLoughlin et al., 2004). 
 
3.4(iv) U937 cell culture 
U937 cells (European collection of cell cultures, Salisbury, UK) were grown in RPMI 1640 medium 
(Gibco, Life Technologies) with penicillin-streptomycin and 5% FCS. After the second passage cells 
were characterised initially using flow cytometry (FACS). The U937 cells were labelled with 
antibodies for CD14 and CD68 (monocyte/macrophage markers) and also for CCL18. Initial FACs data 
indicated a heterogenous cell population, and a new culture was established. 
 Samples of the culture medium were taken to establish which cytokines were produced. After the 
second passage, these cells were split and half were transferred to serum free medium for the 
Figure 6: Mesothelial cell 
stimulation experiment 
3 wells control 
3 wells IL-6 10ng/ml 
3 wells CCL15 100ng/ml  
3 wells CCL15 500ng/ml  
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stimulation experiment; the remaining cells were used to produce a cytospin preparation for 
immunofluorescence to characterise the cells using an antibody to the monocyte marker CD68.  
 
3.4(v) U937 cell stimulation experiment – investigating the action of CCL15 
After 24 hours in serum-free medium, a sample of tissue culture fluid was taken for cytokine ELISAs. 
The cells were spun down and washed twice with Hank’s solution then re-suspended in 16 mls 
serum-free medium. 1ml/well of culture medium and cells was added to each of 15 wells and 
cytokines added as follows: 
 
IL-6 was chosen as a positive control to confirm that the experimental conditions permitted an 
increase in cytokine production levels at 48 hours; IL-6 is known to induce MCP-1 release from 
monocytes without requiring the addition of the soluble IL-6 receptor. 
After 48 hours samples of culture medium were taken for measurements of cytokine levels. 
 
3.5 Comparison of serum and dialysate protein levels 
In order to investigate the relationship between serum and dialysate levels of cytokines, the transfer 
from blood to dialysate of proteins which are known not to be produced within the peritoneum was 
investigated for a number of proteins of varying molecular weight. This allows the construction of a 
graph of dialysate: serum ratio versus molecular weight. The blood samples were taken at the mid-
point of the four hour PET test and the dialysate samples taken at the end of the PET test as for 
cytokine levels. The cytokines range from 7.8 to about 20kDa (Daltons) in molecular weight: 
 
 
 
 
 
Figure 7: U937 cell 
stimulation experiment 
3 wells control 
3 wells IL-6 10ng/ml 
3 wells IL-6 100ng/ml 
3 wells CCL15 10ng/ml  
3 wells CCL15 100ng/ml  
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Protein Molecular weight (kDa) 
CCL18 7.8 
MCP-1 8.7 
CCL15 10 
Angiogenin 14 
IL-6 20.3 
Table 3: Molecular weights of chemokines 
 
The following proteins were chosen as molecular weight markers: 
  
Protein Molecular weight (kDa) 
Creatinine 0.113 
Β2-microglobulin 11 
Prolactin 24 
Albumin 68 
IgG 155 
Table 4: Molecular weights of proteins 
 
These proteins were measured by the biochemistry laboratory (Dr M Donaldson and Dr J Bailey) as 
they are routinely measured analytes in our institution. All the analytes were measured on the 
Abbott Architect analyser (Abbott Laboratories, Maidenhead, UK) except for β2-microglobulin which 
was measured by a microparticle immunoassay on the Abbott Axsym analyser. Twenty paired serum 
and dialysate samples were used to construct a graph of dialysate to serum (D/S) ratio v. molecular 
weight of protein. This was used to calculate an expected D/S ratio for each cytokine, which could 
then be compared to the measured D/S ratio. 
 
3.6 Statistical methods 
All data was analysed using Graph Pad Prism version 4 and SPSS versions 17 and 19 (IBM, New York, 
USA). 
The distribution of continuous variables was checked for normality using histograms, normal Q-Q 
plots and the Shapiro-Wilk and Kolmogorov-Smirnov tests. Any variable not found to be normal in 
distribution was analysed using non-parametric statistics. The Mann-Whitney test is reported for 
comparison of independent samples (Kruskal-Wallis test for three or more groups) and the Wilcoxon 
Signed Rank Test for comparison of related samples (follow-up samples at one year). Two-tailed p 
values are reported. Spearman’s rho is reported for tests of correlation.  
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Multivariate analysis was performed with the help of Dr Bernard North using SPSS v.19 and the R 
project version R.13. Variables were log transformed to a more normal distribution to satisfy model 
requirements. Model fit was assessed by residual plots including Q-Q plots for normality of residuals 
and residuals vs fits plots for linearity of effect of the predictors on the log transformed cytokine 
level. Linear regression was used to analyse the factors determining dialysate cytokine levels; logistic 
regression was used to explore whether EPS could be predicted from clinical and cytokine data. 
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CHAPTER 4 
RESULTS: Levels of cytokines in dialysate and serum 
4.1 Peritoneal dialysis patient cohort: baseline levels of cytokines in dialysate and serum 
4.1(i) Demographics of the patient group 
            
 
 
Baseline samples and data were collected from 151 patients. The mean age of the patients was 58 
years (95% confidence interval 55.75 – 60.24 years). The median duration of peritoneal dialysis at 
the time of sampling was 27 months (range 0.7 – 134.8 months). The distribution of time on dialysis 
is skewed; this is likely to be due to patients transferring to haemodialysis or obtaining a renal 
transplant; however the population contains a significant number of patients who had been using 
peritoneal dialysis for more than five years at the time the baseline samples were taken (28 of 151 
patients). Samples have not been collected from all incident patients during the period of the West 
London PD study; some patients may not have had a PET test and a researcher may not always have 
been able to attend the test. All patients approached consented to take part in the study and were 
enrolled. 
Figure 8: Age distribution of 
peritoneal dialysis population 
Figure 9: Duration of PD at time of 
sampling 
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4.1(ii) Peritoneal dialysis data in the baseline patients 
 
 
            
 
Figure 10: Cause of ESRF in peritoneal 
dialysis patients 
Figure 11: Modality of peritoneal 
dialysis 
 
Figure 12: Creatinine clearance 
results in peritoneal dialysis patients 
Figure 13: Distribution of PET results (D/P 
creatinine) in peritoneal dialysis patients 
The major causes of ESRD in the patient group 
are as would be expected: diabetes, 
glomerulonephritis, hypertension and vascular 
disorders and polycystic kidney disease. Other 
diagnoses include Alport’s syndrome, 
pyelonephritis, reflux and scleroderma. 
 
The proportion of patients using APD did not 
alter greatly during the course of the study, 
being 52% of the first 50 patients, 60% of the 
second 50 patients and 60.7% of the final 51 
patients (in chronological order of recruitment). 
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This is a well-dialysed group with a mean total creatinine clearance of 74.6 L/week (range 41.2 – 
185.8 L/week). The mean D/P creatinine was 0.72 (95% confidence interval 0.7 - 0.74).  
 
 
 
 
 
 
 
 
                                                                                                      
 
 
The mean total fluid removal was 1607.5ml/24 
hours (95% CI 1482-1733mls/24 hours). There is a 
small group of patients who at baseline had poor 
24 hour fluid removal results. This might reflect a 
damaged peritoneal membrane with loss of 
ultrafiltration capacity, so that patients were 
unable to achieve an acceptable amount of fluid 
removal. Alternatively these patients may have had 
the ability to achieve greater 24 hour fluid 
removal, but were not using an appropriate 
prescription at the time.  
Figure 14: Total fluid removal from 
peritoneal dialysis patients 
Figure 15: Residual GFR in peritoneal 
dialysis patients 
The median residual GFR in the peritoneal dialysis 
population was 3.2mls/min (range 0 – 
20.4mls/min). The GFR is calculated by the 
Adequest (Renalsoft version 2.0) software used in 
our department as the mean of urea and creatinine 
clearances, an approximation that helps to 
minimise the error inherent in the calculation of 
creatinine clearance in patients with very little 
renal function. 
Physioneal (Baxter, Deerfield, USA), a relatively 
new and potentially more biocompatible dialysis 
fluid, was used in 80 of the patients at the time of 
sampling. There was a change (an increase) in the 
proportion of patients using Physioneal over the 
period of the study. This means that later-recruited 
patients are more likely to have used Physioneal 
than patients recruited earlier in the study. This 
might be important in the analysis of risk factors 
for future EPS. 
Figure 16: Types of dialysis fluid used in 
peritoneal dialysis patients 
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Peritonitis is not a common event in our population. To time of sample collection, 102 episodes of 
peritonitis were treated in 5129 patient-months, giving an overall rate of 1 episode/50 patient-
months. This is considerably lower than the acceptable limit of 1 episode/18 patient-months cited in 
the ISPD guidelines of 2005 (Piraino et al., 2005). 
 
4.2 Dialysate levels of cytokines are not just a reflection of serum levels 
4.2(i) Median serum and dialysate concentration of cytokines 
Cytokine Serum concentration 
(pg/ml) 
Dialysate concentration 
(pg/ml) 
Peritoneal appearance 
rate (ng/4hrs) 
Median Range Median Range Median Range 
CCL18 121815            24825 – 470788 2438 104 - 17583 6509 261 - 35856 
MCP-1 244.7          33.6 - 745.8 199.1 76.5 - 1294.5 413  100.4 - 2718.4 
IL-6 4.22             0.55 – 86.5 21 1.7 - 423.2 46.7 3.8 - 1860.5 
Angiogenin 832397 311702 – 1681535 45977 7551 - 159222 104544 13592 - 318444 
CCL15 21649   10021- 91386 2242 302 - 9698 4390 726 - 19394 
Table 5: median concentrations of cytokines in serum and dialysate  
Inspection of the median serum and dialysate levels shows that while some cytokines show 
considerable higher serum than dialysate concentrations, there is a higher concentration of IL-6 in 
the dialysate than in the serum. 
 
 
 
Figure 17: Number of previous peritonitis 
episodes at time of sampling PD patients 
The rate of peritonitis episodes per patient-
treated-month did not vary significantly during 
the study period, and was similarly low for 
patients recruited at the beginning and the end 
of the study. 
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4.2(ii)    Dialysate cytokine concentrations do not always correlate with serum cytokine 
concentrations  
If the dialysate concentration of a cytokine was primarily determined by the serum concentration, 
with the cytokine entering the dialysate by diffusion through pores in the peritoneal membrane, a 
strong correlation would be expected between the serum and dialysate concentrations. In order to 
correct for the varying volumes of dialysis fluid at the end of the PET test, when discussing cytokine 
production in the peritoneal space, all dialysate cytokine concentrations are corrected for the 
drained volume at the end of the PET test and expressed as the amount of cytokine (in ng) present 
after the 4 hour dwell (the peritoneal appearance rate). However when considering whether a 
cytokine may have entered the peritoneal space by diffusion from the serum, the dialysate 
concentration is more relevant and this is used here. 
For all correlations between cytokines and clinical factors the Spearman’s rho, or r value, is reported 
as the distribution of cytokine values is not normally distributed. 
The relationship between serum and dialysate CCL15 concentrations shows this expected close 
correlation and to a lesser extent so does the relationship between serum and dialysate CCL18: 
 
 
             
 
 
 
 
 
 
Figure 18: There is a close correlation 
between serum and dialysate CCL15 levels 
Figure 19: There is a less marked 
correlation between serum and dialysate 
CCL18 levels 
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However, this is not the case for angiogenin, MCP-1 and IL-6: 
             
 
 
 
 
 
4.2(iii) Analysis of serum/dialysate protein concentration ratios by molecular weight: some 
dialysate cytokine levels are higher than expected  
In order to further investigate the relationships between serum and dialysate cytokine levels, the 
concentrations of five proteins of varying molecular weights were measured in twenty paired serum 
and dialysate fluid samples. These proteins were selected as being readily measurable, covering a 
wide range of molecular weights and not being synthesised by peritoneal cells. The aim was to use 
this information to construct a plot of molecular weight versus dialysate to serum ratio. This 
approach was used by Mizutani et al (Mizutani et al., 2010) to demonstrate an excess of connective 
tissue growth factor in the dialysate, which they argue indicates local production of the cytokine. 
 
Figure 20: There is little correlation between 
serum and dialysate angiogenin levels  
Figure 21: There is a weak correlation 
between serum and dialysate IL-6 levels 
Figure 22: There is little correlation between 
serum and dialysate MCP-1 levels 
There are only weak correlations between 
the levels of MCP-1, IL-6 and angiogenin in 
the dialysate and in the serum. In addition, 
dialysate MCP-1 levels are slightly higher 
than the serum levels (average dialysate to 
serum ratio 1.159). Dialysate IL-6 levels are 
considerable higher than serum levels 
(average dialysate to serum ratio 9.128). 
This also suggests that these cytokines are 
being produced within the peritoneal space 
rather than diffusing in from the circulation. 
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Molecule Molecular weight D/S ratio 
Creatinine 0.113kDa 0.713 
Β2-microglobulin 11kDa 0.135111 
Prolactin 24kDa 0.075714 
Albumin 68kDa 0.013277 
Immunoglobulin G 155kDa 0.006764 
Table 6: measured dialysate to serum ratios of five marker proteins 
 
Of note, there was no difference in dialysate to serum ratios of the marker proteins between 
patients with and without a history of peritonitis (although only three of twenty patients had ever 
experienced peritonitis).  
GraphPad software was then used to model the relationship between molecular weight and 
dialysate to serum ratio: 
 
 
 
 
 
The expected dialysate to serum ratio could then be calculated from the graph for each cytokine, 
dependent on its molecular weight:  
Figure 23: Non-linear fit of Dialysate to Serum ratio v. log 
(molecular weight) for marker proteins 
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This can then be compared with the measured dialysate to serum ratio for each cytokine: 
Cytokine Predicted D/S ratio Measured D/S ratio 
Angiogenin, MW 14000* 0.113 0.0802 
CCL18 0.176 0.0288 
CCL15 0.147 0.1012 
IL-6 0.082 9.1277 
MCP-1 0.163 1.1592 
Angiogenin, MW 16500* 0.099 0.0802 
Table 7: Predicted and measured dialysate to serum ratios for cytokines 
 *Two molecular weights for angiogenin are given 
 
It is notable that there appears to be less CCL18 within the dialysate than would be expected if 
CCL18 diffused in from the circulation, at least compared to other proteins of a similar molecular 
weight. One possibility is that CCL18 is protein-bound and therefore does not behave as a protein of 
7.8kDalton molecular weight. 
The values for angiogenin and CCL15 are roughly consistent with the possibility that dialysate levels 
of these cytokines are due to diffusion from the circulation. Estimates of molecular weight are 
variable and the differences between predicted and measured dialysate levels are relatively small. 
The results do not exclude the possibility of local production of these cytokines as it is possible that 
they are made by, and remain largely bound to, peritoneal mesothelial or other cell types within the 
peritoneum. This will be further investigated in the cell culture experiment section. 
The values for both MCP-1 and IL-6 are much higher than would be expected if the presence of 
cytokines in dialysate fluid was only due to passive transfer from the circulation. This suggests that 
Figure 24: Dialysate to Serum ratio v. log (molecular 
weight) showing position of cytokines on the curve 
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there is significant local production within the peritoneum of these cytokines. This is consistent with 
a previous study by Zemel et al (Zemel et al., 1992) which showed higher IL-6 levels in the overnight 
effluent dialysate of four patients than would be expected; in this study the restriction coefficients 
of α2 macroglobulin, β2 microglobulin and albumin transfer across the peritoneal membrane were 
used to establish the expected rate of diffusion of IL-6 from serum to dialysate. 
 
4.2(iv) GFR and cytokine levels:  
As small molecules (molecular weight smaller than albumin), cytokines such as MCP-1, CCL15, 
CCL18, angiogenin and IL-6 might be filtered at the glomerulus and the serum level would then be 
expected to show a negative correlation with GFR. The range of GFR (calculated as the mean of urea 
and creatinine clearance) is small in PD patients, with most patients having a GFR between 0 and 
10mls/minute. For most cytokines the association between GFR and serum levels is weak or non-
existent: 
           
 
 
This is consistent with work from our group (Dr Qureshi) showing no correlation between serum 
levels of CCL18 and GFR in over one hundred patients with CKD (GFR range 11-90mls/minute).  
In contrast, there are stronger correlations observed between the appearance rate in the dialysate 
of MCP-1 and IL-6 and the GFR: 
Figure 25: Serum concentrations of CCL18 
correlate only weakly with GFR; CCL15 
shows a similar pattern 
 
Figure 26: Serum concentrations of MCP-1 
do not correlate with GFR; IL-6 serum 
concentrations show a similar pattern 
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The relationships between dialysate cytokines and GFR do not exist only because the serum levels of 
cytokines are affected by the GFR. The correlations between serum levels of cytokine and GFR are 
weak or non-existent, and a closer relationship is usually seen between the dialysate quantity of a 
cytokine and GFR. The association between residual GFR and dialysate cytokine levels could be due 
to the increased levels of inflammation seen generally in patients with reduced renal function, or 
could be related to the increased exposure to dialysate that is necessary to achieve adequate 
clearances in patients with little residual GFR.  
Summary 
In this population of well-dialysed patients, it seems unlikely from this data that dialysate levels of 
cytokines depend only on the serum levels. The concentrations of IL-6 in the dialysate are higher 
than levels seen in the serum, making it likely that IL-6 is produced within the peritoneum. In some 
patients the same is true for MCP-1.  
Analysis of the data describing transfer of proteins of variable molecular weight into the dialysate 
also suggests that there is production of IL-6 and MCP-1 within the peritoneum.  
However, for CCL15 there is a close correlation between serum and dialysate levels. The dialysate to 
serum ratio is also consistent with the possibility that CCL15 might enter the dialysate by passive 
transfer from the circulation. 
For CCL18 the quantities found in the dialysate are lower than would be expected given the 
molecular weight of this cytokine. A relationship between serum and dialysate concentrations is 
Figure 27: Unlike the serum levels, the 
quantity of IL-6 in the dialysate does 
correlate with the GFR 
 
Figure 28: Similarly, the dialysate quantity 
of MCP-1 does correlate with GFR 
although the serum level does not 
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seen, which might suggest that CCL18 enters the dialysate from the circulation. This data is 
consistent with the possibility that CCL18 in the peritoneum is bound to cells and therefore not 
found at the expected higher levels in the dialysate. Alternatively, CCL18 could be made in the 
peritoneum and the relationship with the serum levels might be seen because the same factors that 
determine serum levels also determine peritoneal levels. 
Although angiogenin is found at approximately the expected levels in the dialysate to be consistent 
with the possibility that it enters passively from the circulation, the lack of a close correlation 
between serum and dialysate levels of angiogenin suggests that other factors must influence 
dialysate levels of angiogenin; perhaps properties of the peritoneal membrane or variable amounts 
of intraperitoneal production of angiogenin. 
Residual renal function may be related to the dialysate levels of cytokines, but this is not because 
the serum levels of cytokines are affected by the level of residual renal function; as we have seen, 
dialysate cytokines frequently do not correlate with serum levels of cytokines, and in the GFR range 
of PD patients, serum levels of cytokines in turn do not correlate closely with GFR. It is possible that 
patients with little residual function had greater exposure to inflammation-inducing dialysate or 
another exposure associated with higher dialysate cytokine levels. 
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CHAPTER 5 
RESULTS: Cytokine levels - correlations with clinical factors  
 
5.1 Dialysate cytokine levels correlate with clinically relevant factors 
All quantities of cytokines in dialysate are the total amount in the dialysate effluent at the end of the 
four hour dwell period. This is a more useful result than the concentration of the cytokine in the 
dialysate, as the drained volume of dialysate at the end of the PET test will vary considerably 
between patients. 
 
5.1(i) Duration of peritoneal dialysis 
One of the most important risk factors for both ultrafiltration failure (Davies, 2004) and also for EPS 
(Kawanishi and Moriishi, 2005; Balasubramaniam et al., 2009; Brown et al., 2009b) after the 
cessation of peritoneal dialysis is the total duration of peritoneal dialysis.  
Duration of PD did not differ significantly between the first, second and third group of fifty patients 
recruited for the study. 
The peritoneal appearance rate of some cytokines increases with the duration of peritoneal dialysis 
at the time of sampling. This is most clearly seen when the correlations between duration of PD and 
IL-6 or MCP-1 are examined: 
 
            
 
 
 
The correlations of CCL15 with duration of PD, and CCL18 with duration of PD are less marked 
(although still significant): 
 CCL15: r = 0.1962, p = 0.0296 
 CCL18: r = 0.1708, p = 0.038 
There was no correlation between the dialysate quantity of angiogenin and the duration of PD.  
Figure 29: The dialysate quantity of IL-6 
increases with the duration of PD 
 
Figure 30: The dialysate quantity of MCP-1 
increases with the duration of PD 
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5.1(ii) Membrane transport status 
The dialysate levels of all investigated cytokines correlate closely with the dialysate/plasma 
creatinine (the ratio of dialysate and plasma creatinine concentrations at the end of the PET test). 
This is not surprising in the case of CCL18 and CCL15, as we have seen that the dialysate and serum 
concentrations of these cytokines are closely correlated (section 3.2(ii), figures 17 and 18).  
 
                 
 
 
 
 
Together, these data would suggest that CCL15 and CCL18 might enter the peritoneal space from the 
circulation at a rate which is related to the rate of transfer of creatinine into the dialysate, and that 
this might determine the amount of CCL15 and CCL18 found in the dialysate. This is consistent with 
the data from the study of serum:dialysate protein concentrations (section 3.2(iii)), in which the 
dialysate concentrations of CCL15 and CCL18 were the same or lower than that expected if the 
cytokine moved passively into the dialysate from the circulation. 
 
The remaining three cytokines also show a close correlation between dialysate to plasma creatinine 
ratio and the quantity of cytokine found in the dialysate. However for these three cytokines, we 
know that there is no or a weak relationship between serum and dialysate levels.  
 
Figure 31: There is a significant correlation 
between the dialysate quantity of CCL15 
and the D/P creatinine  
 
Figure 32: There is a significant correlation 
between the dialysate quantity of CCL18 
and the D/P creatinine 
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5.1(iii) Glucose Exposure 
The glucose exposure was calculated as the amount of glucose (in mmol per twenty four hours) in 
the dialysate used by the patient according to their current prescription at the time of the PET and 
adequacy assessment. This is not an ideal measure of glucose exposure as it is only a point measure 
and in theory could differ considerably from previous prescriptions. However, a more 
Figure 33: There is a significant correlation 
between the dialysate quantity of IL-6 and 
the D/P creatinine  
 
Figure 34: There is a significant correlation 
between the dialysate quantity of MCP-1 
and the D/P creatinine  
 
Figure 35: There is a significant correlation 
between the dialysate quantity of 
angiogenin and the D/P creatinine  
 
Since the dialysate concentrations of these 
cytokines are not closely related to their 
respective serum concentrations, it seems 
unlikely that the observed correlation with the 
dialysate/plasma creatinine level has the same 
interpretation as suggested above for CCL18 
and CCL15. One possible interpretation is that 
IL-6, MCP-1 and angiogenin produced in the 
peritoneum are important in determining the 
D/P creatinine. However it is also possible that 
a confounding factor – for example glucose 
exposure or duration of peritoneal dialysis – 
could affect both D/P creatinine and the 
quantity of IL-6, MCP-1 and angiogenin in the 
dialysate.  
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comprehensive measure of glucose exposure would require more detailed longitudinal records of 
the prescription than were available. 
Glucose exposure is determined by the need to remove water from the dialysis patient. It is 
therefore related to: 
- the salt and water intake of the patient 
- the amount of residual urine output 
- the ultrafiltration capacity of the peritoneal membrane 
 
         
 
 
 
 
Interestingly, both IL-6 and MCP-1 levels in the dialysate correlate with glucose exposure. Data from 
comparing serum and dialysate levels of these cytokines suggests that they are both produced 
within the peritoneum, and that dialysate levels are not determined by serum levels or by the ability 
of the cytokines to enter the dialysate from the circulation. The observation that the dialysate levels 
of these cytokines correlates with glucose exposure (as well as D/P creatinine) suggests that these 
cytokines could be involved in the sequence of events from glucose exposure to increasing D/P 
creatinine seen in long term peritoneal dialysis patients. This could be because glucose exposure 
increases the level of MCP-1 and IL-6, and this in turn leads to changes in membrane transport 
properties. Alternatively, increased levels of MCP-1 and IL-6 could affect the peritoneal membrane 
such that greater glucose exposure was required to achieve ultrafiltration requirements. 
 
Figure 36: Glucose exposure is higher in 
patients who have a higher dialysate to 
plasma creatinine ratio 
 
Figure 37: Glucose exposure is higher in 
patients who have less residual urine output 
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Dialysate levels of CCL15 and angiogenin also correlate with glucose exposure. However, the 
serum/dialysate ratios of these cytokines are consistent with the dialysate level being dependent on 
transfer of these cytokines across the peritoneal membrane from the circulation (section 3.2(iii)). It 
is possible that this observed correlation of CCL15 and angiogenin with glucose exposure is simply 
due to the correlation of glucose exposure with the characteristics of the peritoneal membrane, 
rather than being an indication that CCL15 and angiogenin mediate the effects of glucose exposure 
on the peritoneum. The dialysate quantity of CCL18 does not correlate significantly with glucose 
exposure. 
 
5.1(iv) Dialysate volume 
The volume of dialysate used by the patient over a twenty four hour period might show similar 
patterns to the glucose exposure. Patients with a high dialysate to plasma creatinine ratio - fast 
transporters – might be expected to need large volumes of dialysate per twenty four hours to 
achieve adequate ultrafiltration. A common dialysis prescription for a patient with fast membrane 
transport status would involve multiple fairly short duration exchanges on APD in order to maximise 
ultrafiltration. This means a larger volume of fluid is required by fast transporters on APD, and this is 
the result seen in figure 40: 
Figure 38: The level of IL-6 in the dialysate 
correlates with glucose exposure at the 
time of PET 
 
Figure 39: The level of MCP-1 in the 
dialysate correlates with glucose exposure 
at the time of PET 
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The relationships of cytokine levels with dialysate volume must therefore be interpreted in the 
context of this relationship with dialysate to plasma creatinine ratio. 
The significant correlations between both MCP-1 and IL-6 and dialysate volume may be interpreted 
in a similar manner to those with glucose exposure. Dialysate levels of IL-6 and MCP-1 are not 
determined by the membrane transport properties of the peritoneum, but do correlate with 
membrane transport properties (with the dialysate to plasma creatinine ratio). Therefore the 
observed relationship of IL-6 and MCP-1 with dialysate volume may be due to the co-correlation 
with the membrane transport status, or it may be that exposure to large volumes of dialysate 
increases both transport status and IL-6/MCP-1 (perhaps via the implied increase in exposure to 
glucose or other harmful constituents of dialysate). 
 
            
 
 
 
 
Angiogenin and CCL15 also correlate with dialysate volume, but clearly this might be due to the 
relationships between these cytokines and the membrane transport characteristics. However it is 
Figure 40: The volume of dialysate used 
per twenty four hours correlates with the 
D/P creatinine 
 
Figure 41: The volume of dialysate used 
per twenty four hours correlates with the 
quantity of IL-6 in the dialysate 
 
Figure 42: The volume of dialysate used 
per twenty four hours correlates with the 
quantity of MCP-1 in the dialysate 
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worth noting that CCL18, which has a similar relationship with serum levels and D/P creatinine to 
angiogenin and CCL15, correlates with neither glucose exposure nor dialysate volume: 
 
            
 
 
 
 
Angiogenin and CCL15 are both of a similar size as CCL18, so it is interesting that the dialysate levels 
of angiogenin and CCL15 do correlate with dialysate volume and glucose exposure, and the levels of 
CCL18 do not. It implies that levels of these three molecules do not behave in the same manner, and 
this makes it less likely that passive transfer of these molecules from serum to dialysate is the only 
factor determining dialysate cytokine levels. 
 
5.1(v) Peritonitis 
PET tests were always performed at least six weeks after any episode of peritonitis. None of the 
measured cytokine levels were affected by the number of previous peritonitis episodes. There were 
no significant differences between cytokine levels in patients who had never experienced peritonitis 
and those who had. A trend towards a significant difference was seen for MCP-1 dialysate levels 
only; median MCP-1 production being 396ng in the group which had never experienced peritonitis 
and 478.6ng in the group which had experienced at least one episode of peritonitis. The p value for 
this comparison was 0.1, however. In a smaller group of patients (45 prevalent PD patients), Malik et 
al (Malik et al., 2007) previously found a significant relationship between dialysate MCP-1 
concentrations and past peritonitis; the difference in findings may be explained by the use of 
dialysate concentrations rather than total MCP-1 production in this earlier study. 
 
Figure 43: CCL18 levels in dialysate do not 
correlate with glucose exposure 
 
Figure 44: CCL18 levels in dialysate do not 
correlate with dialysate volume 
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5.1(vi) Dialysis modality 
The levels of MCP-1, IL-6 and angiogenin are generally higher in the dialysate effluent from patients 
who are using automated nocturnal dialysis (APD) than from patients who are using manual 
exchanges (CAPD), although there is considerable overlap between the groups: 
 
            
 
 
 
 
 
Figure 45: MCP-1 levels in dialysate are 
not higher in patients who have 
experienced peritonitis 
 
Figure 46: MCP-1 levels are higher in 
patients using APD 
 
Figure 47: IL-6 levels are higher in patients 
using APD 
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Since many cytokine levels correlate with dialysate volume used and glucose exposure it is not 
surprising that cytokine levels are higher in APD patients.  Similarly the use of APD is more common 
in patients with low or no residual function (p < 0.0001) and these patients have higher cytokine 
levels. It is also possible that there is an effect directly related to increased fluid flows and associated 
physical stresses on the peritoneum. 
5.1(vii) ACEi and ARB 
 
 
 
 
 
 
Figure 48: Angiogenin levels are higher in 
patients using APD; note this p value is not 
significant if corrected for multiple 
comparisons 
 
It is likely that the increased levels of these 
cytokines in the dialysate of APD patients relate 
to the reasons why patients use a particular 
modality. While for some it is a lifestyle choice, 
for others who have a high dialysate to plasma 
creatinine ratio it is necessary to perform 
multiple short duration dwells, with a high 
dialysate volume and glucose exposure, to 
achieve adequate ultrafiltration. Anuric patients 
may require APD to achieve adequate creatinine 
clearances.  
 
 
 
The dialysate levels of CCL18 were lower in 
patients who took an ACEi or an angiotensin 
receptor blocker. As discussed in the 
introduction, the angiotensin system may be 
involved in the pathogenesis of peritoneal 
changes and particularly fibrosis. CCL18 is 
associated with fibrosis in other conditions. The 
fall in dialysate levels of CCL18 may be due to a 
fall in serum levels of CCL18 (the distribution of 
D/P creatinine is the same whether ACEi/ARBs 
are taken or not). This result should be treated 
as hypothesis-generating only as the p value 
would not be significant if corrected for 
multiple comparisons. 
Figure 49: Dialysate levels of CCL18 were 
lower in patients who took an ACE 
inhibitor or angiotensin receptor blocker 
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5.1(viii) Diabetes 
Patients with diabetes were not found to have higher levels of cytokines in the dialysate effluent. 
This is interesting in that in the general population patients with diabetes have frequently been 
shown to have higher levels of MCP-1 (Piemonti et al., 2009). It is possible that the high levels of 
glucose in the dialysate mimic the effect of diabetes on cells in the peritoneum, such that all PD 
patients have high MCP-1 production regardless of whether they have diabetes. 
 
5.1(xi) Fluid type 
One problem in assessing the effect of fluid type on cytokine levels in the sample population is that 
the use of Physioneal increased during the study, being 34% in the first 50 patients recruited, 24% in 
the second fifty patients recruited and 100% in the final fifty patients recruited. This is statistically 
significant (p < 0.0001, Krushal-Wallis test). This problem does not occur with other variables such as 
peritonitis rates or duration of PD at time of sampling, and no systematic differences are noted by 
recruitment time for serum and dialysate cytokine levels. 
No significant differences were noted for dialysate cytokines between patients using Dianeal and 
those using Physioneal. 
 
Summary 
In this initial analysis, the levels of cytokines (apart from angiogenin) were seen to increase with 
duration of peritoneal dialysis. All cytokines correlated significantly with the D/P creatinine, but the 
mechanism by which this occurs is likely to differ between cytokines – while CCL18 and CCL15 levels 
in the dialysate might correlate closely with membrane transport properties because they enter the 
dialysate from the circulation, this is not likely to be the case for IL-6 and MCP-1. The relationship 
between these cytokines and the membrane transport of creatinine may be due to a confounding 
factor, such as glucose exposure, which affects both the peritoneal properties and cytokine levels, or 
might be due to an effect of these cytokines on the peritoneal membrane. Cytokines of similar 
molecular weight do not show identical relationships with dialysate volume and glucose exposure, 
suggesting that mechanisms may differ between one cytokine and another. The direction of effect is 
also not clear from this data. 
No correlations were seen between cytokine level and peritonitis history, but interestingly CCL18 
levels were seen to be lower in patients who were taking an ACEi or ARB, suggesting CCL18 may be a 
downstream mediator of the effects of angiotensin on the peritoneum. However, the groups of 
patients who did and did not take these medications may have differed in other respects such as 
duration of PD. 
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5.2 Multivariate analysis 
Multivariate analysis was performed by Dr Bernard North of the Imperial College Statistics Advisory 
Service. 
Multiple regression analysis was performed to identify the joint effect of the following candidate 
predictors: 
 D/P creatinine 
 Duration of PD 
 Glucose exposure 
 Dialysate volume 
 Urine output 
 Residual GFR 
 Fluid type 
 Number of peritonitis episodes 
on the dialysate levels of each of the cytokines CCL18, MCP-1, CCL15, angiogenin and IL-6. 
These candidate predictors were chosen as they are clinically important to the well-being, long term 
prognosis and dialysis management of a patient on peritoneal dialysis. Glucose exposure is known to 
have a long term effect on the characteristics of the peritoneal membrane (Davies et al., 2001); 
residual function is a predictor of mortality in peritoneal dialysis patients (Wang and Lindholm, 
2002). The D/P creatinine is an important determinant of solute clearance, as well as affecting 
achieved ultrafiltration, and might be expected to correlate with the rate of cytokine transfer from 
the circulation (although creatinine is a considerably smaller molecule than cytokines and might not 
pass through the peritoneum by the same route). Fluid type may also be important although the 
newer dialysis fluids containing fewer glucose degradation products and with a neutral pH have not 
so far been shown to have long term benefits on outcome. While single peritonitis episodes often do 
not have an impact on peritoneal membrane function there is evidence that a severe or recurrent 
series of peritonitis events can do so (Davies et al., 1996). Duration of peritoneal dialysis is an 
important predictor to include since both membrane transport and ultrafiltration are known to 
change during the course of time (Davies, 2004). 
All cytokines required log transformation to satisfy model assumptions (the non-transformed 
distribution of cytokines is non-normal); once transformed the distribution of cytokines is acceptably 
close to a normal distribution. Model fit was assessed by residual plots including Q-Q plots for 
normality of residuals and residuals vs fits plots to assess linearity of effect of the predictors on the 
log transformed cytokine level. 
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Log CCL18 
(adj. R2 = 0.243) Unstandardised Coefficients Standardised 
Coefficients 
t Significance 
B Std. Error 
Constant 2.447 0.193  12.675 < 0.001 
D/P creatinine 1.838 0.265 0.498 6.946 < 0.001 
Table 8: Linear regression for CCL18 
Log CCL15 
(adj. R2 = 0.253) Unstandardised Coefficients Standardised 
Coefficients 
t Significance 
B Std. Error 
Constant 2.768 0.164  16.901 < 0.001 
D/P creatinine 0.997 0.237 0.346 4.202 < 0.001 
Glucose Exposure 0.000187 0.000 0.288 3.498 0.001 
Table 9: Linear regression for CCL15 
Log MCP-1 
(adj. R2 = 0.267) Unstandardised Coefficients Standardised 
Coefficients 
t Significance 
B Std. Error 
Constant 1.95 0.108  17.993 < 0.001 
D/P creatinine 0.838 0.159 0.399 5.287 < 0.001 
Dialysate volume 1.518E-5 0.000 0.267 3.583 < 0.001 
Table 10: Linear regression for MCP-1 
 
The effect of dialysate volume might be related to increased fluid flows and stress on the 
peritoneum but is more likely to be due to the increased glucose exposure; with dialysate volume 
excluded from the model the following coefficients are obtained: 
 
(adj. R2 = 0.267) Unstandardised Coefficients Standardised 
Coefficients 
t Significance 
B Std. Error 
Constant 1.95 0.108  17.993 < 0.001 
D/P creatinine 0.838 0.159 0.399 5.287 < 0.001 
Glucose Exposure 1.088E-4 0.000 0.230 3.051 0.003 
Table 11: Linear regression for MCP-1 
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Log Angiogenin 
(adj. R2 = 0.249) Unstandardised Coefficients Standardised 
Coefficients 
t Significance 
B Std. Error 
Constant 4.121 0.124  33.269 < 0.001 
D/P creatinine 1.197 0.170 0.504 7.051 < 0.001 
Table 12: Linear regression for angiogenin 
 
Log IL-6 
(adj. R2 = 0.342) Unstandardised Coefficients Standardised 
Coefficients 
t Significance 
B Std. Error 
Constant 0.380 0.178  2.135 0.034 
D/P creatinine 1.585 0.266 0.442 5.951 < 0.001 
Glucose Exposure 0.000145 0.000 0.183 2.425 0.017 
Duration of PD 0.002 0.001 0.146 1.992 0.048 
Table 13: Linear regression for IL-6 
 
Summary 
It is immediately clear that the strongest predictor for all cytokines in the multivariate analysis is the 
D/P creatinine. Although the other factors which remain significant in the multivariate model do so 
with very small unstandardised coefficients, the standardised coefficients indicate that the effects of 
factors other than D/P creatinine on the regression equation are relevant.  
The outstanding question from this analysis would be the direction of this correlation with the D/P 
creatinine effect. One possibility is that cytokines have an effect on membrane transport properties 
and that this is why, for example, high levels of IL-6 are associated with a high D/P creatinine. This 
effect could occur via changes in the vasculature or the interstitium. The other possibility is that 
cytokine levels in the dialysate are largely dependent on the membrane transport properties 
because cytokines enter the dialysate from the circulation via the peritoneal membrane. This may 
well be the case for some cytokines, especially CCL15, but is not the case for IL-6 and MCP-1 because 
these molecules are found in dialysate at levels which are too high to have occurred by diffusion 
from the circulation. 
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Cytokine D/P creatinine Glucose exposure Duration of PD 
CCL18 p < 0.001   
Angiogenin p < 0.001   
CCL15 p < 0.001 p = 0.001  
MCP-1 p < 0.001 p = 0.003  
IL-6 p < 0.001 p = 0.017 p = 0.048 
Table 14: Summary of significant predictors of dialysate cytokine levels 
 
5.3 Serum cytokine levels 
The relationship between serum and dialysate levels of cytokines is discussed in section 3.2. In 
summary, for some cytokines (CCL15, CCL18 and angiogenin) there is a clear relationship between 
serum and dialysate cytokine levels and the amount of cytokine found in the dialysate appears to be 
related chiefly to serum cytokine level and the membrane transport properties of the patient.  For 
MCP-1 and IL-6 the amount of cytokine found in the dialysate is much higher than would be 
expected if dialysate cytokine levels were determined only by serum cytokine level and transfer 
across the membrane into the peritoneal space, and it is likely that dialysate levels of these 
cytokines are determined by intra-peritoneal production. 
In general, serum levels of cytokines are less closely correlated with peritoneal dialysis-related 
clinical factors than are dialysate levels. There is some evidence in the literature that serum levels of 
inflammatory biomarkers can show a very large variation at varying points in time in individual renal 
patients (LaClair et al., 2008). Repeated measures of serum MCP-1, CCL18, angiogenin and CCL15, 
with samples taken over a period of several weeks or months, were performed in transplanted and 
haemodialysis patients as part of the study (repeated samples were only planned a year apart from 
peritoneal dialysis patients). The coefficient of variation was calculated as a measure of reliability for 
pairs of measurements made on a minimum of fifteen patients for each cytokine. Repeated 
measurement data is not available for IL-6. 
 
Cytokine Number of repeats Coefficient of variation 
MCP-1 15 26.7% 
CCL18 17 26.9% 
CCL15 19 12.5% 
Angiogenin 19 14.3% 
Table 15: Coefficient of variation for repeated cytokine measurement in serum 
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Some of the variation is related to inter-assay variation (between 7 and 8% for these cytokines) and 
the remainder is related to the changes in cytokine levels that occur from day to day and week to 
week in renal patients. 
 
5.3(i)  Duration of peritoneal dialysis 
Serum levels of CCL18, MCP-1, IL-6 and angiogenin do not correlate with the duration of PD (all 
dialysate cytokine levels except angiogenin correlate with the duration of PD).  The serum level of 
CCL15 shows a weak correlation with the duration of peritoneal dialysis (r = 0.217, p = 0.014).  This 
lack of correlation between serum cytokines and dialysis duration is important in the light of the 
increase in dialysate cytokine levels with increased time on PD. Clearly the increase in dialysate 
cytokine concentrations with time is not due to an increase in serum levels. It is possible that the 
increase in CCL15 and CCL18 dialysate cytokine levels over time occurred due to a change in the 
membrane transfer properties with PD duration: 
 
 
 
 
The D/P creatinine describes small molecule transfer and transfer of larger molecules may not show 
the same relationship with dialysis duration. Struijk et al found that the peritoneal membrane 
permeability to macromolecules such as α2 macroglobulin actually fell with time on PD, perhaps 
because of increased connective tissue (Struijk et al., 1991). So for larger cytokines such as IL-6 the 
increase in dialysate cytokine levels with duration of PD is due to neither an increase in serum levels, 
nor the observed change in membrane transport properties as this reflects small molecule transport. 
 
Figure 50: There is an increase in D/P 
creatinine over time 
 
This increase in membrane transport rate for 
small molecules with time has been well 
documented in the literature (Struijk et al., 
1991; Davies et al., 1996). In our study group, 
the D/P creatinine increases from 0.7 in patients 
who have used peritoneal dialysis for a year or 
less to 0.76 in patients who have been on 
peritoneal dialysis for more than four years; this 
is a selected group of stable long term patients, 
however. 
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5.3(ii)  Membrane transport status 
The serum levels of IL-6, MCP-1 and CCL18 correlate with the membrane transport rate. It is likely 
that many factors impact on the serum levels of cytokines in dialysis patients. In turn, cytokine 
mediators of inflammation in the serum could affect the peritoneal membrane, increasing transport 
of small molecules by inducing angiogenesis or vasodilatation.  
Alternatively there could be another factor which correlates with both serum cytokine levels and 
membrane transport status. We have seen in section 3.2 that serum levels of IL-6 and MCP-1 do not 
correlate with the residual GFR, so this is not the potential link between serum levels of these 
cytokines and the peritoneal membrane transport rate. As discussed in section 5.3(i) the duration of 
PD also does not correlate with serum levels of most cytokines. 
            
 
 
 
 
 
    
 
 
Figure 53: There is a positive correlation 
between the serum CCL18 levels and the 
membrane transport rate 
 
Figure 51: There is a small positive 
correlation between the serum IL-6 levels 
and the membrane transport rate 
Figure 50: There is a positive correlation 
between the serum CCL18 levels and the 
membrane transport rate 
 
Figure 52: There is a positive correlation 
between the serum MCP-1 levels and the 
membrane transport rate 
 
Serum levels of CCL18 do correlate with the 
membrane transport rate and also with GFR 
(although weakly). It is possible that serum 
levels of CCL18 correlate with GFR and that 
this is the link between serum CCL18 levels 
and the peritoneal membrane transport rate. 
However, it is also possible that circulating 
CCL18 affects the peritoneal membrane and 
increases small solute permeability directly. 
This could occur via angiogenesis and an 
increase in the effective area for diffusion of 
small solutes. 
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5.3(iii)  Glucose exposure 
     
 
 
 
 
 
5.3(iv)  Dialysate volume 
Similarly there are weak correlations between both CCL15 and CCL18 and the dialysate volume used 
per twenty four hours (CCL15: r =0 .274, p = 0.002; CCL18: r = 0.173, p = 0.035). Again it is difficult to 
disentangle whether this is due to any effects of CCL15 and CCL18 on the peritoneal membrane 
properties, or whether it is secondary to the fact that patients with poor residual function generally 
require larger volumes of dialysate. 
 
5.3(v)  Peritonitis 
None of the study group samples were taken during or within 6 weeks of a peritonitis episode. 
 
 
 
 
The only cytokine for which the serum levels 
correlated with glucose exposure was CCL15. 
This is in contrast to the dialysate levels of 
cytokines, which we have seen in section 
4.1(iii) largely correlated with exposure to 
glucose in the dialysate. In the case of serum 
CCL15 levels, it is possible that the correlation 
of serum CCL15 with residual function is 
responsible for the apparent correlation with 
glucose exposure, since residual function and 
glucose exposure are closely related. 
The serum level of CCL18 was found at higher 
levels in patients with a history of peritonitis, 
although with considerable overlap between 
groups. When the data was analysed as zero, 
one or two or more episodes of peritonitis, 
then the Kruskal-Wallis statistic remained 
significant (p=0.0489). This suggests that there 
may be a persistent increase in serum CCL18 
levels after an episode of peritonitis; however 
the difference is no longer significant if 
corrected for multiple comparisons. 
Figure 54: There is a correlation between 
the serum CCL15 levels and glucose 
exposure 
 
Figure 55: The serum level of CCL18 is 
higher in patients who have experienced 
peritonitis 
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5.3(vi)  Dialysis modality 
There was no difference in serum cytokine levels between patients using CAPD and APD. This is not 
unexpected in that the factors which tend to differ between APD and CAPD – dialysate volume and 
glucose exposure – have not been seen to correlate with most serum cytokine levels. In addition 
some patients will be using APD for lifestyle reasons rather than clinical necessity, and for these 
patients their cytokine levels might well differ from the group with high membrane transport rate 
who need to use APD to achieve adequate ultrafiltration.  
One factor which might have been more prominent in APD, with more frequent fluid exchanges, was 
the role of fluid stress. 
 
5.3(vii)  ACEI 
 
   
 
 
 
 
5.3(viii) Diabetes 
None of the measured cytokines were found to be present at higher levels in PD patients with 
diabetes as compared to patients without diabetes. This is slightly surprising in the case of MCP-1, 
which is known to be found at higher levels in diabetic patients. One possibility is that the levels of 
MCP-1 are generally so high in peritoneal dialysis patients (perhaps because of the high levels of 
exposure to glucose in dialysate) that there is then no difference between diabetic and non-diabetic 
patients. In support of this, work from Dr Tam’s group (A Qureshi) showed that the median level of 
MCP-1 in CKD patients not on dialysis is only 180pg/ml, whereas in the peritoneal dialysis population 
the median level is substantially higher at 245pg/ml. For most cytokines the levels were noted to be 
higher in haemodialysis patients than peritoneal dialysis patients (see section 8.1(i)), but this is not 
the case for MCP-1. 
Serum levels of CCL18 (as well as dialysate 
levels) were found to be higher in samples 
from patients who were not taking an 
angiotensin converting enzyme inhibitor or 
angiotensin receptor blocker than in samples 
from patients who took these medications. 
Activity of the renin-angiotensin system is 
associated with fibrosis in the peritoneum and 
elsewhere.  
Figure 56: The serum level of CCL18 is 
higher in patients who are not taking an 
ACEi or ARB 
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5.3(ix) Fluid type 
 
 
 
 
Summary 
The correlation of serum levels of cytokines with the membrane transport rate is interesting because 
most serum cytokine levels investigated did not correlate strongly, or at all, with other factors such 
as glucose exposure, residual renal function or duration of peritoneal dialysis. This makes it less likely 
that these factors, which are known to be associated with the membrane transport properties of 
peritoneal dialysis patients, are confounding the relationship between serum cytokine levels and the 
D/P creatinine. It may be the case that circulating cytokines affect peritoneal membrane properties 
by inducing angiogenesis or fibrosis. Serum levels of cytokines appear to be quite variable from one 
sample to another if measured repeatedly, however. Serum levels of CCL15 did correlate with 
duration of PD and glucose exposure; this means that it is more difficult to interpret the association 
with membrane transport properties. 
The observation that CCL18 levels were lower in the dialysate of patients who took an ACEi or ARB 
was also observed in the serum levels of CCL18; lower serum levels of CCL18 were also seen in the 
group taking these medications and may be responsible for the lower dialysate levels. 
 
5.4 Multivariate analysis of dialysate cytokine levels including serum levels 
Having explored the relationships between clinical measures and both serum and dialysate cytokine 
levels, the respective serum cytokine level was then added to the multivariate analysis of each 
cytokine level in dialysate to establish whether serum cytokine levels were significant determinants 
of dialysate cytokine levels. As before, cytokine levels were log transformed to satisfy model 
Figure 57: The serum level of angiogenin is 
higher in patients who are using Dianeal 
There is a significant difference in median 
serum angiogenin levels only between the 
group of patients using Physioneal and those 
using Dianeal. This difference is quite small 
(median values 730257 v 914885 pg/ml) and 
the p value of 0.01 is only just significant if 
corrected for multiple comparisons. 
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assumptions. Candidate predictors duration of PD and glucose exposure were also log transformed. 
Model fit was assessed by residual plots including QQ plots for normality of residuals and residuals 
versus fits plots for linearity of the effect of the predictors on the log transformed cytokine level. 
Analysis was performed using SPSS version 19 and the R project version R.13. 
 
(adj R2 = 0.382) Unstandardised Coefficients Standardised 
Coefficients 
t Significance 
B Std. Error 
Constant 2.453 0.172  14.223 < 0.001 
D/P creatinine 1.449 0.245 0.394 5.922 < 0.001 
CCL18 serum 0.000001903 < 0.0001 0.407 6.119 < 0.001 
Table 16: Linear regression for dialysate CCL18 
 
(adj R2 = 0.713) Unstandardised Coefficients Standardised 
Coefficients 
t Significance 
B Std. Error 
Constant - 2.502 0.367  - 6.809 < 0.001 
Log CCL15 serum 1.098 0.081 0.687 13.521 < 0.001 
D/P creatinine 1.218 0.147 0.425 8.312 < 0.001 
Log glucose exp. 0.164 0.072 0.12 2.27 0.025 
Table 17: Linear regression for dialysate CCL15 
 
(adj R2 = 0.277) Unstandardised Coefficients Standardised 
Coefficients 
t Significance 
B Std. Error 
Constant 4.066 0.135  30.148 < 0.001 
D/P creatinine 1.238 0.171 0.522 7.253 < 0.001 
Angiogenin serum 0.000000658 < 0.0001 0.19 2.66 0.009 
Fluid type -0.080 0.039 -0.15 -2.059 0.041 
Table 18: Linear regression for dialysate angiogenin 
 
As expected from the data suggesting that transfer of the cytokine from the circulation to the 
dialysate determines levels of these cytokines in dialysate effluent, the serum levels of CCL18, CCL15 
and angiogenin are significant predictors of the levels of these cytokines in dialysate.  
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(adj R2 = 0.281) Unstandardised Coefficients Standardised 
Coefficients 
t Significance 
B Std. Error 
Constant 1.43 0.216  6.607 < 0.001 
D/P creatinine 0.843 0.156 0.404 5.402 < 0.001 
Log glucose exp. 0.189 0.077 0.184 2.465 0.015 
MCP-1 serum 0.00028 < 0.0001 0.14 1.915 0.057 
Table 19: Linear regression for dialysate MCP-1 
 
(adj R2 = 0.331) Unstandardised Coefficients Standardised 
Coefficients 
t Significance 
B Std. Error 
Constant -0.59 0.355  -1.662 0.099 
D/P creatinine 1.452 0.267 0.41 5.434 <0.001 
Log duration PD 0.124 0.061 0.149 2.046 0.043 
Log glucose exp. 0.331 0.126 0.198 2.625 0.01 
Log IL-6 serum 0.189 0.101 0.132 1.875 0.063 
Table 20: Linear regression for dialysate IL-6 
 
Interestingly, the serum levels of MCP-1 and IL-6 are not significant (at p < 0.05) predictors of the 
dialysate levels of MCP-1 and IL-6 respectively. This finding was expected from the analysis 
suggesting that intra-peritoneal production of IL-6 and MCP-1 is likely to determine dialysate levels, 
and that concentrations of these cytokines in the dialysate effluent – a large volume of fluid only 
transiently exposed to the peritoneum – are often higher than serum concentrations. The near-
significance of serum MCP-1 and IL-6 as predictors of the dialysate cytokine level may be because 
some movement of cytokines takes place from the serum to the dialysate early in the dwell period. 
Alternatively, it is possible that peritoneal production of these cytokines is great enough to influence 
systemic serum levels. 
Another interesting finding is that the D/P creatinine remains a significant predictor of IL-6 and MCP-
1 in the dialysate despite the finding that transport of cytokines across the peritoneal membrane is 
unlikely to determine these dialysate cytokine levels. It is possible that IL-6 and MCP-1 have an effect 
on the peritoneum such that high levels of IL-6 and MCP-1 are associated with a high membrane 
transport rate. Alternatively, both the membrane transport rate and the dialysate cytokine level may 
be affected by a common factor such as glucose exposure.  
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Cytokine D/P creatinine Serum level Glucose 
exposure 
Duration of 
PD 
Fluid type 
CCL18 p < 0.001 p < 0.001    
Angiogenin p < 0.001 p = 0.009   p = 0.041 
CCL15 p < 0.001 p < 0.001 p = 0.025   
MCP-1 p < 0.001 (p = 0.057) p = 0.015   
IL-6 p < 0.001 (p = 0.063) p = 0.01 p = 0.043  
Table 21: summary of significant predictors of dialysate cytokine levels including serum levels 
 
Table 21 shows the significant predictors of dialysate cytokine levels by multivariate analysis. The p 
values for serum levels of MCP-1 and IL-6 are shown because these predictors had a borderline 
significance although not meeting the specified cut-off of 0.05. 
 
Summary 
Multivariate analysis provides some confirmation that dialysate levels of CCL15, angiogenin and 
CCL18 are likely to be determined by serum levels of the cytokine and the transport properties of the 
peritoneal membrane; thus levels of these cytokines measured in dialysate effluent are not 
determined by intra-peritoneal production (even if this may be important in the pathogenesis of 
membrane changes). Serum levels of MCP-1 and IL-6, however, were not significant predictors of 
dialysate levels of these cytokines. Overall, the relatively high dialysate levels of these cytokines and 
the lack of a close correlation with the respective serum level suggests that intra-peritoneal 
production is important in determining the dialysate level of IL-6 and MCP-1. 
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CHAPTER 6 
RESULTS: Follow-up levels at one year 
 
6.1 Follow-up samples at one year 
Follow up samples were obtained from 50 patients. Of the remaining 101 patients, 62 had 
discontinued peritoneal dialysis at the one year time point and had transferred to haemodialysis, 
died, recovered function, transferred to another unit or received a kidney transplant. The absence of 
samples from the remaining patients who were still on PD at one year after the original PET test and 
sample were taken reflects the fact that sometimes there was no opportunity for a sample to be 
collected when the patient attended for their one year PET test. 
 
 
6.1(i) Changes in clinical data at one year 
 
Follow up samples were collected a median of 14.2 months after the first sample collection. 
Examining only the patients with both baseline and follow up samples changes in clinical data were 
seen to be as expected given the known increase in D/P creatinine and decrease in residual renal 
function with time on PD: 
More patients were now on APD (64.6% v.50% at baseline) and more used Physioneal rather than 
Dianeal (60.4% at one year used Physioneal v. 42% at baseline). The residual renal function of the 
patients had declined (from 4mls/minute to 3mls/minute, p < 0.001) and the dialysate/plasma 
Figure 58: patient status at one year and follow-up sample 
collection 
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creatinine ratio had increased (from 0.71 to 0.75, p=0.006). The total creatinine clearance was 
slightly lower and the mean serum creatinine had increased (from 704 to 789µmol/ml, p < 0.001). 
These are all changes that might be anticipated given the well documented natural history of 
peritoneal membrane characteristics over time on peritoneal dialysis. Patients also required more 
dialysate (from a median of 8L per 24 hours, increased to 10.3L per 24 hours, p = 0.001) and 
therefore had a greater exposure to glucose (from a median of 769 to 821mmol/24 hours, p < 
0.001).  
 
6.1(ii) Changes in cytokine levels in follow up data 
 
 Serum Dialysate 
 Median 
difference 
(pg/ml) 
% change in 
medians 
Significance 
(p value) 
Median 
difference 
(ng) 
% change in 
medians 
Significance 
(p value) 
CCL18 +20176 + 32% 0.002 +2398 +47% 0.002 
Angiogenin -342401 - 35% < 0.001 +4343 +21% ns 
MCP-1 +12.8 +17% ns -75 -14% ns 
IL-6 +0.21 +0.5% ns +31.9 +151% 0.01 
CCL15 -784 -2.3% ns +1976 +70% < 0.001 
Table 21: differences in cytokine levels at one year 
 
In the group as a whole we have previously seen that there is little relationship between duration of 
peritoneal dialysis and serum levels of cytokines, while the dialysate levels of IL-6, MCP-1, CCL15 and 
CCL18 show a degree of correlation with duration of PD (section 5.1(i)). However, this may not 
reflect the findings in the fifty patients with follow up samples as they may be a selected group who 
are at a different point in their PD career. 
For CCL18, there is an increase in the amount of cytokine in both serum and dialysate. The increase 
in dialysate CCL18 is proportionately more than the increase in serum CCL18. This suggests that 
either there has been an increase in the permeability of the membrane, so that more CCL18 enters 
the peritoneal space from the serum across the peritoneal membrane, or that there has been an 
increase in the intra-peritoneal production of CCL18. On examining the dialysate to serum cytokine 
ratios at one year (table 10), we see that there has been an increase in D/S ratio for most cytokines: 
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Baseline D/S 
ratio 
One Year 
D/S ratio 
Median / mean 
difference 
% change in 
median /means 
Significance  
(p value) 
CCL18 0.0185 0.0333 +0.0129 +80% 0.002 
Angiogenin 0.0503 0.0767 +0.029 +52% 0.007 
IL-6 5.601 9.932 +1.766 +77% < 0.001 
CCL15 0.085 0.1137 0.0519 +34% <0.001 
MCP-1 0.9252 0.7678 -0.218 -17% 0.001 
Creatinine 0.708 0.75 0.042 + 5.6% 0.006 
Table 22: changes in dialysate/serum ratios of cytokines at one year. Creatinine is included for        
comparison 
This might represent a generalised increase in membrane permeability to cytokines. In this case the 
increase in dialysate CCL18 levels would be due to the combination of an increase in serum levels 
and an increase in membrane permeability to CCL18. Of note, the increase in dialysate to serum 
ratio for CCL18 is much greater than the change seen for creatinine transfer. Creatinine is a 
considerably smaller molecule than CCL18 (molecular weight 0.113kDa versus 7.8kDa) and structural 
changes in the peritoneal membrane may have a different effect on the transfer of these two 
molecules. 
Angiogenin levels have decreased in serum but remained constant in dialysate, again, a possible 
increase in membrane permeability to cytokines may explain why dialysate levels of angiogenin are 
maintained. Alternatively there may have been an increase in angiogenin production in the 
peritoneum. 
Serum and dialysate levels of MCP-1 have not changed significantly over the course of the year. 
For IL-6 and CCL15 the serum levels have remained constant but the dialysate content of these 
cytokines has increased. For IL-6 this is likely to reflect increased intra-peritoneal IL-6 production, 
since it is unlikely that the dialysate levels of IL-6 are determined by the serum level. The increase in 
dialysate CCL15, independently from an increase in serum CCL15, is interesting because dialysate 
CCL15 appears to be determined mainly by the serum level of CCL15 and the membrane 
permeability and CCL15 is not made by peritoneal cells (see Chapter 9). Thus if dialysate CCL15 has 
increased while the serum level has remained constant, it is likely that there has been a change in 
the permeability of the peritoneal membrane to CCL15. This makes it more likely that the increased 
dialysate levels of CCL18 and angiogenin relate to increased membrane permeability to all cytokines. 
The mechanism by which this occurs may be an increased vascular surface area secondary to neo-
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angiogenesis within the peritoneal membrane. Alternatively there may be an increase in the number 
of small pores, which are thought to be clefts between the endothelial cells, without an increase in 
the number of blood vessels. 
This data can be compared with the cross-sectional data relating to cytokine level and time on 
dialysis. It should be noted, however, that the group who have stayed on peritoneal dialysis and had 
a repeat PET may be a selected group who show differing cytokine patterns. In addition, the cross-
sectional data for duration of dialysis includes a very wide range of values. However, as discussed 
below, the cross-sectional data relating to dialysis duration and cytokine levels is broadly similar to 
that expected from the changes seen after an additional one year on dialysis in those patients who 
had a follow-up sample available. 
For CCL18 an increase in both serum and dialysate levels was seen in the one year group. Both 
serum and dialysate levels correlate with duration of dialysis in the cross-sectional survey. However 
the dialysate/serum ratio of CCL18 was found to have increased in the one year samples whilst there 
was no significant correlation of D/S CCL18 ratio with duration of dialysis in the cross-sectional data. 
For angiogenin a fall in serum levels was noted in the one year follow up samples, with an increase in 
D/S angiogenin ratio. In the cross-sectional data no correlations were seen between duration of 
dialysis and angiogenin levels in serum or dialysate, or between duration of dialysis and D/S 
angiogenin ratio. It is possible that this is an effect of selective sampling at one year follow up. 
For IL-6 the dialysate levels, but not the serum levels, increased in the one year samples. In keeping 
with this the D/S ratio of IL-6 also increased. In the cross-sectional data the same pattern was seen, 
with dialysate IL-6 levels and D/S IL-6 ratios correlating with dialysis duration. Serum IL-6 levels did 
not correlate with dialysis duration. 
For CCL15 the dialysate levels and D/S ratio also increased in the one year samples. However, in the 
cross-sectional data, a positive correlation between CCL15 levels in serum and duration of peritoneal 
dialysis was noted as well as between CCL15 levels in the dialysate, with therefore no significant 
correlation between D/S ratio CCL15 and duration of dialysis. 
For MCP-1, there were no significant changes in the dialysate and serum levels in the one year 
samples; the direction of the trend in these parameters meant that the D/S ratio fell slightly at one 
year. In the cross-sectional data a positive correlation between both serum and dialysate levels of 
MCP-1 and duration of dialysis was noted. These differences probably relate to the different patient 
populations. It is possible that changes in MCP-1 production rate vary with the duration of PD; this is 
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not the same in the complete baseline population and the population with one-year follow-up 
samples (median 27 v. 34 months, p = 0.008). 
6.1(iii) High baseline serum angiogenin levels are associated with a greater increase in D/P 
creatinine 
The increase in D/P creatinine was examined to investigate whether those patients in whom the D/P 
creatinine had increased by more than 0.05 over the course of one year (n=23) showed any 
differences in cytokine profile from the group in which D/P creatinine was stable (n=27).  
Serum levels of angiogenin at baseline were higher in the group in which D/P rose (1004549pg/ml v. 
731643pg/ml, p=0.033). 
         
 
 
Serum levels of CCL15 were higher at one year in those patients who had experienced an increase in 
D/P creatinine (26348 v. 17175 pg/ml, p=0.006). Angiogenin may have an effect on the D/P 
creatinine because neovascularisation would increase the transfer of creatinine across the 
peritoneal membrane by increasing the surface area over which movement of creatinine may occur. 
The reasons for the higher serum levels of CCL15 are not clear; it is possible that there is a systemic 
inflammatory response in patients who have an increasing D/P creatinine, although there was no 
increase in systemic IL-6 levels. 
 
 
Figure 59: The baseline serum level of 
angiogenin is higher in patients who have 
an increasing D/P creatinine 
 
Figure 60: The one year serum level of 
CCL15 is higher in patients who have had 
an increase in D/P creatinine 
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Summary 
The data suggests that there is an increase in membrane permeability to the cytokines CCL15, CCL18 
and angiogenin over the course of the one year follow-up period.  This increase in permeability to 
the 7-14kDa cytokines is greater than the increase in permeability to creatinine. The greater increase 
in cytokine permeability than small molecule permeability may perhaps be due to the difference in 
the sizes of these molecules. Perhaps changes in blood vessel number or structure have a 
disproportionate effect on cytokine transport. High levels of angiogenin in the serum are associated 
with a greater increase in the D/P creatinine ratio. This is interesting because neovascularisation 
related to angiogenin could be responsible for the increased membrane permeability. However, the 
association is relatively weak (p = 0.033) and could be a statistical artefact due to multiple 
comparisons.  
The levels of MCP-1 are stable in the group of patients with follow-up samples. Levels of IL-6 
increased in the dialysate. Serum IL-6 levels are stable and dialysate levels of IL-6 are likely to be 
determined by intra-peritoneal IL-6 production. An overall increase in membrane permeability to 
cytokines is not likely to be responsible for the increased levels of IL-6 in the dialysate as dialysate 
levels of IL-6 are higher than serum levels. Additionally IL-6 is a larger molecule and transit across the 
peritoneum of IL-6 may be affected in a different way to the transit of smaller cytokines. 
Comparison with the cross-sectional data looking at correlations between cytokine levels and 
duration of PD shows that a very similar picture is seen for IL-6; the patterns for other cytokines 
differ slightly and this may be due to differences in the patient populations and variation in dialysis 
duration. 
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CHAPTER 7 
RESULTS: Outcome data -  EPS and UFF 
7.1 Patient outcomes 
 
Patient outcomes at one year from sample collection  
 
 
 
 
7.2 Outcomes: EPS 
7.2(i) Clinical predictors for future EPS 
EPS developed in 17 patients in the study cohort. The time from peritoneal dialysis cessation (either 
transplantation or transfer to haemodialysis) until the development of EPS was short in this cohort, 
with median value of 3.12 months (range: 0.6 – 7.7 months); one patient was diagnosed with EPS 
Figure 61: Patient outcomes at one year 
from sample collection. A small number of 
patients had transferred out and their 
outcome is unknown. A substantial 
proportion – nearly half – of all patients 
had stopped PD one year after sample 
collection. 
 
Figure 62: Patient outcomes at November 
2011. The first samples were collected in 
2003 and the last in 2010. 
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while still on peritoneal dialysis and the other 16 developed EPS after stopping PD. The median time 
from baseline sampling to the development of EPS was 13.6 months (range: 4.8 – 46 months); all but 
one of the EPS patients developed EPS within twenty six months of sample collection. The median 
time since diagnosis of the study group patients is now 68 months (range: 35-97 months). Ten of the 
patients with EPS have now died (eight of these patients died of EPS or complications of EPS 
treatment such as TPN-related line sepsis). Of the remaining patients, most are usually well and 
require no nutritional supplements, but still have occasional admissions to hospital with abdominal 
pain, abdominal distension or vomiting. 
 Age Renal 
diagnosis 
Duration 
PD 
(months) 
Peritonitis D/P 
Cre 
GFR 
(mls/
min) 
RRT 
at 
EPS  
Outcome Months to RIP 
or follow-up 
since EPS 
1 70 Hypertension 110 1 0.82 0.35 HD Died - not EPS 16 
2 48 Membranous 87 2 0.91 0 Tx Alive symptomatic 86 
3 49 GN 146 1 0.93 0 Tx Alive symptomatic 69 
4 48 APKD 74 1 0.87 0 HD Died of EPS  14 
5 61 DM 83 1 0.71 0 Tx Died of EPS 10 
6 51 IgA  84 0 0.64 3.51 HD Alive asymptomatic 61 
7 34 ATN 109 1 0.82 0 HD Died of EPS 84 
8 52 Unknown 51 2 0.83 1.26 Tx Alive symptomatic 79 
9 67 GN 137 0 0.89 0 HD Died of EPS 2 
10 65 DM 63 1 0.90 0.71 Tx Died of EPS 22 
11 55 DM 70 0 0.77 9.27 Tx Died of EPS 5 
12 76 Unknown 56 2 0.86 0.75 HD Died - not EPS 3 
13 52 IgA  104 1 0.87 0 HD Alive symptomatic 72 
14 62 Unknown 67 1 0.80 0.62 HD Alive symptomatic 77 
15 70 DM 51 1 0.66 2.12 Tx Alive asymptomatic 64 
16 49 Allport’s 76 0 0.95 0 Tx Died of EPS 43 
17 53 APKD 55 2 0.7 3.13 Tx Died of EPS 1 
Table 23: characteristics of the EPS patients: GFR and D/P creatinine refer to final PET test result on PD 
 
Compared to the remainder of the cohort, patients who developed EPS had been on peritoneal 
dialysis for a longer period of time (total duration of PD 76 versus 40 months). Glucose exposure at 
time of sampling was higher and both urine output and residual GFR lower. 
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Glucose exposure at time of sampling was 1266 v.796mmols/24 hours (higher in the EPS group, p < 
0.001). Urine output was lower (median 40mls/24 hours in the EPS group v. 764 mls/24 hours in the 
non-EPS group). Similarly residual GFR was 0.35 mls/minute in the EPS group and 3.77 mls/minute in 
the non-EPS group. 
 
            
 
 
Figure 63: Total duration of peritoneal 
dialysis was higher in patients who 
developed EPS 
 
Figure 64: Glucose exposure was higher in 
patients who developed EPS 
 
Figure 65: The urine output was lower in 
patients who later developed EPS 
 
Figure 66: The residual GFR was lower in 
patients who later developed EPS 
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A history of ultrafiltration failure was also more common in the EPS group – 47% of EPS patients (27-
71%) v. 8% of non-EPS patients (CI 4-13%), p < 0.001; the incidence of ultrafiltration failure increases 
with the duration of PD. 
 
7.2(ii) Chemokine levels are higher in patients who later develop EPS 
Dialysate levels of IL-6, CCL15 and MCP-1 were higher in patients who later developed EPS. 
 
 EPS No EPS 
MCP-1 658ng (range 390-2718ng) 395ng (range 100-2009ng) 
IL-6 92ng (range 28-471ng) 40ng (range 4-459ng) 
CCL15 8017ng (range 2060-17414ng) 4014ng (range 726-19394ng) 
Table 24: Median dialysate levels of cytokines in EPS and non-EPS patients 
 
 
 
 
Figure 67: The D/P creatinine ratio was 
higher in patients who subsequently 
developed EPS 
 
All of these findings are similar to those 
described in other published series and are as 
expected in a group of patients who have 
spent a long period of time on PD. A history of 
peritonitis was more common in the EPS 
group – 76.5% of EPS patients (CI 56-97%) v 
38% of non-EPS patients (CI 30-46%), p = 
0.004, had had at least one episode of 
peritonitis. Again this may simply reflect more 
months of exposure to the risk of peritonitis.  
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The other difference in later samples from this patient was that serum CCL18 was higher at later 
time points. Using this later value and comparing between the EPS and non-EPS groups, serum 
CCL18 becomes significantly different between the two groups (median 151590 v. 119959 pg/ml); 
however the p value is borderline at 0.039 and this finding may therefore be due to chance. For 
consistency the sample taken at recruitment is used in the analysis, as with all other patients. The 
remaining 16 EPS patients were sampled much closer in time to EPS onset. 
 
Figure 68: The dialysate appearance of 
MCP-1 was higher in patients who 
subsequently developed EPS 
 
Figure 69: The dialysate appearance of IL-
6 was higher in patients who subsequently 
developed EPS 
Figure 70: The dialysate appearance of 
CCL15 was higher in patients who 
subsequently developed EPS 
 
One patient was first sampled nearly four 
years before the onset of EPS. This patient had 
had a follow-up sample and a later sample 
taken four months before EPS was diagnosed; 
the changes in his data during the course of 
the four years before the cessation of PD were 
generally not large (table 25). An exception 
was a lower level of MCP-1 in the dialysate at 
the later date; using this value made minimal 
difference to the median MCP-1 level for the 
EPS group and dialysate MCP-1 remained a 
significant predictor of future EPS.  
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 46 months pre-EPS 
D/P cre = 0.77 
32 months pre-EPS 
D/P cre = 0.88 
4 months pre-EPS 
D/P cre = 0.83 
Serum Dialysate Serum  Dialysate Serum Dialysate 
CCL18 98034 21979 209266 26642 492016 23421 
MCP-1 486 1022 411 640 362 574 
IL-6 4.8 263 - 686 6.9 272 
Angiogenin 838515 163895 798314 131652 891801 167530 
CCL15 42840 11134 37665 7523 26359 15527 
Table 25: serial changes in cytokine levels in a patient who developed EPS 
 
When only the group of patients who had been on PD for more than 46 months at time of sampling 
is considered (33 non-EPS and 14 EPS patients), the duration of PD at sampling is no longer 
significantly different between the two groups (67 months in the EPS patients v. 64 months in the 
non-EPS group); the total duration of PD is also not significantly different (85 v. 73 months). 
Once duration of PD is eliminated as a confounding factor, patients who would later develop EPS 
continue to have significantly lower urine outputs (median 0 v. 491mls/24 hours, p = 0.011) and less 
residual function (median GFR of 0 v. 1.82mls/minute). The glucose exposure remains higher in this 
group (1238mmol v. 900mmol/24hours, p = 0.017) and the D/P creatinine remains higher (0.83 v. 
0.71, p = 0.026) – see table 26. 
This suggests that while the duration of PD is undoubtedly a significant risk factor for the 
development of EPS, glucose exposure, residual function and membrane transport properties are all 
risk markers for EPS development independently of their association with duration of PD. Cytokine 
levels are no longer significant predictors of EPS in this group of long term PD patients only.  
However this data does not prove which (if any) of these factors are part of the pathogenesis of EPS, 
especially as these variables correlate closely with each other. 
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 EPS Non-EPS p value 
Duration PD at sampling (months) 67 (46-135) 64 (47-82) 0.383 
Final duration PD (months) 83 (51-146) 73 (6-116) 0.199 
Glucose exp. (mmol/24 hours) 1238 (563-2319) 900 (300-2391) 0.02 
Residual GFR (mls/min) 0 (0-3.51) 1.82 (0-12.58) 0.008 
Urine output (mls/24 hours) 0 (0-1085) 491 (0-2985) 0.009 
D/P creatinine 0.83 (0.64-0.95) 0.71 (0.42-1) 0.019 
Dialysate CCL18 (ng) 8112 (1472-28265) 6803 (578-35856) 0.92 
Dialysate MCP-1 (ng) 655 (390-2718) 413 (100-2009) 0.062 
Dialysate IL-6 (ng) 86 (28-471) 80.5 (4-308) 0.403 
Dialysate angiogenin (ng) 140290 (21795-309993) 108495 (27800-302629) 0.616 
Dialysate CCL15 (ng) 7927 (2060-17414) 6851 (726-17456) 0.227 
Table 26: Long term PD patients (> 46 months at time of sampling). Median and range are shown 
 
7.3 Historical EPS group 
7.3(i) Description of cohort  
Before the prospective collection of data and samples was initiated at our centre, a number of 
patients had developed EPS. The first case was diagnosed in 1999. The total number of cases which 
were documented was 29, in addition to the study patients for whom a full set of data and clinical 
samples were collected. A complete set of data is not available on all of these historical patients, but 
some basic information could be collected. It is not possible to find matched control patients 
(separate from the study group) for these EPS patients; many ceased peritoneal dialysis some years 
ago and the PET/adequacy data for this cohort of peritoneal dialysis patients is no longer in 
existence.  
 
7.3(ii) Comparison with study group 
The median duration of PD in this historical group of EPS patients was 77.1 months and their age at 
diagnosis of PD was a median of 54.4 years. This compares to 75.86 months on PD and a median age 
of 53.2 years in the study group patients. The median number of peritonitis episodes was 1 in both 
groups and the rate of peritonitis per month was constant at 0.012 episodes / month in both groups. 
The median D/P creatinine was 0.81 in the historical cohort and 0.83 in the study group (at the last 
PET test). The median GFR was 0.35 in the study group and 0 in the historical group and this 
difference was not statistically significant. 15 of the patients were still alive at the end of the study; 
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none are still TPN dependent but some of the patients still have occasional short admissions with 
abdominal pain and distension. The time since diagnosis in this group of patients is a median of 80 
months (range 32-146 months).  
This data is interesting because it suggests that the study group patients are similar in terms of 
membrane function and duration of dialysis to other EPS patients managed at our institution in the 
past, as well as showing similar clinical risk factors for EPS to those described in the literature at 
other institutions. It is therefore more likely that findings in the study group population will apply to 
other peritoneal dialysis and EPS patients. 
 
7.4 Outcomes: Ultrafiltration failure 
7.4(i) Clinical predictors of future UFF 
The definition of UFF used for this study is mainly clinical, since adequate data on ultrafiltration 
capacity were not available for all patients. Ultrafiltration failure was defined as either: 
a) less than 750mls/24 hours of total fluid removed (urine and dialysis ultrafiltration combined) 
or 
b) patient stopping PD because of refractory fluid overload 
Clearly this definition will include some patients who could potentially have increased their 
ultrafiltration volumes by a change in dialysis prescription, or who might have remained on 
peritoneal dialysis if they had limited their salt and water intake further. 
 
Unsurprisingly, patients who went on to develop ultrafiltration failure had a lower urine output and 
residual GFR and used a greater volume of dialysate with a higher glucose exposure. In line with the 
literature, patients who had ultrafiltration failure had been on peritoneal dialysis for longer (32 v. 23 
months, p = 0.037), and had a higher D/P creatinine (0.78 v. 0.71, p = 0.022). 
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 UFF No UFF p value (Mann Whitney test) 
Duration of PD 
(months) 
32 23 0.037 
Glucose exposure 
(mmol/24 hours) 
1028 750 0.021 
Dialysate volume 
(L/day) 
12900 8214 0.007 
Urine output 
(mls/24 hours) 
199 917 <0.001 
GFR  
(ml/minute) 
0.8 4.04 <0.001 
CCL15 dialysate  
(ng) 
7327 4014 0.041 
D/P creatinine 
 
0.78 0.71 0.022 
Table 27: Factors differing between patients who did and did not develop ultrafiltration failure 
 
7.4(ii) CCL15 levels are higher in patients who later develop UFF 
 
 
 
 
 
 
 
Figure 71: The dialysate appearance of 
CCL15 was slightly higher in patients who 
subsequently developed UFF 
 
Although the level of CCL15 was higher in 
patients who went on to develop 
ultrafiltration failure, the difference is fairly 
small and barely statistically significant. It is 
probable that it relates to the higher D/P 
creatinine in this group. 
None of the other cytokines were found at 
higher levels in the group of patients who 
developed ultrafiltration failure, suggesting 
that it is the alteration in membrane transport 
properties which affects the CCL15 level in the 
dialysate. 
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7.5 Can chemokine levels help predict future EPS or UFF?  
With regard to ultrafiltration failure, there is only a very small difference in CCL15 levels between 
the groups who did and not develop ultrafiltration failure. It is likely that this increase in CCL15 level 
in the dialysate is explained by the higher D/P creatinine in this group and cytokines will not add 
anything to available clinical data in terms of the prediction of ultrafiltration failure. 
With regard to EPS, there are three cytokines which were found at a higher level in patients who 
went on to develop EPS. These were MCP-1, IL-6 and CCL15 in the dialysate. When building a 
predictive model to investigate whether these cytokines can predict EPS with any more accuracy 
than the clinical risk factors can, it is necessary to bear in mind the relatively small number of EPS 
patients in our cohort. Peduzzi et al (Peduzzi et al., 1996) demonstrated that a logistic regression 
analysis requires a minimum of about 10 events for each variable investigated; another formulation 
by Hosmer and Lemeshow gives the maximum number of parameters which can be estimated as 
(m/10)-1, where m is the smallest group (in this case, the number of EPS patients) (Hosmer and 
Lemeshow, 2000). Although a more flexible approach is argued by Vittinghoff, permitting perhaps 5-
9 events per variable (Vittinghoff and McCulloch, 2007), as there are only 17 EPS cases it is still not 
possible to investigate a large number of potential predictive variables. Dr North (Imperial College 
statistics advisory service) constructed two logistic regression models, one which uses final duration 
of PD and D/P creatinine as clinical predictors of EPS, and the other using MCP-1, IL-6 and CCL15. The 
clinical predictors were chosen as duration of PD is the most commonly-cited risk factor for EPS in 
the literature and has been demonstrated in multiple dialysis units worldwide. The D/P creatinine 
was chosen as an objective, measurable factor which is supported by other studies in the literature 
in which high D/P creatinine was a risk factor for EPS (Habib et al., 2010). It is noted that in some 
patients with severe membrane damage the D/P creatinine can fall slightly just before the onset of 
EPS (after an early rapid rise) (Sampimon et al., 2010a). This fall in D/P creatinine was associated 
with other late onset features such as loss of ultrafiltration capacity and may be a marker of early 
EPS or at least very significant peritoneal fibrosis. In a study by Lambie et al the D/P creatinine was 
seen to rise only at the last PET test before the discontinuation of PD (Lambie et al., 2010). These 
differences in the timing of increase in D/P creatinine may reflect differences in local practice; the 
Dutch EPS cohort, for example, contains a group of patients who continued on PD for some time 
after a diagnosis of ultrafiltration failure had been made.  
Other possible discriminating features such as high glucose exposure are dependent on the 
clinician’s prescription and therefore may be specific to a particular dialysis centre. Residual renal 
function is difficult to quantify in peritoneal dialysis patients, where it will typically be about 0-
10mls/minute. Creatinine clearance is notoriously unreliable as a measure of renal function at this 
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level of GFR. The usual practice is to take the average value of the creatinine and urea clearances, as 
the measurement errors are in opposite directions for these two substances and the average value 
becomes a reasonable approximation of function. Ultrafiltration capacity might also be a 
discriminating factor, but to some extent the D/P creatinine result covers this measure, since 
patients with a high D/P creatinine have poor ultrafiltration. 
Using logistic regression analysis, a model using the readily available clinical data – duration of PD 
and D/P creatinine - was constructed first. The duration of PD data required log transformation to 
obtain a normal distribution. 
 
 B S.E Wald df Significance Exp(B) 
Log Final duration PD 7.682 2.218 11.992 1 0.001 2169.167 
D/P creatinine 8.23 3.016 7.448 1 0.006 3750.026 
Constant -22.165 4.894 20.509 1 <0.001 0 
Table 28: Logistic regression analysis of EPS predictors 
The Hosmer and Lemeshow test for this regression has a p value of 0.973, and chi squared value of 
2.228, indicating a good model fit. 
In order to assess the usefulness of this analysis in the prediction of EPS, a ROC curve was 
constructed for the regression: 
 
Figure 72: ROC curve of logistic regression; 
predictors of EPS are log(final duration of 
PD) and D/P creatinine 
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The determination of the “best” cut point for such a curve is a matter of debate, and depends on the 
clinical importance of sensitivity versus specificity. In this case, it could be argued that the risk of 
mortality associated with EPS is significant, whereas the risks of changing dialysis modality are less. 
On this basis sensitivity should be optimised. A perhaps more objective method of determining the 
optimal cut point is to choose the coordinates on the ROC curve that have the minimum distance 
from the perfect situation where sensitivity and specificity are both 100%; thus the cut point is 
chosen as that point where (100%-sensitivity)2+(100%-specificity)2 is at a minimum (this is the square 
of the length of the line from the observed regression ROC curve to where “perfect” curve would lie 
by Pythagoras). For the above ROC this occurs where sensitivity is 88.2% (95% CI 64 - 99%) and 
specificity is 76.6% (95% CI 68 – 84%) at a cut point of > 0.1239. The classification table using this cut 
point would be as follows: 
 
Observed Predicted 
No EPS EPS % correct 
EPS ever No EPS 98 30 76.6% 
EPS 2 15 88.2% 
Overall percentage 77.9% 
Table 29: Classification table with cut point of 0.1239 
The choice of cut point is therefore dependent on the weight placed upon not “missing” a possible 
future case of EPS. It is clear that this is a far from perfect tool for predicting the likelihood of future 
EPS, being insufficiently specific at this cut-point. 
Of note, although the predictors used are universally assessed in peritoneal dialysis patients, the 
utility of the predictive equation would be expected to vary with the incidence of EPS in other 
peritoneal dialysis populations.  
The next question asked was whether cytokine levels could be used to produce a more useful 
predictive model. 
Using the three cytokines that were found by univariate analysis to be significantly different 
between EPS and non-EPS patients - IL-6, CCL15 and MCP-1 - (all log transformed) the following 
model is obtained: 
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 B S.E Wald df Significance Exp(B) 
Log MCP-1 3.123 1.778 3.085 1 0.079 22.703 
Log CCL15 1.993 1.318 2.288 1 0.13 7.340 
Log IL-6 1.183 1.064 1.237 1 0.266 3.265 
Constant -20.311 5.883 11.918 1 0.001 0.000 
Table 30: Logistic regression analysis using cytokines to predict EPS 
It can be seen that none of the p values in this model are significant for the individual variables, 
although the overall model is significant at p < 0.001. There is some debate regarding the necessity 
for each term to be significant in a logistic regression model, since the model is dealing with risk 
estimation rather than hypothesis testing (Steyerberg, 2009; Pencina et al., 2008). However the 
situations in which a predictor with a non-significant p value might be retained in a logistic 
regression model are those where there is a rare but strong predictor and a small data set; this is not 
the case in this study. Although using more predictors may slightly increase the area under the ROC 
curve, this does not necessarily mean that the predictive ability of the model is improved. Assessing 
risk prediction models is complex; to demonstrate a benefit with the inclusion of the extra predictors 
further testing such as reclassification (Cook, 2008; Cook, 2007) would be required, although this in 
itself remains a matter of debate (Pepe and Janes, 2011).  For these reasons, the model using three 
cytokines was not examined further. 
Using a conditional forward selection model, the only cytokine of the original three predictors (MCP-
1, IL-6 and CCL15) which remains in the model is MCP-1:  
 
 B S.E Wald df Significance Exp(B) 
Log MCP-1 5.112 1.493 11.722 1 0.001 166.039 
Constant -16.041 4.194 14.632 1 <0.001 0.000 
Table 31: Logistic regression analysis using MCP-1 levels to predict EPS 
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A ROC curve is shown to illustrate the regression: 
 
Inspection of this curve suggests that this is no improvement on the model constructed using clinical 
predictors only, and lies closer to the line of identity. In particular, if the sensitivity is required to be 
reasonably high, the specificity is low. The cut point of > 0.1473 is the closest point on the observed 
ROC curve to the perfect curve (calculated as the point with the least sum of squares). At this point 
sensitivity is 69% (95% CI 41 - 89%) and specificity is 77% (95% CI 69 - 84%)- by no means adequate 
for use in clinical practice. If sensitivity is improved, specificity is poor: a cut point of > 0.1062 gives a 
sensitivity of 75% (95% CI 48 - 93%) and specificity of only 69% (95% CI 60 – 77%). 
 
Combining the duration of peritoneal dialysis with PET and MCP-1 is not an appropriate analysis to 
perform because PET result and MCP-1 are closely correlated. Also this would be equivalent to trying 
to find a predictive subset out of five candidate markers and as such would break the 10-events-per-
variable rule. 
 
Summary 
Using dialysate cytokine levels as predictors of EPS does not have any benefit beyond that of a 
model using the basic clinical parameters, duration of PD and D/P creatinine. Although the model 
using these clinical parameters appeared to have some potential to predict EPS, it would be 
necessary to investigate the performance of the model across different dialysis populations to 
Figure 73: ROC curve of logistic regression; 
the predictor of EPS is log(MCP-1) 
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establish whether it has any utility. Performance of the model in other populations may be expected 
to be less good than in the sample population; there is likely to be optimism due to over-fitting in a 
model that was not pre-defined before the study commenced. Data from our patient population 
suggests that, in a patient who is approaching four years on peritoneal dialysis, clinical features 
associated with EPS after the cessation of PD are lack of residual renal function, high glucose 
requirements and high D/P creatinine. Raised levels of cytokines in the dialysate will at the most 
confirm a clinical impression that the patient is at higher risk for EPS post transfer to haemodialysis 
or transplantation; they are not sufficient to use alone as a predictive tool. 
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CHAPTER 8 
RESULTS: Serum cytokine levels in EPS and non-EPS patients 
 
8.1 Serum cytokine levels in PD, HD and transplanted patients 
8.1(i) Serum cytokine levels vary between HD, PD and transplanted patients and this is not due 
solely to GFR 
Samples were collected from patients who were currently on PD, patients on HD with no history of 
PD (n=9) and transplanted patients with no history of PD (n=11). Levels of cytokines were found to 
vary significantly between modalities, being in general highest in the HD group and lowest in the 
transplanted group. 
             
 
 
The levels of the cytokines IL-6 and MCP-1 in serum do not correlate with GFR within the GFR range 
of PD and HD patients (usually 0-10mls/minute) and the levels of CCL18 and CCL15 correlated only 
weakly with GFR in this range. Residual GFR is not regularly measured in our haemodialysis 
population but this was a group of very long duration ESRD patients and little or no residual function 
would be expected. GFR differences cannot completely explain the observed patterns in the 
peritoneal and haemodialysis groups since some cytokines (angiogenin and MCP-1) show no 
difference between peritoneal dialysis and haemodialysis patients and in contrast CCL18 and CCL15 
are found at higher levels in haemodialysis patients. 
Figure 74: Levels of MCP-1 in patients with 
differing forms of renal replacement 
modality 
 
Figure 75: Levels of CCL15 in patients with 
differing forms of renal replacement 
modality 
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In the transplant population the range of GFR is much higher and this might result in lower serum 
levels of cytokines in this group. A negative correlation between GFR and cytokine levels was noted 
for MCP-1, CCL18, angiogenin and CCL15 across the range of GFR values found from PD to transplant 
patients. This is only an approximation of any true relationship with renal function since the 
calculated GFR used for the transplant population and that used for the PD population (the mean of 
creatinine clearance and urea clearance) are both estimations. HD patient data was not included as 
residual GFR is not routinely measured in the HD population.  
            
Figure 76: Levels of CCL18 in patients with 
differing forms of renal replacement 
modality 
 
Figure 77: Levels of angiogenin in patients 
with differing forms of renal replacement 
modality 
 
Figure 78: CCL18 serum levels correlate 
with GFR across the range seen in PD and 
transplant patients 
 
Figure 79: Angiogenin serum levels 
correlate with GFR across the range seen 
in PD and transplant patients 
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There are many potential confounders, such as the immunosuppressants taken by transplanted 
patients, which may underlie this correlation. Interestingly, Qureshi (work from Dr Tam’s group) 
looked at the relationship between serum CCL18 and GFR in over a hundred CKD patients (GFR range 
11 to 90) and found no correlation between serum CCL18 and GFR. This suggests that the differences 
in CCL18 levels between different modality groups are likely to be at least partly secondary to factors 
such as increased inflammation in the dialysis population and immunosuppression in the 
transplanted population rather than variation in residual or transplant function. 
8.2 Serum cytokine levels in EPS patients after cessation of PD 
8.2(i) Serum cytokine levels in transplanted patients do not differ between EPS and non-EPS 
patients 
Samples were collected from patients with a diagnosis of EPS post-transplantation. These patients 
were then matched by age, sex and duration of ESRD to a control group of patients who had never 
used PD. 
No significant differences were found between the levels of CCL18, MCP-1, CCL15 and angiogenin in 
the EPS and non-EPS transplant patients.  
Figure 80: MCP-1 serum levels correlate 
more weakly with GFR across the range 
seen in PD and transplant patients 
 
Figure 81: CCL15 serum levels correlate 
with GFR across the range seen in PD and 
transplant patients 
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It is likely that there are many complicating factors affecting cytokine levels in transplant patients 
such as immunosuppressant use. 
 
8.2(ii) Serum CCL18 levels are higher in haemodialysis patients with EPS than in non-EPS HD 
patients 
Samples were also collected from EPS patients now on haemodialysis, and haemodialysis patients 
matched for age, sex, dialysis unit and duration of ESRF who had never been on PD. No difference 
was found between EPS and non-EPS patients for MCP-1, CCL15 and angiogenin, but levels of CCL18 
Figure 82: There is no difference between 
CCL15 levels in transplanted patients who 
have and have not been diagnosed with 
EPS 
 
Figure 83: There is no difference between 
CCL18 levels in transplanted patients who 
have and have not been diagnosed with 
EPS 
 
 
Figure 84: There is no difference between 
MCP-1 levels in transplanted patients who 
have and have not been diagnosed with 
EPS 
MCP-1 serum levels correlate more weakly 
with GFR across the range seen in PD and 
transplant patients. 
 
Figure 85: There is no difference between 
angiogenin levels in transplanted patients 
who have and have not been diagnosed 
with EPS 
MCP-1 serum levels correlate more weakly 
with GFR across the range seen in PD and 
transplant patients. 
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were significantly different between the EPS and non-EPS groups. There was considerable overlap 
between the groups: 
 
 
 
 
 
Figure 86: There is a significant difference 
between CCL18 levels in HD patients who 
have and have not been diagnosed with 
EPS 
It should be note that this is only a very small 
group of patients – there are ten samples from 
EPS patients who remain alive and are 
maintained on haemodialysis. However it is 
interesting that it is CCL18 which appears to 
become high after some time from diagnosis 
of EPS. These samples were collected at an 
average of 32 months after the diagnosis of 
EPS was made in these patients. These 
patients were not acutely unwell with 
inflammatory features of EPS such as ascites, 
fever and weight loss. Instead they were 
experiencing recurrent episodes of bowel 
obstruction, with symptoms relating to fibrosis 
around the bowel. As discussed in the 
introduction, CCL18 is known to be involved in 
the pathogenesis of fibrosis. 
Figure 87: There is no significant 
difference between CCL15 levels in HD 
patients who have and have not been 
diagnosed with EPS 
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Summary 
In summary, there is a significantly higher level of CCL18 in haemodialysis patients with established 
EPS. This is not seen in transplanted patients with EPS, perhaps because of the effects of 
immunosuppression on the production of cytokines. It is less likely that the renal function of 
transplant patients obscures any differences in CCL18. CCL18 might be involved in ongoing fibrosis in 
these HD patients with symptoms of repeated obstruction due to EPS. All cytokines are found at 
higher levels in dialysis patients than in transplanted patients; the mechanism for this is not clear but 
may reflect both the use of immunosuppression in the transplanted population and perhaps the 
almost complete absence of renal clearance in the dialysis population. 
 
 
 
 
 
 
Figure 88: There is no significant 
difference between angiogenin levels in 
HD patients who have and have not been 
diagnosed with EPS 
Figure 89: There is no significant 
difference between MCP-1 levels in HD 
patients who have and have not been 
diagnosed with EPS 
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CHAPTER 9 
RESULTS: Cytokine production by mesothelial cells in culture  
 
9.1 Peritoneal mesothelial cells in culture  
9.1(i) Peritoneal mesothelial cells in culture show varying morphology 
In order to establish whether mesothelial cells can produce cytokines, dialysate effluent samples 
from overnight bags were used as a source of mesothelial cells for culture. Mesothelial cells were 
cultured as described in section 3.4(i). Photographs of mesothelial cells in culture show varying 
morphology: 
 
 
 
 
Figure 90: Human peritoneal mesothelial cells in culture with a cuboidal morphology. These 
cells were taken from a patient who had only very recently started peritoneal dialysis. The 
picture was taken after 37 days in culture before the first passage; these are slow growing 
cells 
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Figure 91: Human peritoneal mesothelial cells in culture. Some of these cells are rounded 
but some have a more elongated shape. Day 22 passage 1 
 
Figure 92: Human peritoneal mesothelial cells in culture. More of these cells have an 
elongated shape. This patient had been on PD for 27 months. Day 15 passage 1 
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9.1(ii) Peritoneal mesothelial cells in culture stain for epithelial and mesenchymal markers 
Mesothelial cells from were stained for the epithelial marker cytokeratin 18 and the mesenchymal 
markers alpha smooth muscle actin and vimentin. The epithelial marker cytokeratin would be 
expected to be positive in mesothelial cells. The alpha smooth muscle and vimentin staining would 
be expected to be variable; these are mesenchymal markers and will be positive in cells during or 
after epithelial to mesenchymal transition. It was not possible to culture sufficient numbers of cells 
from any single patient to both perform staining and carry out the stimulation experiment (see 
section 9.2) so these pictures are from further patient samples cultured under the same conditions 
as those used for the stimulation experiments. 
While the cells were in culture, samples of the culture medium were taken and cytokine production 
measured by ELISA. 
 
 
 
 
 
Figure 93: Human peritoneal mesothelial cells in culture. These cells have a more fibroblast-
like appearance. Day 14 passage 1 
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Cytokeratin (epithelial marker) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 94a: Human peritoneal 
mesothelial cells in culture x20. 
Typical negative control for 
cytokeratin staining, using Marvel 
block 
 
Figure 94b: Human peritoneal 
mesothelial cells in culture x20. 
Positive staining for cytokeratin (seen 
in all samples) 
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Vimentin: 
 
 
 
  
 
 
Figure 95a: Human peritoneal 
mesothelial cells in culture x20. 
Typical negative control for vimentin 
staining 
 
Figure 95b: Human peritoneal 
mesothelial cells in culture x20. The 
cells from this patient show strongly 
positive staining for vimentin 
 
Figure 95c: Human peritoneal 
mesothelial cells in culture x20. Fewer 
of the cells from this patient show 
positive staining for vimentin 
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Alpha SMA: 
 
 
 
 
 
 
Figure 96a: Human peritoneal 
mesothelial cells in culture x20. 
Typical negative control for alpha 
SMA 
 
Figure 96c: Human peritoneal 
mesothelial cells in culture x20. Fewer 
of the cells from this patient, as with 
the vimentin stain on the same 
patient’s cells, show positive staining 
for alpha SMA 
 
Figure 96b: Human peritoneal 
mesothelial cells in culture x20. The 
cells from this patient are strongly 
positive for alpha SMA (and were also 
strongly positive for vimentin) 
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9.1(iii) Peritoneal mesothelial cells in culture produce CCL18 
Samples were taken each time the tissue culture medium was changed and levels of CCL18 in the 
culture medium were measured by ELISA. The results are displayed as pg/ml/day, since the interval 
between changes of culture medium varied. It is not possible to count the cells at each change of 
medium as they are adherent to the culture flask. 
 
Patient Renal 
diagnosis 
Duration PD 
(months) 
D/P 
creatinine 
Residual GFR 
(mls/minute) 
Glucose exp. 
(mmol/24hr) 
Peritonitis 
episodes 
1  Unknown 24 0.85 0.4 878 0 
2  Hypertension 22 0.81 8.7 414 2 
3  Diabetes 5 0.65 11.7 150 0 
4  Diabetes 1 0.88 3.2 750 0 
5  Diabetes 2 0.51 1.0 638 0 
6  Obstruction 16 0.62 4.9 240 0 
7  Unknown 31 0.77 4.1 750 0 
Table 32: Clinical data of patients who gave overnight dialysate samples for cell culture experiments 
 
 
The source of CCL18 in the culture medium could be the peritoneal mesothelial cells. Alternatively it 
is possible that there were also other cell types cultured along with the mesothelial cells, despite the 
culture conditions being most suitable for mesothelial cell growth. The production of CCL18 by 
alternatively activated macrophages in the peritoneum is well documented (Bellón et al., 2011); 
macrophage-like cells were however not observed in the culture. Dendritic cells have also been 
shown to produce CCL18 (Schutyser et al., 2005) and other tissue-specific cells have been seen to 
produce CCL18 in our laboratory (unpublished data). CCL18 may be actively secreted by mesothelial 
or other cell types into the culture medium. Because the medium was immediately centrifuged at 
Figure 97: CCL18 production by human 
peritoneal mesothelial cells in culture. Each 
column shows the CCL18 levels measured in 
tissue culture medium for one patient. Each 
point represents a sample of tissue culture 
medium taken at the time of changing the 
medium, corrected for number of days since 
last change of medium. Variation in levels is 
expected as these results are not corrected for 
cell number. CCL18 was not detected in tissue 
culture medium that had not been exposed to 
mesothelial cells. 
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4°C after collection (to reduce cell lysis) and only the supernatant was analysed for cytokines it is not 
likely that the detected CCL18 was released from damaged cells after sample collection. However it 
is possible that CCL18 in the culture medium was present because some cells that had been 
damaged or died prior to collection of the sample had released intra-cellular stores of CCL18, rather 
than the release of CCL18 being due to active secretion.  
The possibility of local production of CCL18 within the peritoneum is interesting because we have 
seen in section 5.2 that levels of CCL18 measured in the dialysate effluent are dependent on the 
membrane transport properties. Levels of CCL18 in the dialysate are lower than would be expected 
by passive transfer of a 14kDa protein from the circulation (section 4.2(iii)), which suggests CCL18 
may be protein bound either within the circulation or to the peritoneum. We could speculate that 
locally produced CCL18 is not released into the dialysate (hence the low levels found in effluent 
dialysate) but may still have a local effect to promote fibrosis. 
 
9.1(iv) Peritoneal mesothelial cells in culture produce angiogenin 
Levels of angiogenin were also measured in samples of culture medium which were taken during 
culture of the mesothelial cells. Angiogenin was not detectable in the unused tissue culture medium 
(lower level of detection 20pg/ml). 
 
Angiogenin is known to be produced by a variety of cell types including cancer cells (stromal tissue) 
(Etoh et al., 2000), fibroblasts (Lioté et al., 2003) and renal proximal tubular cells (Nakamura et al., 
2006) – the mRNA is found is a wide variety of cells (Rybak et al., 1987). It is likely, therefore, that 
the peritoneal mesothelial cells can produce angiogenin. In vivo angiogenin production is increased 
by hypoxia and also by IL-6 (Verselis et al., 1999). It is possible that within a thickened and fibrotic 
peritoneal membrane there is hypoxia and angiogenin release which drives neovascularisation. 
Alternatively high levels of inflammation and IL-6 might drive angiogenin production in the 
Figure 98: Angiogenin production by human 
peritoneal mesothelial cells in culture. Each 
column shows the angiogenin levels measured 
in tissue culture medium for one patient during 
the period the cells were in culture. Each point 
represents a sample of tissue culture medium 
taken at the time of changing the medium, 
corrected for number of days since last change 
of medium. Variation in levels is expected as 
these results are not corrected for cell number. 
Angiogenin was not detected in tissue culture 
medium that had not been exposed to 
mesothelial cells. 
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peritoneum. Levels of angiogenin in the dialysate were chiefly related to serum levels of angiogenin 
and the transport characteristics of the peritoneal membrane. However, this does not exclude the 
possibility of local production of angiogenin by the peritoneal cells. This local production might not 
greatly elevate dialysate angiogenin levels but could still have an important paracrine effect. 
 
9.1(v) Peritoneal mesothelial cells in culture produce MCP-1 
 
 
Peritoneal mesothelial cells have been previously reported to produce MCP-1 (Lee et al., 2001; 
Wong et al., 2003). Production of MCP-1 is seen here by the peritoneal mesothelial cells in culture. 
This appears to be occurring at higher levels (in terms of pg/ml/day) than that of other cytokines, 
and might well be contributing substantially to the levels of MCP-1 observed in the dialysate 
effluent. 
 
9.1 (vi) Peritoneal mesothelial cells in culture do not produce CCL15 
No CCL15 was detected in the tissue culture fluid from the mesothelial cell culture, suggesting that 
these cells do not produce CCL15. CCL15 is known to be produced in the gut (Pardigol et al., 1998), 
and may well enter the peritoneal cavity via the peritoneal membrane. This would be consistent 
with the observations that CCL15 levels in the dialysate correlate strongly with serum levels and that 
membrane transport characteristics are a strong predictor of dialysate CCL15 levels. 
 
 
 
 
 
 
Figure 99: MCP-1 production by human 
peritoneal mesothelial cells in culture. Each 
column shows the MCP-1 levels measured in 
tissue culture medium for one patient during the 
period the cells were in culture. Each point 
represents a sample of tissue culture medium 
taken at the time of changing the medium, 
corrected for number of days since last change of 
medium. Variation in levels is expected as these 
results are not corrected for cell number. MCP-1 
was not detected in tissue culture medium that 
had not been exposed to mesothelial cells. 
 
132 
 
9.2 Stimulation of peritoneal mesothelial cells 
9.2(i) Peritoneal mesothelial cell cytokine production is not affected by addition of CCL15 
CCL15 was found in the dialysate effluent, and levels of CCL15 in the dialysate effluent correlate with 
those of other cytokines, but CCL15 does not appear to be made by the mesothelial cells. However 
CCL15 might still have a role to affect the nature of the inflammatory response in the peritoneum. 
CCL15 was used to stimulate the mesothelial cells in culture to investigate whether addition of 
CCL15 to the culture fluid had any effect on levels of cytokine production. This experiment was 
performed twice with three patient samples on each occasion. The higher level of CCL15 stimulation 
was used on the repeat experiment only. 
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 100: There is no significant 
difference in MCP-1 production by 
mesothelial cells after CCL15 stimulation 
Figure 101: There is no significant 
difference in CCL18 production by 
mesothelial cells after CCL15 stimulation 
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9.2(ii) Peritoneal mesothelial cell cytokine production is not affected by addition of IL-6 
IL-6 also had no effect on the production of cytokines by the peritoneal mesothelial cells. This is 
probably explained by the observation by Hurst et al (Hurst et al., 2001) that unlike leukocytes, 
mesothelial cells may not have an IL-6 receptor and responses to IL-6 then require the presence of 
the soluble IL-6 receptor. 
 
9.3 Cytokine production by U937 cells 
In order to assess whether CCL15 might have any effect on monocytes within the peritoneum, the 
effect of CCL15 stimulation on cytokine production by U937 cells was assessed. 
U937 cells are a monocyte cell line. Increased production of MCP-1 from monocytes after 
stimulation with CCL15 was shown by Lee et al (Lee et al., 2002). Baseline production of CCL18 and 
CCL15 was low or non-existent by the U937 cell line and no significant changes were seen post 
stimulation. In addition, no effect on MCP-1 production was seen after stimulation of U937 cells with 
CCL15 in these culture conditions: 
 
Figure 102: There is no significant 
difference in angiogenin production by 
mesothelial cells after CCL15 stimulation 
The lack of response to stimulation by CCL15 may 
mean that this cytokine does not have an 
important role in the pathogenesis of peritoneal 
changes and is only a marker of increased 
peritoneal permeability. It is also possible that this 
culture system was not suitable for demonstrating 
an effect of CCL15 and that in vivo, where 
monocytes, macrophages and leukocytes are also 
present, CCL15 might have a relevant biological 
effect. Finally, changing to serum-free medium 
before the stimulation experiment had not 
resulted in a low baseline level of cytokine 
production prior to stimulation and it may be that 
cytokine production was already maximal prior to 
stimulation. 
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Summary 
Cells which have been cultured from the overnight bag of dialysate effluent fluid under conditions 
expected to promote the growth of mesothelial cells show varying morphologies. Cells stain for the 
epithelial marker cytokeratin and variably for the mesenchymal markers vimentin and alpha SMA, in 
keeping with the literature describing EMT in PD patient mesothelial cells. 
MCP-1, CCL18 and angiogenin are detected in the tissue culture medium after exposure to these cell 
cultures. CCL15 is not detected. This suggests that there is local production of these cytokines, but 
not of CCL15. Despite the low levels of CCL18 and angiogenin these cytokines could have a local 
effect on the peritoneal membrane. 
No effect on cytokine production was seen after CCL15 stimulation of either the peritoneal cell 
cultures or a monocyte culture. Further work is required to define the role of CCL15; it may be that 
the effects of CCL15 cannot be seen in a cell culture system because interactions with other 
molecules or cells of the immune system are required. 
 
However, a marked increase in MCP-1 
production was seen after stimulation 
of the U937 cells with IL-6. This 
suggests that experimental factors 
such as time from stimulation of the 
cells before collecting samples of 
tissue fluid were unlikely to be the 
reason why no response to CCL15 was 
seen.  
Figure 103: CCL15 stimulation did not 
affect the levels of MCP-1 production  
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Chapter 10 
Radiology: CT as a screening method for EPS 
This part of the study was published in Nephrology Dialysis Transplantation (Nephrol Dial Transplant 
2011 Apr;26(4):1374-9 “Screening for Encapsulating Sclerosing Peritonitis: Role of CT Scanning”) - 
see Appendix C. 
 
10.1 Methods 
The aim of this part of the study was to investigate the validity of CT scanning of peritoneal dialysis 
patients as a screening method for future EPS. It is known that CT scanning is useful in the 
symptomatic patient to help confirm the diagnosis of EPS (Tarzi et al., 2008; Vlijm et al., 2009), but 
many units also use CT as a form of screening. 
This was a retrospective study. Sufficient and appropriately timed CT scans were available for twenty 
patients who had developed EPS. For each patient a CT scan taken at least three months prior to the 
development of symptoms of EPS was selected (pre-diagnostic CT scan), together with a CT scan 
taken when EPS was clinically apparent (post-diagnostic CT scan). The notes, discharge summaries 
and electronic records, including the indication for CT scanning, were reviewed to determine when 
the patient first became symptomatic and to determine whether there were even minor bowel 
symptoms at the time the pre-diagnostic CT was performed.  
CT scans from twenty control patients were also scored. These were peritoneal dialysis patients who 
had CT scans for indications such as screening, investigation of possible malignancy or as part of a 
pre-transplant work-up. None of these patients have developed EPS after over 2.5 years of follow-
up; the majority have changed dialysis modality to haemodialysis or received a transplant. The 
median duration of PD at the time of scanning in the control group was 3.2 years. 
CT scans were performed at the Hammersmith Hospital using a GE Lightspeed 8 slice scanner (GE 
Milwaukee, WI) or at Charing Cross Hospital using a Siemens Somatron Sensation 16 slice scanner 
(Siemens, Erlangen, Germany). Intravenous contrast was given (100mls of Ultravist 300 was the 
standard during the period within which the scans were obtained); one pre-diagnostic scan had 
intra-peritoneal contrast. Contrast was injected peripherally at 3mls/second and the abdominal and 
pelvic images were acquired at 60 seconds post-contrast in the venous portal phase.  
CT scans were scored by three radiologists using the system described by Tarzi et al (Tarzi et al., 
2008). Each scan was scored blindly and a mean score obtained.  
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Score Peritoneal thickening Peritoneal calcification Loculations 
0 Not identified Not identified Not present 
1 Localised area < 20% Localised area < 20% < 3 locules 
2 > 20% >20% 3-6 locules 
3 > 50% >50% > 6 locules 
4 > 80% of peritoneum >80% of peritoneum  
 Bowel Wall Thickening Bowel Dilatation Bowel Tethering 
0 Not identified Not identified Not present 
1 Localised bowel Localised bowel Mild tethering 
2 > 20% of bowel > 20% of bowel Moderate tethering 
3 > 50% of bowel > 50% of bowel Marked tethering 
4 > 80% of bowel > 80% of bowel  
Table 33: CT scoring system. The highest score is 22 and scores above 2.5 are abnormal 
This system of scoring CT scans for the changes characteristic of EPS was shown by Tarzi et al (Tarzi 
et al., 2008) to be reproducible, with kappa values for inter-observer variability showing good 
agreement between radiologists. A score is determined for each of the CT features of EPS – 
peritoneal thickening, peritoneal calcification, fluid loculations, bowel wall thickening, bowel 
dilatation and bowel tethering and these scores are added to obtain a final total score. 
 
10.2 Results 
10.2(i) CT is not a suitable screening method for EPS in stable PD patients 
The median CT scores were 1 in the control group, 2 in the pre-diagnostic group and 9 in scans 
performed at the time of diagnosis of EPS. The difference between the scores of the control group 
scans and the scores of scans taken from patients with clinical symptoms of EPS was highly 
significant (p < 0.001), as found previously (Tarzi et al., 2008). There was a statistically significant 
difference between the scores of the pre-diagnostic group and the scores of the control group (p = 
0.003); however, inspection of the results shows that there is considerable overlap between the two 
groups and in particular a score of 1 or 2 was common in both groups.  
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This means that there were ten patients who had a CT scan score which was considered normal but 
then developed symptomatic EPS (with an abnormal scan) within a period of time which could be as 
little as three or four months (range 3.7 – 37 months). There was no correlation between the pre-
diagnostic CT scan score and the time period before the development of EPS. This may well be 
because all the patients in this group developed EPS after the cessation of PD. The timing of EPS 
onset was therefore determined by the reasons for stopping PD – transplantation, severe peritonitis 
etc. 
This data strongly suggests that in PD patients who undergo a “screening” CT, the possibility of EPS 
on cessation of peritoneal dialysis is not excluded by a normal scan. 
The lack of usefulness of CT scanning as a screening test for EPS can be illustrated by the ROC curve: 
Figure 104: CT scan scores are 
significantly higher in the pre-
diagnostic group than the control 
group; however, half of the pre-
diagnostic scans scored in the same 
range as the control scans making 
CT scanning a poor choice of 
screening test 
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10.2(ii) Minor abdominal symptoms and an abnormal CT may indicate a higher risk of EPS 
When the pre-diagnostic group is separated into those who had had a minor episode of symptoms 
and those who were documented as asymptomatic, a significant difference in scan score between 
the symptomatic and control groups is seen (no difference was seen between the asymptomatic and 
the control groups).  In total 12 patients were documented to be completely asymptomatic at the 
time of the pre-diagnostic scan, which was performed for reasons such as screening prior to 
transplantation or retroperitoneal haematoma. EPS was diagnosed a median of 7.9 months after the 
pre-diagnostic scan in these patients (range 3.4 – 32 months). The other 8 patients had had a brief 
(one or two days) hospital admission with transient symptoms such as constipation or abdominal 
pain, which had prompted the CT scan. These symptoms had then resolved (persistent symptoms 
would have suggested that the diagnosis of EPS should have been made earlier). In fact symptoms of 
EPS appeared at a median of 11.6 months after the pre-diagnostic scans were performed in this 
group (range 5 – 37 months), slightly later than was seen in the asymptomatic group. 
 
Figure 105: ROC curve for CT scan 
scores as a predictor of EPS. The 
area under the curve is only 0.772 
and the line lies close to the line of 
identity. CT has a sensitivity and 
specificity of 70% with a cut off of a 
score of 1.25, which is clearly not 
adequate for clinical purposes 
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The median score of the PD controls was 1; the median score of the group with no symptoms was 
1.75 (not significantly higher). The median score in the group who had had an episode of abdominal 
symptoms was 4.5, which was significantly higher than the control group. 
10.2 (iii) Does CT scanning help to predict EPS in patients with transient abdominal symptoms? 
A group of 8 peritoneal dialysis patients were identified who had had a CT scan for abdominal 
symptoms such as abdominal pain, change in bowel habit and weight loss, who had not then 
developed EPS. The CT scan scores in this group were significantly different from the scores in the 
group of symptomatic patients who had gone on to develop EPS; the median score in the group who 
did not develop EPS was 1, and in the group who did develop EPS the CT scan score was 4.5 (p = 
0.02). 
 
Figure 106: A significant difference 
is seen between the group of PD 
patients who had experienced a 
transient episode of abdominal 
symptoms and the control group. A 
smaller proportion of briefly 
symptomatic patients had a normal 
scan score than was seen in the pre-
diagnostic group as a whole 
Figure 107: Looking at PD patients 
who had experienced a transient 
episode of abdominal symptoms, CT 
scan scores were higher in the 
group who went on to develop EPS 
than in the group that did not 
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This data suggests that a CT scan may be of use if a PD patient develops a transient episode of 
abdominal symptoms. Although a CT score >2 appears to be highly predictive of EPS in this data 
(85% of symptomatic patients with a CT score greater than 2 developed EPS), this is not a randomly 
selected sample of PD patients with abdominal symptoms and in practice the low prevalence of EPS 
means that the positive predictive value of CT scanning in symptomatic patients would not be this 
high. It does appear from this data that a high CT score may imply a risk of future EPS which is 
greater than the risk conferred by an episode of abdominal symptoms with a normal CT; this 
requires confirmation in a prospective study.  
 
Summary 
CT scanning is not suitable as a screening test for future EPS in stable peritoneal dialysis patients 
since many patients developed EPS within months of a normal CT scan. The presence of even 
transient abdominal symptoms and an abnormal CT scan did appear to be associated with a higher 
risk of EPS after the cessation of PD. Although data from our survey of symptoms in peritoneal 
dialysis patients (see Appendix B) suggests that many patients experience abdominal symptoms, few 
rate them as severe (the median severity score was 0 for all symptoms except loss of appetite). 
Perhaps CT scanning is indicated in PD patients who complain of any episodes of more severe 
symptoms, even if those symptoms have quickly resolved. CT scanning would then provide 
information which could be combined with other clinical data such as duration of PD and membrane 
transport status to improve the overall risk assessment of the patient.  
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CHAPTER 11: 
 
Final discussion and conclusions 
 
As a  mode of renal replacement therapy, peritoneal dialysis provides outcomes for patients which 
are broadly similar to haemodialysis (Quinn et al., 2011), (Chiu et al., 2011) and for some patients 
there are particular advantages to peritoneal dialysis. For example the life-style advantages of a 
home-based therapy may be considerable for some; for others difficulties with vascular access may 
make haemodialysis problematic. However, considerable evidence suggests that the performance of 
peritoneal dialysis in the long term is limited by changes in the peritoneal membrane structure 
(Williams et al., 2002) and function (Davies et al., 2001).  
The pathogenesis of the epithelial to mesenchymal transition and sub-mesothelial fibrosis seen in 
long term peritoneal dialysis patients is not yet fully defined. There are multiple factors associated 
with peritoneal dialysis which may potentially contribute to membrane damage. Uraemia (Williams 
et al., 2002), glucose (Davies et al., 2005) and its degradation products (Hirahara et al., 2009), 
advanced glycosylation end-products (De Vriese et al., 2006), fluid flow stresses (Aoki et al., 2011b), 
activation of the renin-angiotensin system (Chang et al., 2011) and peritoneal infection (Davies et al., 
1996) are all implicated.  
In keeping with the many possible causes of peritoneal damage, there may also be multiple 
mediators of inflammation and fibrosis involved, with more than one pathway combining to result in 
a common histological and functional outcome. This is the case with fibrosis and EMT in other 
systems such as renal fibrosis (Liu, 2010), where more than one interacting pathway leads to the 
development of EMT. The pathways from acute inflammation to fibrosis in the peritoneum are not 
well-defined, but it is likely that similar multiple signalling pathways exist.  
We could consider the changes in the peritoneum as being related to acute and chronic 
inflammation, vascular changes and fibrosis. Within the peritoneum, IL-6 is well established in the 
literature to be involved in acute inflammation and the switch from acute to chronic inflammation 
(Hurst et al., 2001) and also is associated with functional changes in the peritoneal membrane 
(Pecoits-Filho et al., 2002a). Similarly, VEGF is known to induce angiogenesis in multiple systems and 
has been demonstrated to be involved in the genesis of peritoneal blood vessel changes (De Vriese 
et al., 2001). TGF-β is perhaps the best established mediator of peritoneal fibrosis; there is evidence 
for TGF-β causing both induction of EMT (Loureiro et al., 2011) and production of matrix by 
fibroblasts (Medcalf et al., 2001) . 
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However, it is likely that other mediators of peritoneal damage exist given the many factors 
observed in clinical studies to be associated with peritoneal membrane damage. In addition other 
molecules will be involved in the same pathway as the better-known mediators of peritoneal 
damage and could be potential therapeutic targets in the future. For example, CTGF is likely to be a 
downstream mediator of TGF-β activity (Leung et al., 2009).  
The cytokines investigated in this study were chosen as both being present in a multiplex array assay 
of dialysate effluent and having a biologically plausible role to play in the pathogenesis of peritoneal 
changes. As CCL15 initially attracts an influx of neutrophils but becomes a chemoattractant for 
monocytes after local processing by neutrophil cathespin or matrix metalloproteases (Richter et al., 
2005; Starr et al., 2011), it may be involved with IL-6 in a change from acute to chronic inflammation 
as well as having a potential role in angiogenesis (Hwang et al., 2004). MCP-1 is associated with 
chronic inflammation, especially related to hyperglycaemia (Dragomir and Simionescu, 2006), 
making it a good candidate mediator in the peritoneum where glucose is implicated as a cause of 
pathology. CCL18 is associated with fibrosis in humans (Schutyser et al., 2005; Luzina et al., 2006a) in 
a TGF-β independent manner, suggesting it may act downstream of TGF-β or by a separate pathway. 
Angiogenin has been shown to be essential for the action of VEGF (Kishimoto et al., 2005), and 
therefore might well be required for peritoneal vascular changes to occur. 
 
 
 
 
 
 
Figure 108: Some possible pathways resulting in peritoneal fibrosis. Other pathways and 
mediators are likely to exist. ROS=reactive oxygen species, EMT=epithelial to mesenchymal 
transition, CTGF=connective tissue growth factor, TGF-β=transforming growth factor-β, 
MCP-1=monocyte chemotactic protein-1, NOS=nitric oxide synthase, IL-6=interleukin-6, IL-
1β=interleukin-1β, TNFα=tumour necrosis factor α, CCL15=leukotactin, and CCL18=PARC, 
pulmonary and activation-regulated chemokine 
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This study is based on data collected from patients at their usual peritoneal equilibration tests. 
Patients were not selected for the study – samples were collected whenever the researcher was 
available to attend the PET. No patients were excluded from the study. The data is therefore 
representative of patients encountered in normal clinical practice. Both clinical data and cytokine  
levels were studied in order to obtain as complete a picture as possible. Levels of cytokines were 
investigated in both the dialysate effluent and serum, as it was expected that there might be a 
relationship between cytokine levels in the two compartments. In order to assess the relative 
contributions of the multiple clinical factors found to correlate with cytokine levels, multivariate 
analysis was performed. Cytokine production by mesothelial cells was studied, and the potential 
actions of the novel cytokine CCL15 on mesothelial cells were investigated in a cell culture model. 
 
Cytokines are present in the dialysate and levels correlate with clinical markers associated with 
peritoneal damage. 
The results of this study indicate that these cytokines are present in the effluent dialysate of 
peritoneal dialysis patients. The presence of CCL15 in dialysate effluent has not previously been 
reported. In addition, the levels of cytokines within the dialysate correlate with confirmed clinical 
risk factors for peritoneal damage such as duration of peritoneal dialysis, glucose exposure and lack 
of residual renal function. On multivariate analysis the most significant clinical feature which 
predicted dialysate cytokine levels was the D/P creatinine. D/P creatinine increases with duration of 
Figure 109: Some possible pathways resulting in peritoneal angiogenesis. Other pathways 
and mediators are likely to exist. ROS=reactive oxygen species, TGF-β=transforming 
growth factor-β, AGE=advanced glycosylation end product, GDP=glucose degradation 
product and VEGF=vascular endothelial growth factor 
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PD and glucose exposure; it describes the rate of transfer of the small molecule creatinine across the 
peritoneal membrane. The correlation of cytokine levels with D/P creatinine has a number of 
potential underlying mechanisms; the mechanism need not be the same for each cytokine. 
 
Dialysate CCL15 levels depend on transfer across the peritoneal membrane from the circulation 
Several different explanations for the observation that dialysate cytokines correlate with D/P 
creatinine can be suggested. One is that cytokine levels in the dialysate are determined by serum 
dialysate levels and membrane permeability; that is, intra-peritoneal production of cytokine is not 
important in determining dialysate cytokine levels. This appears true for CCL15, which is produced in 
the gut (Pardigol et al., 1998) but was not made by peritoneal cells in culture. It is found in dialysate 
at levels roughly expected from its molecular weight and serum concentration when compared to 
other proteins that enter from the circulation. It is likely that this cytokine does enter the dialysate 
across the peritoneal membrane; thus the correlation between CCL15 levels in dialysate and 
membrane transport rate for creatinine is not unexpected and does not imply that CCL15 
determines the membrane transfer properties for small solutes. 
 
Dialysate levels of MCP-1 and IL-6 are not determined by transfer from the circulation 
Another potential explanation for the correlation of dialysate cytokine levels with the D/P creatinine 
is that the transport properties of the membrane are influenced by the cytokines. This might be true, 
for example, of MCP-1 and IL-6. MCP-1 (Lee et al., 2001) is produced by peritoneal cells, as is IL-6 
(Topley et al., 1993). MCP-1 was found in tissue culture medium from peritoneal mesothelial cells at 
considerably higher levels than was seen for other cytokines. In addition, the study investigating 
transfer across the peritoneal membrane of proteins of varied molecular weight demonstrates that 
levels of both MCP-1 and IL-6 in the dialysate effluent fluid are higher than would be expected if 
dialysate levels were determined chiefly by passive transfer of cytokine from the circulation. It is 
therefore likely that local production of MCP-1 and IL-6 has a significant impact on the levels found 
in dialysate. In addition MCP-1 and IL-6 levels in dialysate only show a weak correlation with serum 
levels. Therefore the existence of a correlation between both MCP-1 and IL-6 and the D/P creatinine 
result suggests that these cytokines may affect the membrane transport properties. Alternatively, 
both MCP-1 and IL-6 levels in dialysate and the peritoneal membrane transport rate could be 
increased by another factor (such as glucose exposure) and MCP-1/IL-6 might have no direct role in 
mediating membrane changes.  
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Although there is local production of CCL18 and angiogenin, levels in dialysate effluent are correlated 
with serum levels and membrane properties. 
For CCL18 and angiogenin the data suggests a different interpretation. The ELISAs performed on 
culture medium from peritoneal cell cultures suggest that these cytokines are also produced by 
peritoneal cells; however the amounts detected are considerably lower than the amounts of MCP-1 
that were detected in culture medium. There is no evidence from the experiment investigating 
transfer of proteins by molecular weight to suggest that there is excess angiogenin in the dialysate 
compared to the quantity that might be expected to enter from the circulation during the four hour 
dwell, and there was even less CCL18 than expected. It may be that although there is local 
production of these cytokines, which could have important paracrine effects, concentrations found 
in the dialysate effluent are determined by cytokine transfer from the circulation across the 
peritoneal membrane rather than by this level of local production. This does not mean that CCL18 
and angiogenin do not have any effects on the peritoneal membrane, but there is no clear evidence 
from this study that they affect small solute transfer. The correlations observed between dialysate 
levels of CCL18, angiogenin, CCL15 and clinical data such as glucose exposure and duration of dialysis 
might well be due to the relationships between these clinical factors and the membrane transport 
properties of the patient, which in turn determines the dialysate cytokine quantity. 
Interestingly serum levels of MCP-1, IL-6 and CCL18 also correlate with the membrane transport 
factor. Perhaps circulating cytokines could also affect the peritoneal membrane, as well as those 
produced locally. 
 
After one year of follow-up an increase in membrane permeability to cytokines increases the 
dialysate levels of angiogenin, CCL15 and CCl18. 
The changes in cytokine levels seen in the one year follow-up samples are consistent with an 
increase in membrane permeability to the cytokines CCL15, angiogenin and CCL18. This is not 
unexpected given an increase in the D/P creatinine with time is well-recognised in PD patients; it 
may represent an increase in the number of blood vessels in the peritoneum with time and hence an 
increase in the available area for solute transfer. In this respect it is interesting that patients who 
had an increase in D/P creatinine ratio at one year had higher serum angiogenin levels – although 
the membrane change is a localised process. It may not be a statistically robust finding and further 
study with a larger group of follow-up samples would be needed to confirm or refute this possibility. 
The levels of MCP-1 in serum and dialysate are stable at one year, despite the increase in D/P 
creatinine; again, this is consistent with the levels of MCP-1 in dialysate being chiefly due to 
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peritoneal production of MCP-1. Increased levels of IL-6 in dialysate samples at one year are likely to 
reflect increased intra-peritoneal IL-6 production. 
 
The action of CCL15 within the peritoneum is not established 
Although the finding of CCL15 in the effluent dialysate fluid is interesting and novel, the role of 
CCL15 in the peritoneum remains unclear. No effect on cytokine production was seen when CCL15 
was used to stimulate either peritoneal cells or monocyte cells in culture, although others have 
shown response in monocytes to CCL15 stimulation (Lee et al., 2002). Clearly CCL15 might have 
effects on other cytokines or molecules that were not measured. In addition it may be that other 
factors are required for CCL15 activity to occur – other cell types or soluble factors may be present in 
the peritoneum which are absent from the tissue culture situation. 
 
There is some evidence that CCL18 is involved in ongoing EPS after cessation of PD 
In support of a possible role of CCL18 in the development of EPS, CCL18 is found at higher levels in 
the serum of haemodialysis patients with EPS than haemodialysis patients of similar age, sex and 
dialysis duration who had never undergone PD. The number of patients available for this part of the 
study was small, however. Bellón et al found CCL18 levels were higher in the dialysate of 6 
peritoneal dialysis patients who later developed EPS (Bellón et al., 2011), and in an analysis of 106 
patients our group previously noted higher levels of dialysate and serum CCL18 in 7 patients who 
subsequently developed EPS (Ahmad et al., 2010) during 12 months of follow-up. In the larger group 
of patients investigated in this study levels of dialysate and serum CCL18 were not markers for later 
EPS; however in this analysis patients were included who developed EPS more than one year after 
sampling (median 14 months, range 3 – 46 months) and this may explain the lack of association 
between CCL18 levels and later EPS. However, the findings of raised CCL18 levels in such a small 
group of haemodialysis patients (n=10 EPS patients on haemodialysis were sampled) should be 
considered as preliminary only. 
 
Radiological screening for EPS using CT scanning is not useful in asymptomatic PD patients 
The demonstration that severe symptomatic EPS can develop within months of stopping peritoneal 
dialysis even in patients with a recently normal CT scan shows that CT scanning of asymptomatic PD 
patients is not an appropriate screening method. This is an important finding, as patients 
contemplating transplantation or transfer to haemodialysis require counselling as to their risk of EPS 
after modality change and the information they are given should be as accurate as possible. 
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However an abnormal CT scan, performed in the context of a history of even transient abdominal 
symptoms, should raise concerns that the patient is vulnerable to the development of EPS after the 
cessation of PD. 
 
Dialysate cytokine levels in this study are not suitable as biomarkers for the prediction of EPS 
Using these dialysate cytokine levels as predictors of EPS does not have any benefit beyond that of a 
simple model using the duration of PD and D/P creatinine, which had some potential to predict EPS 
in our population. Whether this clinically-based model would be useful and reproducible in other 
populations would require further investigation, as it is likely to perform less well in a new 
population with potentially a different incidence of EPS. At the best it will help to quantify a risk 
associated with long duration of PD and fast transporter status which is already appreciated by 
clinicians. Assessment of cytokines as potential biomarkers combined with clinical markers in this 
study was to some extent limited by the small number of EPS patients (17), which limits the number 
of predictors that can be analysed. 
The use of cytokines – or other small proteins - in the dialysate fluid as a biomarker which could help 
to define the risk of future EPS in a patient who is currently stable on peritoneal dialysis is an exciting 
concept. Dialysate is easy to collect and cytokines can be measured with reasonable inter-assay 
variability using standard commercially available ELISA kits. Given the current lack of radiological 
methods to assess for later EPS risk in stable PD patients, and the difficulties inherent in the 
collection and interpretation of peritoneal biopsies, a small molecule marker which could be 
measured in effluent dialysate would be highly useful to clinicians and patients. When considering 
dialysate cytokines as possible biomarkers for EPS it is worth considering that a cytokine might 
function well as a biomarker even if it is not involved in the pathogenesis of EPS or produced by 
peritoneal cells; for this application it is only the strength of the association of the cytokine level with 
EPS which is relevant. Conversely, a cytokine which is causally involved in the pathogenesis of EPS 
might not show dialysate levels that can be used as a biomarker because it is produced in the 
peritoneum in small quantities, is largely bound to cells and acts in a paracrine fashion, while overall 
dialysate levels are determined by influx of the cytokine from the circulation. CCL18, for example, 
might be in this category; it is seen at high levels in the serum of EPS patients but in dialysate levels 
are lower than predicted from its molecular weight and are not associated with later EPS.  
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Cytokine Predictors of dialysate levels Peritoneal 
production 
in cell 
culture? 
Dialysate level 
determined by 
intra-peritoneal 
production? 
Higher 
levels in 
pre-EPS 
patients? 
D/P 
creatinine 
Serum level Other factor 
CCL18 p < 0.001 p < 0.001  Yes No No 
Angiogenin p < 0.001 p = 0.009 Fluid type 
p = 0.041 
Yes No No 
CCL15 p < 0.001 p < 0.001 Glucose exp 
p = 0.025 
No No Yes 
MCP-1 p < 0.001 (p = 0.057) Glucose exp 
p = 0.015 
Yes Yes Yes 
IL-6 p < 0.001 (p = 0.063) Glucose exp  
p = 0.01 
Duration PD 
p =0.043 
Yes  
(shown by 
other 
groups) 
Yes Yes 
Table 34: Summary of findings relating to dialysate cytokine levels 
 
Areas for further study 
The potential role of CCL15 in the peritoneum is not clear and this could be further studied by 
studying the mechanism of action of CCL15 in a different cell culture system, examining more 
broadly for changes in cytokine production profiles. It would be interesting to investigate the effect 
of CCL15 on peritoneal macrophages or a fibroblast culture. 
The ability of cytokines such as MCP-1 and CCL18 to worsen peritoneal fibrosis could be investigated 
in an animal model of chronic peritoneal dialysis, as could the ability of angiogenin to promote 
vascular changes in the peritoneal membrane. 
The production of matrix elements by the cells of the peritoneum has not been investigated 
extensively in the literature and could be an interesting avenue to pursue, since this is an important 
part of the pathology. There is some evidence implicating matrix-metalloprotease (MMP) levels in 
the pathogenesis of peritoneal sclerosis, and intra-peritoneal production of MMPs has been 
demonstrated (Hirahara et al., 2011). However it may be the balance between the activity of the 
MMPs and tissue inhibitors of MMPs which is more important in fibrosis. MMPs may also be 
relevant as an early step in neo-angiogenesis (downstream of angiogenin). It would be interesting to 
investigate the response of peritoneal cells in culture conditions to the application of cytokines in 
terms of the production of matrix components such as collagen, fibronectin and proteoglycans. 
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These components are generally derived from fibroblasts, so may also be produced by mesothelial 
cells that have undergone EMT.  
It would be useful to examine the expression of cytokines in peritoneal biopsy material; this might 
also help to define which cell types produce the cytokines detected in dialysate. 
 
Final remarks 
Cytokines are produced by peritoneal cells, and are present in the effluent dialysate of peritoneal 
dialysis patients at levels which correlate with important clinical features. There is evidence that 
dialysate levels of MCP-1 and IL-6 are determined by intraperitoneal production, while transfer from 
the circulation could determine dialysate levels of CCL18, CCL15 and angiogenin. The relatively low 
levels of CCL18 in dialysate relative to serum levels suggest it may be bound to protein in the 
peritoneum. Although dialysate cytokine levels are very accessible and convenient, measuring the 
levels in dialysate effluent does not necessarily reflect any local, paracrine activity of the cytokine 
within the peritoneum. 
Cytokines – CCL15, MCP-1 and IL-6 - were found at higher levels in the dialysate of patients who later 
developed EPS; in addition CCL18 is found at higher levels in EPS patients maintained on HD. It may 
be that cytokines are involved in the pathogenesis of EPS but it is also possible that cytokine levels 
are just acting as markers of other mediators more directly involved in the development of 
membrane damage. Although in this study cytokine levels could not be used alone to predict the 
later onset of EPS, raised levels of cytokines in the dialysate might help to confirm a clinical 
impression (based on duration of PD, lack of residual renal function, high glucose requirements and 
high D/P creatinine) that the patient is at relatively high risk of EPS after cessation of PD. Further 
investigation of this possibility requires a large, multi-centre prospective study, with adequate 
numbers of EPS patients. The clinical assessment of risk would be further increased if an episode of 
even transient abdominal symptoms had occurred; in these patients a CT scan which detected 
abnormalities similar in nature to those found in patients with EPS would be a further marker of 
higher risk of symptomatic EPS after the cessation of PD.  
Until a more reliable method of quantifying the risk of EPS is available to clinicians and patients, the 
clinician must continue to use all the available information in the context of the patient’s general 
condition and wishes to guide decisions, especially regarding duration of peritoneal dialysis. The 
search for a reliable and readily measured biomarker of EPS risk should continue to be a priority for 
PD researchers. 
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Appendix A:  
Symptoms Questionnaire 
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Appendix B  
Symptoms in stable PD patients (data presented at the EuroPD meeting in Strasbourg, October 
2009) 
 
 
 
 
 
 
Figure 107: Percentage of patients experiencing each symptom 
Figure 108: Median severity score for each symptom 
155 
 
Appendix C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
156 
 
 
 
 
 
 
157 
 
 
 
 
158 
 
 
 
 
 
 
 
159 
 
 
 
 
 
160 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
161 
 
Appendix D 
 
 
162 
 
 
163 
 
 
164 
 
 
165 
 
 
166 
 
 
167 
 
 
168 
 
 
169 
 
 
170 
 
 
 
171 
 
 
 
172 
 
 
173 
 
 
 
174 
 
 
175 
 
 
176 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
177 
 
REFERENCES 
 
Ahmad, S., North, B. V., Qureshi, A., Malik, A., Bhangal, G., Tarzi, R. M., Brown, E. A. and Tam, F. W. 
(2010) CCL18 in peritoneal dialysis patients and encapsulating peritoneal sclerosis. Eur J Clin 
Invest, 40, 1067-1073. 
Ahmad, S., Sehmi, J., Ahmad-Zakhi, K., Clemenger, M., Levy, J. and Brown, E. (2006) Impact of new 
dialysis solutions on peritonitis rates. Kidney Int Suppl, S63-66. 
Aoki, S., Ikeda, S., Takezawa, T., Kishi, T., Makino, J., Uchihashi, K., Matsunobu, A., Noguchi, M., 
Sugihara, H. and Toda, S. (2011a) Prolonged effect of fluid flow stress on the proliferative 
activity of mesothelial cells after abrupt discontinuation of fluid streaming. Biochemical and 
Biophysical Research Communications, 416, 391-396. 
Aoki, S., Makino, J., Nagashima, A., Takezawa, T., Nomoto, N., Uchihashi, K., Matsunobu, A., Sanai, T., 
Sugihara, H. and Toda, S. (2011b) Fluid flow stress affects peritoneal cell kinetics: possible 
pathogenesis of peritoneal fibrosis. Perit Dial Int, 31, 466-476. 
Arakelyan, A., Kriegova, E., Kubistova, Z., Mrazek, F., Kverka, M., du Bois, R. M., Kolek, V. and Petrek, 
M. (2009) Protein levels of CC chemokine ligand (CCL)15, CCL16 and macrophage stimulating 
protein in patients with sarcoidosis. Clin Exp Immunol, 155, 457-465. 
Aroeira, L., Aguilera, A., Selgas, R., Ramírez-Huesca, M., Pérez-Lozano, M., Cirugeda, A., Bajo, M., del 
Peso, G., Sánchez-Tomero, J., Jiménez-Heffernan, J. and López-Cabrera, M. (2005) 
Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute 
transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney 
Dis, 46, 938-948. 
Aroeira, L., Aguilera, A., Sánchez-Tomero, J., Bajo, M., del Peso, G., Jiménez-Heffernan, J., Selgas, R. 
and López-Cabrera, M. (2007) Epithelial to mesenchymal transition and peritoneal 
membrane failure in peritoneal dialysis patients: pathologic significance and potential 
therapeutic interventions. J Am Soc Nephrol, 18, 2004-2013. 
Atamas, S., Luzina, I., Choi, J., Tsymbalyuk, N., Carbonetti, N., Singh, I., Trojanowska, M., Jimenez, S. 
and White, B. (2003) Pulmonary and activation-regulated chemokine stimulates collagen 
production in lung fibroblasts. Am J Respir Cell Mol Biol, 29, 743-749. 
Balasubramaniam, G., Brown, E., Davenport, A., Cairns, H., Cooper, B., Fan, S., Farrington, K., 
Gallagher, H., Harnett, P., Krausze, S. and Steddon, S. (2009) The Pan-Thames EPS study: 
treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant, 24, 
3209-3215. 
Bellón, T., Martínez, V., Lucendo, B., del Peso, G., Castro, M. J., Aroeira, L. S., Rodríguez-Sanz, A., 
Ossorio, M., Sánchez-Villanueva, R., Selgas, R. and Bajo, M. A. (2011) Alternative activation 
of macrophages in human peritoneum: implications for peritoneal fibrosis. Nephrol Dial 
Transplant, 26, 2995-3005. 
Boot, R., Verhoek, M., de Fost, M., Hollak, C., Maas, M., Bleijlevens, B., van Breemen, M., van Meurs, 
M., Boven, L., Laman, J., Moran, M., Cox, T. and Aerts, J. (2004) Marked elevation of the 
chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing 
therapeutic intervention. Blood, 103, 33-39. 
Boulanger, E., Grossin, N., Wautier, M., Taamma, R. and Wautier, J. (2007) Mesothelial RAGE 
activation by AGEs enhances VEGF release and potentiates capillary tube formation. Kidney 
Int, 71, 126-133. 
Brown, E., Davies, S., Rutherford, P., Meeus, F., Borras, M., Riegel, W., Divino Filho, J., Vonesh, E. and 
van Bree, M. (2003) Survival of functionally anuric patients on automated peritoneal dialysis: 
the European APD Outcome Study. J Am Soc Nephrol, 14, 2948-2957. 
Brown, E., Van Biesen, W., Finkelstein, F., Hurst, H., Johnson, D., Kawanishi, H., Pecoits-Filho, R. and 
Woodrow, G. (2009a) Length of time on peritoneal dialysis and encapsulating peritoneal 
sclerosis: position paper for ISPD. Perit Dial Int, 29, 595-600. 
178 
 
Brown, M., Simpson, K., Kerssens, J. and Mactier, R. (2009b) Encapsulating peritoneal sclerosis in the 
new millennium: a national cohort study. Clin J Am Soc Nephrol, 4, 1222-1229. 
Chan, T. and Yung, S. (2007) Studying the effects of new peritoneal dialysis solutions on the 
peritoneum. Perit Dial Int, 27 Suppl 2, S87-93. 
Chang, J., Jiang, Z., Zhang, H., Zhu, H., Zhou, S. F. and Yu, X. (2011) NADPH oxidase-dependent 
formation of reactive oxygen species contributes to angiotensin II-induced epithelial-
mesenchymal transition in rat peritoneal mesothelial cells. Int J Mol Med, 28, 405-412. 
Chen, J., Yao, Y., Gong, C., Yu, F., Su, S., Liu, B., Deng, H., Wang, F., Lin, L., Yao, H., Su, F., Anderson, K. 
S., Liu, Q., Ewen, M. E., Yao, X. and Song, E. (2011) CCL18 from tumor-associated 
macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell, 19, 541-555. 
Cheng, S., Pollock, A., Mahimkar, R., Olson, J. and Lovett, D. (2006) Matrix metalloproteinase 2 and 
basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J, 
20, 1898-1900. 
Chiarelli, F., Pomilio, M., Mohn, A., Tumini, S., Verrotti, A., Mezzetti, A., Cipollone, F., Wasniewska, 
M., Morgese, G. and Spagnoli, A. (2002) Serum angiogenin concentrations in young patients 
with diabetes mellitus. Eur J Clin Invest, 32, 110-114. 
Chiu, Y. W., Jiwakanon, S., Lukowsky, L., Duong, U., Kalantar-Zadeh, K. and Mehrotra, R. (2011) An 
update on the comparisons of mortality outcomes of hemodialysis and peritoneal dialysis 
patients. Semin Nephrol, 31, 152-158. 
Choi, H., Kim, D., Lee, T., Moon, S., Han, S., Lee, J., Kim, B., Park, H., Choi, K., Ha, S., Han, D. and Lee, 
H. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose 
degradation product concentration: an open randomized prospective trial. Perit Dial Int, 28, 
174-182. 
Churchill, D. (1998) Implications of the Canada-USA (CANUSA) study of the adequacy of dialysis on 
peritoneal dialysis schedule. Nephrol Dial Transplant, 13 Suppl 6, 158-163. 
Combet, S., Ferrier, M., Van Landschoot, M., Stoenoiu, M., Moulin, P., Miyata, T., Lameire, N. and 
Devuyst, O. (2001) Chronic uremia induces permeability changes, increased nitric oxide 
synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol, 12, 
2146-2157. 
Cook, N. R. (2007) Use and misuse of the receiver operating characteristic curve in risk prediction. 
Circulation, 115, 928-935. 
Cook, N. R. (2008) Statistical evaluation of prognostic versus diagnostic models: beyond the ROC 
curve. Clin Chem, 54, 17-23. 
Cronin, S., Greenway, M. J., Ennis, S., Kieran, D., Green, A., Prehn, J. H. and Hardiman, O. (2006) 
Elevated serum angiogenin levels in ALS. Neurology, 67, 1833-1836. 
Daugirdas, J., Blake, P. and Ing, T. ( 2001) Handbook of dialysis, Lipincott Williams and Wilkins. 
Davies, S. (2004) Longitudinal relationship between solute transport and ultrafiltration capacity in 
peritoneal dialysis patients. Kidney Int, 66, 2437-2445. 
Davies, S. and Brown, E. (2007) EAPOS: what have we learned? Perit Dial Int, 27, 131-135. 
Davies, S., Brown, E., Frandsen, N., Rodrigues, A., Rodriguez-Carmona, A., Vychytil, A., Macnamara, 
E., Ekstrand, A., Tranaeus, A. and Filho, J. (2005) Longitudinal membrane function in 
functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and 
icodextrin prescription. Kidney Int, 67, 1609-1615. 
Davies, S., Bryan, J., Phillips, L. and Russell, G. (1996) Longitudinal changes in peritoneal kinetics: the 
effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant, 11, 498-506. 
Davies, S., Phillips, L., Naish, P. and Russell, G. (2001) Peritoneal glucose exposure and changes in 
membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol, 12, 1046-
1051. 
Davies, S. J., Brown, E. A., Reigel, W., Clutterbuck, E., Heimbürger, O., Diaz, N. V., Mellote, G. J., 
Perez-Contreras, J., Scanziani, R., D'Auzac, C., Kuypers, D., Divino Filho, J. C. and Group, E. 
179 
 
(2006) What is the link between poor ultrafiltration and increased mortality in anuric 
patients on automated peritoneal dialysis? Analysis of data from EAPOS. Perit Dial Int, 26, 
458-465. 
Davies, S. J., Phillips, L., Naish, P. F. and Russell, G. I. (2002) Quantifying comorbidity in peritoneal 
dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant, 
17, 1085-1092. 
de Freitas, D., Jordaan, A., Williams, R., Alderdice, J., Curwell, J., Hurst, H., Hutchison, A., Brenchley, 
P., Augustine, T. and Summers, A. (2008) Nutritional management of patients undergoing 
surgery following diagnosis with encapsulating peritoneal sclerosis. Perit Dial Int, 28, 271-
276. 
De Vriese, A., Tilton, R., Mortier, S. and Lameire, N. (2006) Myofibroblast transdifferentiation of 
mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. 
Nephrol Dial Transplant, 21, 2549-2555. 
De Vriese, A., Tilton, R., Stephan, C. and Lameire, N. (2001) Vascular endothelial growth factor is 
essential for hyperglycemia-induced structural and functional alterations of the peritoneal 
membrane. J Am Soc Nephrol, 12, 1734-1741. 
del Peso, G., Bajo, M., Gil, F., Aguilera, A., Ros, S., Costero, O., Castro, M. and Selgas, R. (2003) 
Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial, 19, 32-
35. 
Del Peso, G., Jiménez-Heffernan, J., Bajo, M., Aroeira, L., Aguilera, A., Fernández-Perpén, A., 
Cirugeda, A., Castro, M., de Gracia, R., Sánchez-Villanueva, R., Sánchez-Tomero, J., López-
Cabrera, M. and Selgas, R. (2008) Epithelial-to-mesenchymal transition of mesothelial cells is 
an early event during peritoneal dialysis and is associated with high peritoneal transport. 
Kidney Int Suppl, S26-33. 
Dragomir, E. and Simionescu, M. (2006) Monocyte chemoattractant protein-1--a major contributor 
to the inflammatory process associated with diabetes. Arch Physiol Biochem, 112, 239-244. 
Eltringham, W., Espiner, H., Windsor, C., Griffiths, D., Davies, J., Baddeley, H., Read, A. and Blunt, R. 
(1977) Sclerosing peritonitis due to practolol: a report on 9 cases and their surgical 
management. Br J Surg, 64, 229-235. 
Etoh, T., Shibuta, K., Barnard, G. F., Kitano, S. and Mori, M. (2000) Angiogenin expression in human 
colorectal cancer: the role of focal macrophage infiltration. Clin Cancer Res, 6, 3545-3551. 
Fang, W., Mullan, R., Shah, H., Mujais, S., Bargman, J. and Oreopoulos, D. Comparison between 
bicarbonate/lactate and standard lactate dialysis solution in peritoneal transport and 
ultrafiltration: a prospective, crossover single-dwell study. Perit Dial Int, 28, 35-43. 
Fett, J. W., Strydom, D. J., Lobb, R. R., Alderman, E. M., Bethune, J. L., Riordan, J. F. and Vallee, B. L. 
(1985) Isolation and characterization of angiogenin, an angiogenic protein from human 
carcinoma cells. Biochemistry, 24, 5480-5486. 
Fielding, C., McLoughlin, R., Parker, C., Roberts, G., Colmont, C., Kift-Morgan, A., Williams, J., Jones, 
S. and Topley, N. (2008) Recurrent peritonitis causes a dysregulation of the peritoneal 
cytokine network. In Renal AssociationGlasgow. 
Fieren, M., Betjes, M., Korte, M. and Boer, W. (2007) Posttransplant encapsulating peritoneal 
sclerosis: a worrying new trend? Perit Dial Int, 27, 619-624. 
Forssmann, U., Mägert, H., Adermann, K., Escher, S. and Forssmann, W. (2001) Hemofiltrate CC 
chemokines with unique biochemical properties: HCC-1/CCL14a and HCC-2/CCL15. J Leukoc 
Biol, 70, 357-366. 
Garosi, G., Cappelletti, F. and Di Paolo, N. (2006) Fibrosis and sclerosis: different disorders or 
different stages? Contrib Nephrol, 150, 62-69. 
Habib, A. M., Preston, E. and Davenport, A. (2010) Risk factors for developing encapsulating 
peritoneal sclerosis in the icodextrin era of peritoneal dialysis prescription. Nephrol Dial 
Transplant, 25, 1633-1638. 
180 
 
Haringman, J. J., Smeets, T. J., Reinders-Blankert, P. and Tak, P. P. (2006) Chemokine and chemokine 
receptor expression in paired peripheral blood mononuclear cells and synovial tissue of 
patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann Rheum Dis, 65, 
294-300. 
Heimbürger, O., Waniewski, J., Werynski, A., Tranaeus, A. and Lindholm, B. (1990) Peritoneal 
transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int, 38, 
495-506. 
Hieshima, K., Imai, T., Baba, M., Shoudai, K., Ishizuka, K., Nakagawa, T., Tsuruta, J., Takeya, M., 
Sakaki, Y., Takatsuki, K., Miura, R., Opdenakker, G., Van Damme, J., Yoshie, O. and 
Nomiyama, H. (1997) A novel human CC chemokine PARC that is most homologous to 
macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, 
but not for monocytes. J Immunol, 159, 1140-1149. 
Hirahara, I., Inoue, M., Umino, T., Saito, O., Muto, S. and Kusano, E. (2011) Matrix metalloproteinase 
levels in the drained dialysate reflect the peritoneal solute transport rate: a multicentre 
study in Japan. Nephrol Dial Transplant, 26, 1695-1701. 
Hirahara, I., Ishibashi, Y., Kaname, S., Kusano, E. and Fujita, T. (2009) Methylglyoxal induces 
peritoneal thickening by mesenchymal-like mesothelial cells in rats. Nephrol Dial Transplant, 
24, 437-447. 
Honda, K., Nitta, K., Horita, S., Tsukada, M., Itabashi, M., Nihei, H., Akiba, T. and Oda, H. (2003) 
Histologic criteria for diagnosing encapsulating peritoneal sclerosis in continuous ambulatory 
peritoneal dialysis patients. Adv Perit Dial, 19, 169-175. 
Honda, K., Nitta, K., Horita, S., Yumura, W., Nihei, H., Nagai, R., Ikeda, K. and Horiuchi, S. (1999) 
Accumulation of advanced glycation end products in the peritoneal vasculature of 
continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial 
Transplant, 14, 1541-1549. 
Honda, K. and Oda, H. (2005) Pathology of encapsulating peritoneal sclerosis. Perit Dial Int, 25 Suppl 
4, S19-29. 
Hosmer, D. W. and Lemeshow, S. (2000) Applied logistic regression, Wiley, New York. 
Hur, J., Kim, K., Park, M. and Yu, J. (2004) Abdominal cocoon: preoperative diagnostic clues from 
radiologic imaging with pathologic correlation. AJR Am J Roentgenol, 182, 639-641. 
Hurst, S., Wilkinson, T., McLoughlin, R., Jones, S., Horiuchi, S., Yamamoto, N., Rose-John, S., Fuller, 
G., Topley, N. and Jones, S. (2001) Il-6 and its soluble receptor orchestrate a temporal switch 
in the pattern of leukocyte recruitment seen during acute inflammation. Immunity, 14, 705-
714. 
Hwang, J., Kim, C., Son, K., Han, K., Lee, K., Kleinman, H., Ko, J., Na, D., Kwon, B., Gho, Y. and Kim, J. 
(2004) Angiogenic activity of human CC chemokine CCL15 in vitro and in vivo. FEBS Lett, 570, 
47-51. 
Hüser, N., Stangl, M., Lutz, J., Fend, F., Kreymann, B. and Gaa, J. (2006) Sclerosing encapsulating 
peritonitis: MRI diagnosis. Eur Radiol, 16, 238-239. 
Jiménez-Heffernan, J. A., Aguilera, A., Aroeira, L. S., Lara-Pezzi, E., Bajo, M. A., del Peso, G., Ramírez, 
M., Gamallo, C., Sánchez-Tomero, J. A., Alvarez, V., López-Cabrera, M. and Selgas, R. (2004) 
Immunohistochemical characterization of fibroblast subpopulations in normal peritoneal 
tissue and in peritoneal dialysis-induced fibrosis. Virchows Arch, 444, 247-256. 
Johnson, D., Cho, Y., Livingston, B., Hawley, C., McDonald, S., Brown, F., Rosman, J., Bannister, K. and 
Wiggins, K. (2010) Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. 
Kidney Int, 77, 904-912. 
Kagami, S. (2011) Involvement of glomerular renin-angiotensin system (RAS) activation in the 
development and progression of glomerular injury. Clin Exp Nephrol. 
181 
 
Kang, D., Hong, Y., Lim, H., Choi, J., Han, D. and Yoon, K. (1999) High glucose solution and spent 
dialysate stimulate the synthesis of transforming growth factor-beta1 of human peritoneal 
mesothelial cells: effect of cytokine costimulation. Perit Dial Int, 19, 221-230. 
Kawaguchi, Y., Hasegawa, T., Nakayama, M., Kubo, H. and Shigematu, T. (1997) Issues affecting the 
longevity of the continuous peritoneal dialysis therapy. Kidney Int Suppl, 62, S105-107. 
Kawanishi, H., Fujimori, A., Tsuchida, K., Takemoto, Y., Tomo, T., Minakuchi, J., Yamamoto, T., Kim, 
M., Numata, A., Choh, S. and Naito, H. (2005) Markers in peritoneal effluent for withdrawal 
from peritoneal dialysis: multicenter prospective study in Japan. Adv Perit Dial, 21, 134-138. 
Kawanishi, H. and Moriishi, M. (2005) Epidemiology of encapsulating peritoneal sclerosis in Japan. 
Perit Dial Int, 25 Suppl 4, S14-18. 
Kawanishi, H., Moriishi, M., Ide, K. and Dohi, K. (2008) Recommendation of the surgical option for 
treatment of encapsulating peritoneal sclerosis. Perit Dial Int, 28 Suppl 3, S205-210. 
Ke, C. Y., Lee, C. C., Lee, C. J., Subeq, Y. M., Lee, R. P. and Hsu, B. G. (2010) Aliskiren ameliorates 
chlorhexidine digluconate-induced peritoneal fibrosis in rats. Eur J Clin Invest, 40, 301-309. 
Kim, S. M., Jang, H. R., Lee, Y. J., Lee, J. E., Huh, W. S., Kim, D. J., Oh, H. Y. and Kim, Y. G. (2011) 
Urinary angiotensinogen levels reflect the severity of renal histopathology in patients with 
chronic kidney disease. Clin Nephrol, 76, 117-123. 
Kishimoto, K., Liu, S., Tsuji, T., Olson, K. and Hu, G. (2005) Endogenous angiogenin in endothelial cells 
is a general requirement for cell proliferation and angiogenesis. Oncogene, 24, 445-456. 
Kodera, M., Hasegawa, M., Komura, K., Yanaba, K., Takehara, K. and Sato, S. (2005) Serum 
pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic 
sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum, 52, 2889-2896. 
Kokubo, S., Sakai, N., Furuichi, K., Toyama, T., Kitajima, S., Okumura, T., Matsushima, K., Kaneko, S. 
and Wada, T. (2011) Activation of p38 mitogen-activated protein kinase promotes peritoneal 
fibrosis by regulating fibrocytes. Perit Dial Int. 
Kolesnyk, I., Noordzij, M., Dekker, F., Boeschoten, E. and Krediet, R. (2009) A positive effect of AII 
inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial 
Transplant, 24, 272-277. 
Korte, M., Fieren, M., Sampimon, D., Lingsma, H., Weimar, W., Betjes, M. and Study, o. b. o. t. i. o. t. 
D. M. E. (2010) Tamoxifen is associated with lower mortality of encapsulating peritoneal 
sclerosis: results of the Dutch Multicentre EPS Study. Nephrol Dial Transplant. 
Korte, M., Yo, M., Betjes, M., Fieren, M., van Saase, J., Boer, W., Weimar, W. and Zietse, R. (2007) 
Increasing incidence of severe encapsulating peritoneal sclerosis after kidney 
transplantation. Nephrol Dial Transplant, 22, 2412-2414. 
Korte, M. R., Habib, S. M., Lingsma, H., Weimar, W. and Betjes, M. G. (2011) Posttransplantation 
encapsulating peritoneal sclerosis contributes significantly to mortality after kidney 
transplantation. Am J Transplant, 11, 599-605. 
Krediet, R., Coester, A., Parikova, A., Smit, W. and Struijk, D. (2008) New insights into the physiology 
of peritoneal fluid transport. Perit Dial Int, 28 Suppl 3, S144-149. 
Krediet, R., Lindholm, B. and Rippe, B. (2000) Pathophysiology of peritoneal membrane failure. Perit 
Dial Int, 20 Suppl 4, S22-42. 
Kristan, S. S., Malovrh, M. M., Silar, M., Kern, I., Flezar, M., Kosnik, M., Suskovic, S. and Korosec, P. 
(2009) Airway angiogenesis in patients with rhinitis and controlled asthma. Clin Exp Allergy, 
39, 354-360. 
Kwon, S. H., Ju, S. A., Kang, J. H., Kim, C. S., Yoo, H. M. and Yu, R. (2008) Chemokine Lkn-1/CCL15 
enhances matrix metalloproteinase-9 release from human macrophages and macrophage-
derived foam cells. Nutr Res Pract, 2, 134-137. 
La Milia, V., Limardo, M., Virga, G., Crepaldi, M. and Locatelli, F. (2007) Simultaneous measurement 
of peritoneal glucose and free water osmotic conductances. Kidney Int, 72, 643-650. 
182 
 
LaClair, R., O'Neal, K., Ofner, S., Sosa, M. J., Labarrere, C. A. and Moe, S. M. (2008) Precision of 
biomarkers to define chronic inflammation in CKD. Am J Nephrol, 28, 808-812. 
Lai, K. N., Lai, K. B., Lam, C. W., Chan, T. M., Li, F. K. and Leung, J. C. (2000) Changes of cytokine 
profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J 
Kidney Dis, 35, 644-652. 
Lamb, E., Cattell, W. and Dawnay, A. (1995) In vitro formation of advanced glycation end products in 
peritoneal dialysis fluid. Kidney Int, 47, 1768-1774. 
Lambie, M. L., John, B., Mushahar, L., Huckvale, C. and Davies, S. J. (2010) The peritoneal osmotic 
conductance is low well before the diagnosis of EPS is made. Kidney International, 78, 611-
618. 
Lee, S., Kim, B., Yang, W., Kim, S., Park, S. and Park, J. (2001) High glucose induces MCP-1 expression 
partly via tyrosine kinase-AP-1 pathway in peritoneal mesothelial cells. Kidney Int, 60, 55-64. 
Lee, W., Kim, S., Jeong, E., Choi, Y., Kim, D., Lee, B., Cho, Y., Kwon, B. and Park, J. (2002) A novel 
chemokine, Leukotactin-1, induces chemotaxis, pro-atherogenic cytokines, and tissue factor 
expression in atherosclerosis. Atherosclerosis, 161, 255-260. 
Leung, J. C., Chan, L. Y., Tam, K. Y., Tang, S. C., Lam, M. F., Cheng, A. S., Chu, K. M. and Lai, K. N. 
(2009) Regulation of CCN2/CTGF and related cytokines in cultured peritoneal cells under 
conditions simulating peritoneal dialysis. Nephrol Dial Transplant, 24, 458-469. 
Li, M., Hering-Smith, K. S., Simon, E. E. and Batuman, V. (2008) Myeloma light chains induce 
epithelial-mesenchymal transition in human renal proximal tubule epithelial cells. Nephrol 
Dial Transplant, 23, 860-870. 
Libetta, C., Esposito, P., Sepe, V., Guastoni, C., Zucchi, M., Meloni, F. and Dal Canton, A. (2011) 
Effects of different peritoneal dialysis fluids on the TH1/TH2 balance. Eur Cytokine Netw, 22, 
24-31. 
Lioté, F., Champy, R., Moenner, M., Boval-Boizard, B. and Badet, J. (2003) Elevated angiogenin levels 
in synovial fluid from patients with inflammatory arthritis and secretion of angiogenin by 
cultured synovial fibroblasts. Clin Exp Immunol, 132, 163-168. 
Lip, G. Y. and Blann, A. D. (2004) Thrombogenesis, atherogenesis and angiogenesis in vascular 
disease: a new 'vascular triad'. Ann Med, 36, 119-125. 
Liu, Y. (2004) Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, 
molecular mechanism, and therapeutic intervention. J Am Soc Nephrol, 15, 1-12. 
Liu, Y. (2010) New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc 
Nephrol, 21, 212-222. 
Lo, W., Chan, K., Leung, A., Pang, S. and Tse, C. (1991) Sclerosing peritonitis complicating prolonged 
use of chlorhexidine in alcohol in the connection procedure for continuous ambulatory 
peritoneal dialysis. Perit Dial Int, 11, 166-172. 
Loureiro, J., Aguilera, A., Selgas, R., Sandoval, P., Albar-Vizcaíno, P., Pérez-Lozano, M. L., Ruiz-Carpio, 
V., Majano, P. L., Lamas, S., Rodríguez-Pascual, F., Borras-Cuesta, F., Dotor, J. and López-
Cabrera, M. (2011) Blocking TGF-β1 protects the peritoneal membrane from dialysate-
induced damage. J Am Soc Nephrol, 22, 1682-1695. 
Lui, S., Chan, T., Lai, K. and Lo, W. (2007) Tuberculous and fungal peritonitis in patients undergoing 
continuous ambulatory peritoneal dialysis. Perit Dial Int, 27 Suppl 2, S263-266. 
Luzina, I., Papadimitriou, J., Anderson, R., Pochetuhen, K. and Atamas, S. (2006a) Induction of 
prolonged infiltration of T lymphocytes and transient T lymphocyte-dependent collagen 
deposition in mouse lungs following adenoviral gene transfer of CCL18. Arthritis Rheum, 54, 
2643-2655. 
Luzina, I., Tsymbalyuk, N., Choi, J., Hasday, J. and Atamas, S. (2006b) CCL18-stimulated upregulation 
of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity. J 
Cell Physiol, 206, 221-228. 
183 
 
López-Cabrera, M., Aguilera, A., Aroeira, L., Ramírez-Huesca, M., Pérez-Lozano, M., Jiménez-
Heffernan, J., Bajo, M., del Peso, G., Sánchez-Tomero, J. and Selgas, R. (2006) Ex vivo analysis 
of dialysis effluent-derived mesothelial cells as an approach to unveiling the mechanism of 
peritoneal membrane failure. Perit Dial Int, 26, 26-34. 
Malik, A., Little, M., Henriksson, M., Tam, F. and Brown, E. (2007) Peritonitis, peritoneal 
inflammation and membrane permeability: a longitudinal study of dialysate and serum MCP-
1 in stable patients on peritoneal dialysis. J Nephrol, 20, 340-349. 
Mandl-Weber, S., Cohen, C., Haslinger, B., Kretzler, M. and Sitter, T. (2002) Vascular endothelial 
growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int, 
61, 570-578. 
Mandl-Weber, S., Haslinger, B., Schalkwijk, C. and Sitter, T. (2001) Early glycated albumin, but not 
advanced glycated albumin, methylglyoxal, or 3-deoxyglucosone increases the expression of 
PAI-1 in human peritoneal mesothelial cells. Perit Dial Int, 21, 487-494. 
Margetts, P., Bonniaud, P., Liu, L., Hoff, C., Holmes, C., West-Mays, J. and Kelly, M. (2005) Transient 
overexpression of TGF-{beta}1 induces epithelial mesenchymal transition in the rodent 
peritoneum. J Am Soc Nephrol, 16, 425-436. 
Margetts, P., Gyorffy, S., Kolb, M., Yu, L., Hoff, C., Holmes, C. and Gauldie, J. (2002) Antiangiogenic 
and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am 
Soc Nephrol, 13, 721-728. 
Margetts, P., Kolb, M., Galt, T., Hoff, C., Shockley, T. and Gauldie, J. (2001) Gene transfer of 
transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J 
Am Soc Nephrol, 12, 2029-2039. 
Maruyama, Y. and Nakayama, M. (2008) Encapsulating peritoneal sclerosis in Japan. Perit Dial Int, 28 
Suppl 3, S201-204. 
McLaughlin, R. L., Phukan, J., McCormack, W., Lynch, D. S., Greenway, M., Cronin, S., Saunders, J., 
Slowik, A., Tomik, B., Andersen, P. M., Bradley, D. G., Jakeman, P. and Hardiman, O. (2010) 
Angiogenin levels and ANG genotypes: dysregulation in amyotrophic lateral sclerosis. PLoS 
One, 5, e15402. 
McLoughlin, R., Hurst, S., Nowell, M., Harris, D., Horiuchi, S., Morgan, L., Wilkinson, T., Yamamoto, 
N., Topley, N. and Jones, S. (2004) Differential regulation of neutrophil-activating 
chemokines by IL-6 and its soluble receptor isoforms. J Immunol, 172, 5676-5683. 
Medcalf, J., Walls, J., Pawluczyk, I. and Harris, K. (2001) Effects of glucose dialysate on extracellular 
matrix production by human peritoneal mesothelial cells (HPMC): the role of TGF-beta. 
Nephrol Dial Transplant, 16, 1885-1892. 
Mekeel, K., Moss, A., Reddy, K., Douglas, D. and Mulligan, D. (2009) Sclerosing peritonitis and 
mortality after liver transplantation. Liver Transpl, 15, 435-439. 
Michels, W., Zweers, M., Smit, W., Korevaar, J., Struijk, D., van Westrhenen, R. and Krediet, R. (2004) 
Does lymphatic absorption change with the duration of peritoneal dialysis? Perit Dial Int, 24, 
347-352. 
Miyata, T., Horie, K., Ueda, Y., Fujita, Y., Izuhara, Y., Hirano, H., Uchida, K., Saito, A., van Ypersele de 
Strihou, C. and Kurokawa, K. (2000) Advanced glycation and lipidoxidation of the peritoneal 
membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. 
Kidney Int, 58, 425-435. 
Mizutani, M., Ito, Y., Mizuno, M., Nishimura, H., Suzuki, Y., Hattori, R., Matsukawa, Y., Imai, M., 
Oliver, N., Goldschmeding, R., Aten, J., Krediet, R., Yuzawa, Y. and Matsuo, S. (2010) 
Connective tissue growth factor (CTGF/CCN2) is increased in peritoneal dialysis patients with 
high peritoneal solute transport rate. Am J Physiol Renal Physiol, 298, F721-733. 
Moon, S., Han, S., Kim, D., Lee, J., Kim, B., Kang, S., Choi, K., Lee, H. and Han, D. (2008) Risk factors 
for adverse outcomes after peritonitis-related technique failure. Perit Dial Int, 28, 352-360. 
184 
 
Moore, B. B., Murray, L., Das, A., Wilke, C. A., Herrygers, A. B. and Toews, G. B. (2006) The role of 
CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol, 35, 175-
181. 
Mujais, S., Nolph, K., Gokal, R., Blake, P., Burkart, J., Coles, G., Kawaguchi, Y., Kawanishi, H., Korbet, 
S., Krediet, R., Lindholm, B., Oreopoulos, D., Rippe, B. and Selgas, R. (2000) Evaluation and 
management of ultrafiltration problems in peritoneal dialysis. International Society for 
Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. 
Perit Dial Int, 20 Suppl 4, S5-21. 
Nakamoto, H., Imai, H., Fukushima, R., Ishida, Y., Yamanouchi, Y. and Suzuki, H. (2008) Role of the 
renin-angiotensin system in the pathogenesis of peritoneal fibrosis. Perit Dial Int, 28 Suppl 3, 
S83-87. 
Nakamura, M., Yamabe, H., Osawa, H., Nakamura, N., Shimada, M., Kumasaka, R., Murakami, R., 
Fujita, T., Osanai, T. and Okumura, K. (2006) Hypoxic conditions stimulate the production of 
angiogenin and vascular endothelial growth factor by human renal proximal tubular 
epithelial cells in culture. Nephrol Dial Transplant, 21, 1489-1495. 
Nakayama, M., Maruyama, Y. and Numata, M. (2005) Encapsulating peritoneal sclerosis is a separate 
entity: Con. Perit Dial Int, 25 Suppl 3, S107-109. 
Nilsson, U., Abrahamsson, A. and Dabrosin, C. (2010) Angiogenin regulation by estradiol in breast 
tissue: tamoxifen inhibits its nuclear translocation and anti-angiogenin therapy reduces 
breast cancer growth in vivo. Clin Cancer Res, 16, 3659-3669. 
Nilsson Åberg, U. W., Saarinen, N., Abrahamsson, A., Nurmi, T., Engblom, S. and Dabrosin, C. (2011) 
Tamoxifen and flaxseed alter angiogenesis regulators in normal human breast tissue in vivo. 
PLoS One, 6, e25720. 
Nishino, T. and Devuyst, O. (2008) Clinical application of aquaporin research: aquaporin-1 in the 
peritoneal membrane. Pflugers Arch, 456, 721-727. 
Noh, H., Ha, H., Yu, M., Kim, Y., Kim, J. and Lee, H. (2005) Angiotensin II mediates high glucose-
induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species. 
Perit Dial Int, 25, 38-47. 
Noh, H., Kim, J., Han, K., Lee, G., Song, J., Chung, S., Jeon, J., Ha, H. and Lee, H. (2006) Oxidative 
stress during peritoneal dialysis: implications in functional and structural changes in the 
membrane. Kidney Int, 69, 2022-2028. 
Numata, M., Nakayama, M., Nimura, S., Kawakami, M., Lindholm, B. and Kawaguchi, Y. (2003) 
Association between an increased surface area of peritoneal microvessels and a high 
peritoneal solute transport rate. Perit Dial Int, 23, 116-122. 
O'Neill, L. A. J. and Bowie, A. (2001) Interleukin protocols, Humana Press, Totowa, NJ. 
Oymak, Y., Velioğlu, A., Haklar, G., Ozener, C. and Yalçin, A. S. (2003) Early detection of peritonitis in 
continuous ambulatory peritoneal dialysis patients by cytokine measurements. Clin Chem 
Lab Med, 41, 640-645. 
Pajek, J., Kveder, R., Bren, A., Gucek, A., Ihan, A., Osredkar, J. and Lindholm, B. (2008) Short-term 
effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fluid on 
peritoneal and systemic inflammation in CAPD patients: a randomized controlled study. Perit 
Dial Int, 28, 44-52. 
Paniagua, R., Amato, D., Vonesh, E., Correa-Rotter, R., Ramos, A., Moran, J. and Mujais, S. (2002) 
Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, 
a prospective, randomized, controlled trial. J Am Soc Nephrol, 13, 1307-1320. 
Pardigol, A., Forssmann, U., Zucht, H., Loetscher, P., Schulz-Knappe, P., Baggiolini, M., Forssmann, W. 
and Mägert, H. (1998) HCC-2, a human chemokine: gene structure, expression pattern, and 
biological activity. Proc Natl Acad Sci U S A, 95, 6308-6313. 
185 
 
Parikova, A., Smit, W., Struijk, D. and Krediet, R. (2006) Analysis of fluid transport pathways and their 
determinants in peritoneal dialysis patients with ultrafiltration failure. Kidney Int, 70, 1988-
1994. 
Patel, P., Sekiguchi, Y., Oh, K., Patterson, S., Kolb, M. and Margetts, P. (2010) Smad3-dependent and 
-independent pathways are involved in peritoneal membrane injury. Kidney Int, 77, 319-328. 
Pecoits-Filho, R., Araújo, M., Lindholm, B., Stenvinkel, P., Abensur, H., Romão, J. J., Marcondes, M., 
De Oliveira, A. and Noronha, I. (2002a) Plasma and dialysate IL-6 and VEGF concentrations 
are associated with high peritoneal solute transport rate. Nephrol Dial Transplant, 17, 1480-
1486. 
Pecoits-Filho, R., Bárány, P., Lindholm, B., Heimbürger, O. and Stenvinkel, P. (2002b) Interleukin-6 is 
an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial 
Transplant, 17, 1684-1688. 
Pecoits-Filho, R., Lindholm, B., Axelsson, J. and Stenvinkel, P. (2003) Update on interleukin-6 and its 
role in chronic renal failure. Nephrol Dial Transplant, 18, 1042-1045. 
Peduzzi, P., Concato, J., Kemper, E., Holford, T. R. and Feinstein, A. R. (1996) A simulation study of 
the number of events per variable in logistic regression analysis. J Clin Epidemiol, 49, 1373-
1379. 
Pencina, M. J., D'Agostino, R. B. and Vasan, R. S. (2008) Evaluating the added predictive ability of a 
new marker: from area under the ROC curve to reclassification and beyond. Stat Med, 27, 
157-172; discussion 207-112. 
Pepe, M. S. and Janes, H. (2011) Commentary: Reporting standards are needed for evaluations of 
risk reclassification. Int J Epidemiol, 40, 1106-1108. 
Pereira, B. J., Snodgrass, B., Barber, G., Perella, C., Chopra, S. and King, A. J. (1995) Cytokine 
production during in vitro hemodialysis with new and formaldehyde- or renalin-reprocessed 
cellulose dialyzers. J Am Soc Nephrol, 6, 1304-1308. 
Peterson, S., Poposki, J. A., Nagarkar, D. R., Chustz, R. T., Peters, A. T., Suh, L. A., Carter, R., Norton, 
J., Harris, K. E., Grammer, L. C., Tan, B. K., Chandra, R. K., Conley, D. B., Kern, R. C., Schleimer, 
R. P. and Kato, A. (2012) Increased expression of CC chemokine ligand 18 in patients with 
chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol, 129, 119-127.e119. 
Piemonti, L., Calori, G., Lattuada, G., Mercalli, A., Ragogna, F., Garancini, M. P., Ruotolo, G., Luzi, L. 
and Perseghin, G. (2009) Association between plasma monocyte chemoattractant protein-1 
concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic 
individuals. Diabetes Care, 32, 2105-2110. 
Piraino, B., Bailie, G. R., Bernardini, J., Boeschoten, E., Gupta, A., Holmes, C., Kuijper, E. J., Li, P. K., 
Lye, W. C., Mujais, S., Paterson, D. L., Fontan, M. P., Ramos, A., Schaefer, F., Uttley, L. and 
Committee, I. A. H. A. (2005) Peritoneal dialysis-related infections recommendations: 2005 
update. Perit Dial Int, 25, 107-131. 
Quinn, R. R., Hux, J. E., Oliver, M. J., Austin, P. C., Tonelli, M. and Laupacis, A. (2011) Selection bias 
explains apparent differential mortality between dialysis modalities. J Am Soc Nephrol, 22, 
1534-1542. 
Richter, R., Bistrian, R., Escher, S., Forssmann, W., Vakili, J., Henschler, R., Spodsberg, N., Frimpong-
Boateng, A. and Forssmann, U. (2005) Quantum proteolytic activation of chemokine CCL15 
by neutrophil granulocytes modulates mononuclear cell adhesiveness. J Immunol, 175, 
1599-1608. 
Ring, T., Merkus, M. and Krediet, R. (2000) Physical symptoms and quality of life in patients on 
chronic dialysis: results of the netherlands cooperative study on adequacy of dialysis 
(NECOSAD). Nephrol Dial Transplant, 15, 280-281. 
Rippe, B., Stelin, G. and Haraldsson, B. (1991) Computer simulations of peritoneal fluid transport in 
CAPD. Kidney Int, 40, 315-325. 
186 
 
Rippe, B. and Venturoli, D. (2007) Simulations of osmotic ultrafiltration failure in CAPD using a serial 
three-pore membrane/fiber matrix model. Am J Physiol Renal Physiol, 292, F1035-1043. 
Ro, Y., Hamada, C., Inaba, M., Io, H., Kaneko, K. and Tomino, Y. (2007) Inhibitory effects of matrix 
metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine 
gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant, 22, 2838-2848. 
Rocco, M. V., Gassman, J. J., Wang, S. R. and Kaplan, R. M. (1997) Cross-sectional study of quality of 
life and symptoms in chronic renal disease patients: the Modification of Diet in Renal 
Disease Study. Am J Kidney Dis, 29, 888-896. 
Rybak, S. M., Fett, J. W., Yao, Q. Z. and Vallee, B. L. (1987) Angiogenin mRNA in human tumor and 
normal cells. Biochem Biophys Res Commun, 146, 1240-1248. 
Sakai, N., Wada, T., Furuichi, K., Shimizu, K., Kokubo, S., Hara, A., Yamahana, J., Okumura, T., 
Matsushima, K., Yokoyama, H. and Kaneko, S. (2006) MCP-1/CCR2-dependent loop for 
fibrogenesis in human peripheral CD14-positive monocytes. J Leukoc Biol, 79, 555-563. 
Sampimon, D., Coester, A., Struijk, D. and Krediet, R. (2010a) The time course of peritoneal transport 
parameters in peritoneal dialysis patients who develop encapsulating peritoneal sclerosis. 
Nephrol Dial Transplant, 26, 291-298. 
Sampimon, D., Korte, M., Barreto, D., Vlijm, A., de Waart, R., Struijk, D. and Krediet, R. (2010b) Early 
diagnostic markers for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int, 
30, 163-169. 
Santibañez, J. F., Quintanilla, M. and Bernabeu, C. (2011) TGF-β/TGF-β receptor system and its role in 
physiological and pathological conditions. Clin Sci (Lond), 121, 233-251. 
Sauter, M., Cohen, C., Wörnle, M., Mussack, T., Ladurner, R. and Sitter, T. (2007) ACE inhibitor and 
AT1-receptor blocker attenuate the production of VEGF in mesothelial cells. Perit Dial Int, 
27, 167-172. 
Schindler, R., Krautzig, S., Lufft, V., Lonnemann, G., Mahiout, A., Marra, M. N., Shaldon, S. and Koch, 
K. M. (1996) Induction of interleukin-1 and interleukin-1 receptor antagonist during 
contaminated in-vitro dialysis with whole blood. Nephrol Dial Transplant, 11, 101-108. 
Schraufstatter, I. U., Zhao, M., Khaldoyanidi, S. K. and Discipio, R. G. (2011) The Chemokine CCL18 
causes Maturation of Cultured Monocytes to Macrophages in the M2 Spectrum. 
Immunology. 
Schutyser, E., Richmond, A. and Van Damme, J. (2005) Involvement of CC chemokine ligand 18 
(CCL18) in normal and pathological processes. J Leukoc Biol, 78, 14-26. 
Sekiguchi, Y., Zhang, J., Patterson, S., Liu, L., Hamada, C., Tomino, Y. and Margetts, P. J. (2011) 
Rapamycin inhibits transforming growth factor β induced peritoneal angiogenesis by 
blocking the secondary hypoxic response. J Cell Mol Med. 
Selgas, R., Aguilera, A., Bajo, A., Loureiro, J., Del Peso, G., Aroeira, L. S., Ramirez-Cuesta, M., Perez-
Lozano, M. L., Jimenez-Heffernan, J. A., Sanchez-Tomero, J. A., Fernandez-Perpen, A. and 
Lopez-Cabrera, m. (2006) Effects of tamoxifen on epithelial-to-mesenchymal transition 
(EMT), fibrosis and angiogenesis of mesothelial cells. In ASNSan Diego. 
Selgas, R., del Peso, G., Bajo, M., Molina, S., Cirugeda, A., Sánchez-Tomero, J., Castro, M., Castro, M. 
and Vara, F. (2001) Vascular endothelial growth factor (VEGF) levels in peritoneal dialysis 
effluent. J Nephrol, 14, 270-274. 
Shahbaz, A. U., Sun, Y., Bhattacharya, S. K., Ahokas, R. A., Gerling, I. C., McGee, J. E. and Weber, K. T. 
(2010) Fibrosis in hypertensive heart disease: molecular pathways and cardioprotective 
strategies. J Hypertens, 28 Suppl 1, S25-32. 
Sherif, A., Nakayama, M., Maruyama, Y., Yoshida, H., Yamamoto, H., Yokoyama, K. and Kawakami, M. 
(2006) Quantitative assessment of the peritoneal vessel density and vasculopathy in CAPD 
patients. Nephrol Dial Transplant, 21, 1675-1681. 
187 
 
Siebert, J., Reiwer-Gostomska, M., Mysliwska, J., Marek, N., Raczynska, K. and Glasner, L. (2010) 
Glycemic control influences serum angiogenin concentrations in patients with type 2 
diabetes. Diabetes Care, 33, 1829-1830. 
Smit, W., Schouten, N., van den Berg, N., Langedijk, M., Struijk, D. and Krediet, R. (2004) Analysis of 
the prevalence and causes of ultrafiltration failure during long-term peritoneal dialysis: a 
cross-sectional study. Perit Dial Int, 24, 562-570. 
Starr, A. E., Dufour, A., Maier, J. and Overall, C. M. (2011) Biochemical analysis of matrix 
metalloproteinase activation of chemokines CCL15 and CCL23 and increased 
glycosaminoglycan binding of CCL16. J Biol Chem. 
Steyerberg, E. W. (2009) Clinical Prediction Models A Practical Approach to Development, Validation, 
and Updating. In Statistics for Biology and Health, Vol. Chapter 11 p193 Springer-Verlag New 
York, New York, NY. 
Struijk, D. G., Krediet, R. T., Koomen, G. C., Hoek, F. J., Boeschoten, E. W., vd Reijden, H. J. and Arisz, 
L. (1991) Functional characteristics of the peritoneal membrane in long-term continuous 
ambulatory peritoneal dialysis. Nephron, 59, 213-220. 
Strydom, D. (1998) The angiogenins. Cell Mol Life Sci, 54, 811-824. 
Szeto, C. and Chow, K. (2007) Gram-negative peritonitis--the Achilles heel of peritoneal dialysis? 
Perit Dial Int, 27 Suppl 2, S267-271. 
Szeto, C., Chow, K., Poon, P., Szeto, C., Wong, T. and Li, P. (2004) Genetic polymorphism of VEGF: 
Impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis 
patients. Kidney Int, 65, 1947-1955. 
Tarakçioğlu, M., Erbağci, A. B., Usalan, C., Deveci, R. and Kocabaş, R. (2003) Acute effect of 
hemodialysis on serum levels of the proinflammatory cytokines. Mediators Inflamm, 12, 15-
19. 
Tarzi, R., Frank, J., Ahmad, S., Levy, J. and Brown, E. (2006) Fluorodeoxyglucose positron emission 
tomography detects the inflammatory phase of sclerosing peritonitis. Perit Dial Int, 26, 224-
230. 
Tarzi, R., Lim, A., Moser, S., Ahmad, S., George, A., Balasubramaniam, G., Clutterbuck, E., Gedroyc, 
W. and Brown, E. (2008) Assessing the validity of an abdominal CT scoring system in the 
diagnosis of encapsulating peritoneal sclerosis. Clin J Am Soc Nephrol, 3, 1702-1710. 
Tello-Montoliu, A., Patel, J. V. and Lip, G. Y. (2006) Angiogenin: a review of the pathophysiology and 
potential clinical applications. J Thromb Haemost, 4, 1864-1874. 
Thong, M., van Dijk, S., Noordzij, M., Boeschoten, E., Krediet, R., Dekker, F. and Kaptein, A. (2009) 
Symptom clusters in incident dialysis patients: associations with clinical variables and quality 
of life. Nephrol Dial Transplant, 24, 225-230. 
Topley, N., Jörres, A., Luttmann, W., Petersen, M. M., Lang, M. J., Thierauch, K. H., Müller, C., Coles, 
G. A., Davies, M. and Williams, J. D. (1993) Human peritoneal mesothelial cells synthesize 
interleukin-6: induction by IL-1 beta and TNF alpha. Kidney Int, 43, 226-233. 
Tranquilli, A. L., Landi, B., Corradetti, A., Giannubilo, S. R., Sartini, D., Pozzi, V. and Emanuelli, M. 
(2007) Inflammatory cytokines patterns in the placenta of pregnancies complicated by HELLP 
(hemolysis, elevated liver enzyme, and low platelet) syndrome. Cytokine, 40, 82-88. 
Urbich, C., De Souza, A. I., Rossig, L., Yin, X., Xing, Q., Prokopi, M., Drozdov, I., Steiner, M., Breuss, J., 
Xu, Q., Dimmeler, S. and Mayr, M. (2011) Proteomic characterization of human early pro-
angiogenic cells. J Mol Cell Cardiol, 50, 333-336. 
van Westrhenen, R., Zweers, M., Kunne, C., de Waart, D., van der Wal, A. and Krediet, R. (2008) A 
pyruvate-buffered dialysis fluid induces less peritoneal angiogenesis and fibrosis than a 
conventional solution. Perit Dial Int, 28, 487-496. 
Verselis, S. J., Olson, K. A. and Fett, J. W. (1999) Regulation of angiogenin expression in human 
HepG2 hepatoma cells by mediators of the acute-phase response. Biochem Biophys Res 
Commun, 259, 178-184. 
188 
 
Vittinghoff, E. and McCulloch, C. E. (2007) Relaxing the rule of ten events per variable in logistic and 
Cox regression. Am J Epidemiol, 165, 710-718. 
Vlijm, A., Stoker, J., Bipat, S., Spijkerboer, A., Phoa, S., Maes, R., Struijk, D. and Krediet, R. (2009) 
Computed tomographic findings characteristic for encapsulating peritoneal sclerosis: a case-
control study. Perit Dial Int, 29, 517-522. 
Wada, T., Sakai, N., Matsushima, K. and Kaneko, S. (2007) Fibrocytes: a new insight into kidney 
fibrosis. Kidney Int, 72, 269-273. 
Wang, T. and Lindholm, B. (2002) Beyond CANUSA, DOQI, ADEMEX: what's next? Adequacy of 
Peritoneal Dialysis in Mexico. Canada-USA. Dialysis Outcomes Quality Initiative. Perit Dial Int, 
22, 555-562. 
Weisbord, S., Fried, L., Arnold, R., Fine, M., Levenson, D., Peterson, R. and Switzer, G. (2005) 
Prevalence, severity, and importance of physical and emotional symptoms in chronic 
hemodialysis patients. J Am Soc Nephrol, 16, 2487-2494. 
Weisbord, S. D., Fried, L. F., Arnold, R. M., Rotondi, A. J., Fine, M. J., Levenson, D. J. and Switzer, G. E. 
(2004) Development of a symptom assessment instrument for chronic hemodialysis 
patients: the Dialysis Symptom Index. J Pain Symptom Manage, 27, 226-240. 
Wiggins, K., Johnson, D., Craig, J. and Strippoli, G. (2007) Treatment of peritoneal dialysis-associated 
peritonitis: a systematic review of randomized controlled trials. Am J Kidney Dis, 50, 967-
988. 
Williams, J., Craig, K., Topley, N., Von Ruhland, C., Fallon, M., Newman, G., Mackenzie, R. and 
Williams, G. (2002) Morphologic changes in the peritoneal membrane of patients with renal 
disease. J Am Soc Nephrol, 13, 470-479. 
Williams, J., Topley, N., Craig, K., Mackenzie, R., Pischetsrieder, M., Lage, C. and Passlick-Deetjen, J. 
(2004) The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid 
(balance) on the peritoneal membrane. Kidney Int, 66, 408-418. 
Wong, T., Phillips, A., Witowski, J. and Topley, N. (2003) Glucose-mediated induction of TGF-beta 1 
and MCP-1 in mesothelial cells in vitro is osmolality and polyol pathway dependent. Kidney 
Int, 63, 1404-1416. 
Woodrow, G., Augustine, T., Brown, E. A., Cowling, M., El-Sherbini, N., Hurst, H., Williams, P. F. and 
Williams, R. (2009) UK Encapsulating Peritoneal Sclerosis Clinical Practice Guidelines. 
Woolard, J., Wang, W. Y., Bevan, H. S., Qiu, Y., Morbidelli, L., Pritchard-Jones, R. O., Cui, T. G., 
Sugiono, M., Waine, E., Perrin, R., Foster, R., Digby-Bell, J., Shields, J. D., Whittles, C. E., 
Mushens, R. E., Gillatt, D. A., Ziche, M., Harper, S. J. and Bates, D. O. (2004) VEGF165b, an 
inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo 
effect on angiogenesis and endogenous protein expression. Cancer Res, 64, 7822-7835. 
Wright, B., Summers, A., Fenner, J., Gillott, R., Hutchinson, C. E., Spencer, P. A., Wilkie, M., Hurst, H., 
Herrick, S., Brenchley, P., Augustine, T. and Bardhan, K. D. (2011) Initial observations using a 
novel "cine" magnetic resonance imaging technique to detect changes in abdominal motion 
caused by encapsulating peritoneal sclerosis. Perit Dial Int, 31, 287-290. 
Yamamoto, R., Otsuka, Y., Nakayama, M., Maruyama, Y., Katoh, N., Ikeda, M., Yamamoto, H., 
Yokoyama, K., Kawaguchi, Y. and Matsushima, M. (2005) Risk factors for encapsulating 
peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment. Clin Exp 
Nephrol, 9, 148-152. 
Yamamoto, T., Nagasue, K., Okuno, S. and Yamakawa, T. (2010) The role of peritoneal lavage and the 
prognostic significance of mesothelial cell area in preventing encapsulating peritoneal 
sclerosis. Perit Dial Int, 30, 343-352. 
Youn, B., Zhang, S., Lee, E., Park, D., Broxmeyer, H., Murphy, P., Locati, M., Pease, J., Kim, K., Antol, K. 
and Kwon, B. (1997) Molecular cloning of leukotactin-1: a novel human beta-chemokine, a 
chemoattractant for neutrophils, monocytes, and lymphocytes, and a potent agonist at CC 
chemokine receptors 1 and 3. J Immunol, 159, 5201-5205. 
189 
 
Yuan, Y., Wang, F., Liu, X. H., Gong, D. J., Cheng, H. Z. and Huang, S. D. (2009) Angiogenin is involved 
in lung adenocarcinoma cell proliferation and angiogenesis. Lung Cancer, 66, 28-36. 
Yáñez-Mó, M., Lara-Pezzi, E., Selgas, R., Ramírez-Huesca, M., Domínguez-Jiménez, C., Jiménez-
Heffernan, J., Aguilera, A., Sánchez-Tomero, J., Bajo, M., Alvarez, V., Castro, M., del Peso, G., 
Cirujeda, A., Gamallo, C., Sánchez-Madrid, F. and López-Cabrera, M. (2003) Peritoneal 
dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med, 348, 
403-413. 
Zbylut, J., Twardowski, K., Nolph, O., Khanna, R., Prowant, B., Ryan, L., Moore, H. and M, N. (1987) 
Peritoneal Equilibration Test. Peritoneal Dialysis International, 7, 2948-2957. 
Zemel, D., ten Berge, R. J., Struijk, D. G., Bloemena, E., Koomen, G. C. and Krediet, R. T. (1992) 
Interleukin-6 in CAPD patients without peritonitis: relationship to the intrinsic permeability 
of the peritoneal membrane. Clin Nephrol, 37, 97-103. 
Zhu, F., Li, T., Qiu, F., Fan, J., Zhou, Q., Ding, X., Nie, J. and Yu, X. (2010) Preventive effect of Notch 
signaling inhibition by a gamma-secretase inhibitor on peritoneal dialysis fluid-induced 
peritoneal fibrosis in rats. Am J Pathol, 176, 650-659. 
 
 
